Nitrogen-containing heterocyclic compound and use thereof
By developing a nitrogen-containing heterocyclic compound with a highly selective aldosterone synthase inhibitor, the drug resistance problem caused by elevated aldosterone in refractory hypertension was solved, and effective inhibition of aldosterone synthase was achieved, providing Safer and effective treatment options.
Patent Information
- Application Number
- PCT/CN2024/092687
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-01
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-21
AI Technical Summary
The prior art is difficult to effectively treat refractory hypertension, especially due to drug resistance problems caused by elevated aldosterone. The selective inhibition of aldosterone synthetase by existing drugs is difficult to achieve, affecting the therapeutic effect.
Provide a nitrogen-containing heterocyclic compound, which has a significant CYP11B2 enzyme inhibitory activity through its stereoisomer or pharmaceutically acceptable salt form, has a weak inhibitory effect on CYP11B1 as a highly selective aldosterone synthase inhibitor. , hardly affects the synthesis of cortisol, has excellent selectivity and safety.
The compounds have good in vivo pharmacokinetic properties, high bioavailability, long half-life, good oral absorption, meet oral administration once a day, and have low inhibitory effect on CYP enzymes, reducing the risk of drug interactions, and providing safer and more effective The choice of treatment of refractory hypertension.
Smart Images

Figure CN2024092687_21112024_PF_FP_ABST
Abstract
Description
Nitrogen-containing heterocyclic compounds and their applications
[0001] This application claims priority to:
[0002] Application number: CN202310537851.9, filing date: May 12, 2023;
[0003] Application number: CN202311235509.X, application date: September 22, 2023;
[0004] Application number: CN202311542512.6, filing date: November 17, 2023;
[0005] Application number: CN202410027233.4, application date: January 8, 2024;
[0006] Application number: CN202410149461.9, application date: February 1, 2024. Technical Field
[0007] The present invention relates to a nitrogen-containing heterocyclic compound and application thereof, and specifically discloses a compound represented by formula (II), its stereoisomers and pharmaceutically acceptable salts thereof. Background Art
[0008] Hypertension is a clinical syndrome characterized by elevated systemic arterial blood pressure (systolic and / or diastolic) (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg), which may be accompanied by functional or organic damage to organs such as the heart, brain, and kidneys. Commonly used medications for the treatment of hypertension include calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), diuretics, and beta-blockers, as well as fixed-combination combinations of these drugs. In addition, alpha-blockers or other antihypertensive drugs (such as renin inhibitors and centrally acting drugs) are sometimes used in certain hypertensive patients.
[0009] For adult patients with hypertension requiring medication, initial treatment with any of the three antihypertensive drug classes (diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, calcium channel blockers) is recommended as first-line therapy. For patients whose blood pressure is not controlled to target with monotherapy, combination antihypertensive drug therapy has become a cornerstone of antihypertensive treatment. To achieve target blood pressure, most patients with hypertension require two or more antihypertensive drugs. If a patient's blood pressure remains above 140 mmHg despite taking at least three antihypertensive drugs from different classes (one of which is a diuretic), this is considered refractory hypertension. For patients with refractory hypertension, a fourth drug, such as a beta-blocker, aldosterone receptor antagonist, triamterene, clonidine, or an alpha-blocker, may be added to the three-drug combination.
[0010] Since 2007, no new antihypertensive drugs have been approved for marketing, and a large number of patients with refractory hypertension remain undertreated. Both refractory hypertension and hyperaldosteronism are characterized by sodium and water retention. In clinical studies, Baxdrostat demonstrated a dose-related reduction in blood pressure and aldosterone secretion, suggesting that aldosterone is a key factor in drug resistance in patients with refractory hypertension. The main drug targets for treating refractory hypertension by lowering aldosterone levels include blocking the mineralocorticoid receptor and inhibiting aldosterone synthase.
[0011] Aldosterone is encoded by the CYP11B2 gene, which simultaneously functions as an 11-β-hydroxylase, an 18-hydroxylase, and an 18-dehydrogenase. It primarily functions in the final step of aldosterone synthesis, using 11-deoxycorticosterone (11-DOC) as a substrate to produce aldosterone. CYP11B1 and CYP11B2 share 93% amino acid sequence similarity, and inhibition of CYP11B1 activity may lead to adrenal insufficiency. Highly selective inhibition of aldosterone synthase is essential but difficult to achieve. Baxdrostat, a small molecule, highly selective aldosterone synthase inhibitor, has been demonstrated in Phase 2 trials to offer four key advantages: significant antihypertensive efficacy, no effect on cortisol levels, minimal serum potassium elevation, and no accumulation of steroid precursors. Baxdrostat, at a dose of 2 mg, is effective in lowering both systolic and diastolic blood pressure in patients with refractory hypertension, with a favorable safety and tolerability profile.
[0012] In summary, the development of selective aldosterone synthase inhibitors is a new drug with great potential for the treatment of diseases related to elevated aldosterone (including refractory hypertension and primary aldosteronism), providing more options for clinical treatment.
[0013] Summary of the Invention
[0014] The present invention provides a compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0015] in,
[0016] Ring A is selected from Ring A1 and Ring A2;
[0017] Ring A1 is selected from
[0018] Ring A2 is selected from described are each independently optionally substituted with 1, 2 or 3 R1;
[0019] Ring B is selected from Ring B1 and Ring B2;
[0020] Ring B1 is selected from phenyl, pyridyl and pyridazinyl, and the phenyl, pyridyl and pyridazinyl are each independently optionally substituted by 1, 2 or 3 R6;
[0021] Ring B2 is selected from 5-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R6;
[0022] T is selected from a single bond, CH2, NH and O;
[0023] T1 is selected from O and CR4R5;
[0024] R1 is selected from H, =NR, C 1-3 Alkyl and C 1-3 alkyl halide;
[0025] Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy, wherein R2, R3, R4 and R5 cannot all be H at the same time;
[0026] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group;
[0027] Alternatively, R4 and R4 together with the carbon atom to which they are attached form a cyclopropyl group;
[0028] Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group;
[0029] Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0030] Structural unit Selected from
[0031] R 71 is selected from 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R a replaced by;
[0032] R 81 selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0033] Ring C is selected from ring C1 and ring C2;
[0034] Ring C1 is selected from C substituted with one R9 5-6 Cycloalkyl, wherein R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=O)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace;
[0035] Ring C2 is selected from described Each independently optionally replaced by 1, 2 or 3 R e replace;
[0036] Each R a are independently selected from F, Cl, Br, I, C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl;
[0037] Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl;
[0038] R c and R d Together with the carbon atoms to which they are attached, they form C 3-5 Cycloalkyl or 5-6 membered heterocycloalkyl;
[0039] Each R e are independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR;
[0040] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens;
[0041] n is 0 or 1;
[0042] is a single bond or a double bond;
[0043] The "hetero" in the 5-membered heteroaryl, 5-6-membered heteroaryl, and 4-6-membered heterocycloalkyl group represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N;
[0044] The conditions are:
[0045] 1) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from C2; or,
[0046] 2) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from C substituted with one R9 5-6 When cycloalkyl, the R9 is selected from
[0047] The present invention provides a compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0048] in,
[0049] Ring A is selected from Ring A1 and Ring A2;
[0050] Ring A1 is selected from
[0051] Ring A2 is selected from described are each independently optionally substituted with 1, 2 or 3 R1;
[0052] Ring B is selected from Ring B1 and Ring B2;
[0053] Ring B1 is selected from phenyl, pyridyl and pyridazinyl, and the phenyl, pyridyl and pyridazinyl are each independently optionally substituted by 1, 2 or 3 R6;
[0054] Ring B2 is selected from 5-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R6;
[0055] T is selected from a single bond, CH2, NH and O;
[0056] T1 is selected from O and CR4R5;
[0057] R1 is selected from H, =NR, C 1-3 Alkyl and C 1-3 alkyl halide;
[0058] Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy, wherein R2, R3, R4 and R5 cannot all be H at the same time;
[0059] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group;
[0060] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl group;
[0061] Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group;
[0062] Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0063] Structural unit Selected from
[0064] R 71 is selected from 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R a replaced by;
[0065] R 81 selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0066] Ring C is selected from ring C1 and ring C2;
[0067] Ring C1 is selected from cyclohexyl substituted by 1 R9, wherein R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=O)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace;
[0068] Ring C2 is selected from described Each independently optionally replaced by 1, 2 or 3 R e replace;
[0069] Each R a are independently selected from F, Cl, Br, I, C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl;
[0070] Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl;
[0071] R c and R d Together with the carbon atoms to which they are attached, they form C 3-5 Cycloalkyl or 5-6 membered heterocycloalkyl;
[0072] Each R e are independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR;
[0073] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens;
[0074] n is 0 or 1;
[0075] is a single bond or a double bond;
[0076] The "hetero" in the 5-membered heteroaryl, 5-6-membered heteroaryl, and 4-6-membered heterocycloalkyl group represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N;
[0077] The conditions are:
[0078] 1) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from C2; or,
[0079] 2) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from cyclohexyl substituted with one R9, said R9 is selected from
[0080] The present invention provides a compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0081] in,
[0082] Ring A is selected from Ring A1 and Ring A2;
[0083] Ring A1 is selected from
[0084] Ring A2 is selected from described are each independently optionally substituted with 1, 2 or 3 R1;
[0085] Ring B is selected from Ring B1 and Ring B2;
[0086] Ring B1 is selected from phenyl and pyridyl, and the phenyl and pyridyl are each independently optionally substituted with 1, 2 or 3 R6;
[0087] Ring B2 is selected from 5-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R6;
[0088] T is selected from CH2, NH and O;
[0089] T1 is selected from O and CR4R5;
[0090] R1 is selected from H, =NR, C 1-3 Alkyl and C 1-3 alkyl halide;
[0091] Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy, wherein R2, R3, R4 and R5 cannot all be H at the same time;
[0092] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group;
[0093] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl group;
[0094] Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group;
[0095] Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0096] Structural unit Selected from
[0097] R 71 is selected from 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R a replaced by;
[0098] R 81 selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0099] Ring C is selected from ring C1 and ring C2;
[0100] Ring C1 is selected from cyclohexyl substituted by 1 R9, wherein R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=O)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace;
[0101] Ring C2 is selected from described Each independently optionally replaced by 1, 2 or 3 R e replace;
[0102] Each R a are independently selected from F, Cl, Br, I, C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl;
[0103] Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl;
[0104] R c and R d Together with the carbon atoms to which they are attached, they form C 3-5 Cycloalkyl or 5-6 membered heterocycloalkyl;
[0105] Each R e are independently selected from F, Cl, Br, I, ═O, C1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR;
[0106] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens;
[0107] n is 0 or 1;
[0108] is a single bond or a double bond;
[0109] The "hetero" in the 5-membered heteroaryl, 5-6-membered heteroaryl, and 4-6-membered heterocycloalkyl group represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N;
[0110] The conditions are:
[0111] 1) When Ring A is selected from A1, Ring B is selected from B1, and Ring C is selected from C2; or,
[0112] 2) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from cyclohexyl substituted with one R9, said R9 is selected from
[0113] The present invention provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0114] in,
[0115] Ring B is selected from Ring B1 and Ring B2;
[0116] Ring B1 is selected from phenyl, which is optionally substituted with 1, 2 or 3 R6;
[0117] Ring B2 is selected from 5-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R6;
[0118] Ring A is selected from Ring A1 and Ring A2;
[0119] Ring A1 is selected from
[0120] Ring A2 is selected from described are each independently optionally substituted with 1, 2 or 3 R1;
[0121] E is selected from CH and N;
[0122] T is selected from CH2, NH and O;
[0123] Ring C is selected from ring C1 and ring C2;
[0124] Ring C1 is selected from cyclohexyl substituted by 1 R9, wherein R9 is selected from -NHC(=O)CH2CH3;
[0125] Ring C2 is selected from described Each independently optionally substituted by 1, 2 or 3 R e replace;
[0126] Each R1 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy and =NR;
[0127] Each R6 is independently selected from F, Cl, Br, I and C 1-3 alkyl;
[0128] R c and R d The carbon atoms to which they are attached together form C 3-5 Cycloalkyl or 5-6 membered heterocycloalkyl;
[0129] Each R e are independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy and -NHC(=O)-C 1-3 Alkylamino;
[0130] R f Selected from =NR,
[0131] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 halogens;
[0132] n is 0 or 1;
[0133] is a single bond or a double bond;
[0134] The "hetero" in the 5-membered heteroaryl, 5-6-membered heteroaryl and 5-6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S, N and C(=O);
[0135] The conditions are:
[0136] When ring A is selected from A1 and ring B is selected from B1, ring C is selected from C2.
[0137] In some embodiments of the present invention, the above R is selected from CH3, CH2CH3, CF3, OCH3 and OCF3, and other variables are as defined in the present invention.
[0138] In some embodiments of the present invention, the above R a is selected from -S(=O)2-CH2CH3, and other variables are as defined herein.
[0139] In some embodiments of the present invention, the above R b are independently selected from F, Cl, Br, I, CH3, -C(=O)-CH2CH3 and -NHC(=O)-CH2CH3, and other variables are as defined in the present invention.
[0140] In some embodiments of the present invention, the above R c and R d Together with the carbon atoms to which they are attached, they form Other variables are as defined in the present invention.
[0141] In some embodiments of the present invention, the above R e is selected from -NHC(=O)-CH2CH3, =NCH3 and =N-OCH3, and the other variables are as defined herein.
[0142] In some embodiments of the present invention, the above R e They are independently selected from F, Cl, Br, I, CH3, CH2CH3, OCH3, OCH2CH3, NCH3, NCH2CH3, -NHC(=O)-CH3, -NHC(=O)-CH2CH3, -NHC(=O)-OCH3 and -NHC(=O)-NCH3, and other variables are as defined in the present invention.
[0143] In some embodiments of the present invention, the above R f Selected from =NCH3、=N-OCH3、 Other variables are as defined in the present invention.
[0144] In some embodiments of the present invention, the above R1 is selected from CH3, and other variables are as defined in the present invention.
[0145] In some embodiments of the present invention, each of the above R1 is independently selected from F, Cl, Br, I, CH3, OCH3 and =N-OCH3, and other variables are as defined in the present invention.
[0146] In some embodiments of the present invention, each of R2, R3, R4 and R5 is independently selected from H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3, OCH3, OCH2CH3, wherein R2, R3, R4 and R5 cannot all be H at the same time, and other variables are as defined in the present invention.
[0147] In some embodiments of the present invention, the above R2 is selected from H and F, and other variables are as defined in the present invention.
[0148] In some embodiments of the present invention, the above-mentioned R5 is selected from H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3 and OCH3, and other variables are as defined in the present invention.
[0149] In some embodiments of the present invention, each R6 is independently selected from F, and other variables are as defined in the present invention.
[0150] In some embodiments of the present invention, each of the above R6 is independently selected from F, Cl, Br, I and CH3, and other variables are as defined in the present invention.
[0151] In some embodiments of the present invention, the above R 71 Selected from Other variables are as defined in the present invention.
[0152] In some embodiments of the present invention, the above R 81 is selected from H, and other variables are as defined in the present invention.
[0153] In some embodiments of the present invention, the above R9 is selected from -NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetyl, piperidinyl and The -NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl and piperidinyl are each independently optionally substituted by 1, 2 or 3 R b Substitution, other variables are as defined in the present invention.
[0154] In some embodiments of the present invention, the above R9 is selected from described Each independently optionally substituted by 1, 2 or 3 Rb Substitution, other variables are as defined in the present invention.
[0155] In some embodiments of the present invention, the above R9 is selected from Other variables are as defined in the present invention.
[0156] In some embodiments of the present invention, the ring B1 is selected from Other variables are as defined in the present invention.
[0157] In some embodiments of the present invention, the ring B1 is selected from Other variables are as defined in the present invention.
[0158] In some embodiments of the present invention, the ring B1 is selected from phenyl, and other variables are as defined in the present invention.
[0159] In some embodiments of the present invention, the ring B2 is selected from thienyl, thiazolyl, imidazolyl and pyrazolyl, and the thienyl, thiazolyl, imidazolyl and pyrazolyl are independently optionally substituted with 1, 2 or 3 R6, and other variables are as defined in the present invention.
[0160] In some embodiments of the present invention, the ring B2 is selected from described Each is independently optionally substituted with 1, 2 or 3 R6, and other variables are as defined herein.
[0161] In some embodiments of the present invention, the ring B2 is selected from Other variables are as defined in the present invention.
[0162] In some embodiments of the present invention, the ring B2 is selected from Other variables are as defined in the present invention. In some embodiments of the present invention, the ring A2 is selected from Other variables are as defined in the present invention.
[0163] In some embodiments of the present invention, the ring A2 is selected from Other variables are as defined in the present invention.
[0164] In some embodiments of the present invention, the ring A2 is selected from Other variables are as defined in the present invention.
[0165] In some embodiments of the present invention, the ring C1 is selected from Other variables are as defined in the present invention.
[0166] In some embodiments of the present invention, the ring C1 is selected from Other variables are as defined in the present invention.
[0167] In some embodiments of the present invention, the ring C1 is selected from Other variables are as defined in the present invention.
[0168] In some embodiments of the present invention, the ring C1 is selected from Other variables are as defined in the present invention.
[0169] In some embodiments of the present invention, the ring C1 is selected from Other variables are as defined in the present invention.
[0170] In some embodiments of the present invention, the ring C2 is selected from Description Each independently optionally substituted by 1, 2 or 3 R e Substitution, other variables are as defined in the present invention.
[0171] In some embodiments of the present invention, the ring C2 of the compound of formula (I) is selected from described Each independently optionally substituted by 1, 2 or 3 R g Substitution, other variables are as defined in the present invention.
[0172] In some embodiments of the present invention, the ring C2 is selected from Other variables are as defined in the present invention.
[0173] In some embodiments of the present invention, the ring C2 of the compound of formula (I) is selected from Other variables are as defined in the present invention.
[0174] In some embodiments of the present invention, the ring C2 of the compound of formula (I) is selected from Other variables are as defined in the present invention.
[0175] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.
[0176] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.
[0177] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0178] in,
[0179] is a single bond or a double bond;
[0180] T2 is selected from CH and N;
[0181] T4 is selected from CH and N;
[0182] T3 is selected from C and N;
[0183] Ring E is selected from
[0184] m is selected from 0, 1, 2 and 3;
[0185] p is selected from 0, 1 and 2;
[0186] Ring B is selected from Ring B1 and Ring B2;
[0187] Ring B1 is selected from phenyl, pyridyl and pyridazinyl;
[0188] Ring B2 is selected from 5-membered heteroaryl;
[0189] T, T1, R1, R2, R3, R6, L, R7 and R8 are as defined herein.
[0190] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0191] in,
[0192] Ring B is selected from phenyl, pyridyl, pyridazinyl and 5-membered heteroaryl;
[0193] R1 is selected from H, C 1-3 Alkyl and C 1-3 alkyl halide;
[0194] Each R2 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1-3 haloalkoxy;
[0195] Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0196] R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=O)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace;
[0197] Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl;
[0198] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens;
[0199] m is selected from 0, 1, 2 and 3;
[0200] is a single bond or a double bond;
[0201] The “hetero” in the 5-membered heteroaryl, 5-6-membered heteroaryl and 4-6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N.
[0202] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0203] in,
[0204] Ring B is selected from phenyl, pyridyl, pyridazinyl and 5-membered heteroaryl;
[0205] T1 is selected from O and CR4R5;
[0206] R1 is selected from H, C 1-3 Alkyl and C 1-3 alkyl halide;
[0207] Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy;
[0208] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group;
[0209] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl group;
[0210] Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group;
[0211] Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0212] Each R e are independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR;
[0213] R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens;
[0214] m is selected from 0, 1, 2 and 3;
[0215] is a single bond or a double bond;
[0216] The "hetero" in the 5-membered heteroaryl group represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N.
[0217] In some embodiments of the present invention, in the above formula (P-1) When R3 and R4 are not present, and T1 is selected from a double bond, R3 and R4 are not present, and the other variables are as defined herein.
[0218] In some embodiments of the present invention, the structural unit in the above formula (P-1) Selected from Other variables are as defined in the present invention.
[0219] In some embodiments of the present invention, the structural unit in the above formula (P-1) Selected from Other variables are as defined in the present invention.
[0220] In some embodiments of the present invention, in the above formula (III-2) is selected from a double bond, R3 and R4 are absent, and the other variables are as defined herein.
[0221] In some embodiments of the present invention, the structural unit in the above formula (III-2) Selected from Other variables are as defined in the present invention.
[0222] In some embodiments of the present invention, the structural unit in the above formula (III-2) Selected from Other variables are as defined in the present invention.
[0223] In some embodiments of the present invention, the structural unit in the above formula (III-2) Selected from Other variables are as defined in the present invention.
[0224] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0225] in,
[0226] is a single bond or a double bond;
[0227] T2 is selected from CH and N;
[0228] T4 is selected from CH and N;
[0229] T3 is selected from C and N;
[0230] Ring E is selected from
[0231] m is selected from 0, 1, 2 and 3;
[0232] p is selected from 0, 1 and 2;
[0233] Ring B
[0234] selected from Ring B1 and Ring B2;
[0235] Ring B1 is selected from phenyl, pyridyl and pyridazinyl;
[0236] Ring B2 is selected from 5-membered heteroaryl;
[0237] T, T1, R1, R2, R3, R6, L, R7 and R8 are as defined herein.
[0238] In some embodiments of the present invention, in the above formula (III'-2) is selected from a double bond, T1 is selected from CR5, and other variables are as defined in the present invention.
[0239] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0240] T2 is selected from CH and N;
[0241] T3 is selected from C and N;
[0242] Ring E is selected from
[0243] m is selected from 0, 1, 2 and 3;
[0244] Ring B2 is selected from 5-membered heteroaryl;
[0245] T, T1, R1, R2, R3, R6, L, R7 and R8 are as defined herein.
[0246] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0247] in,
[0248] is a single bond or a double bond;
[0249] T2 is selected from CH and N;
[0250] T4 is selected from CH and N;
[0251] Ring B2 is selected from 5-membered heteroaryl;
[0252] R1, R2, R3, R4, R5, R6, L, R7, R8 and m are as defined herein.
[0253] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0254] in,
[0255] is a single bond or a double bond;
[0256] T5 selected from CR 61 and N;
[0257] R 61 selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0258] R1, R2, R5, R6, R e and m are as defined in the present invention.
[0259] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0260] in,
[0261] is a single bond or a double bond;
[0262] T5 selected from CR 61 and N;
[0263] R 61 selected from H, F, Cl, Br, I and C 1-3 alkyl;
[0264] R1, R2, R3, R5, R6, R9, R 71 、R 81 and m are as defined in the present invention.
[0265] Some other solutions of the present invention are obtained by arbitrarily combining the above variables.
[0266] The present invention also provides a compound represented by the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0267] The present invention also provides a compound represented by the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0268] The present invention also provides the use of the above compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating diseases related to aldosterone synthase inhibitors.
[0269] The present invention also provides the use of the above compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating refractory hypertension.
[0270] Technical Effects
[0271] The compounds of the present invention have high CYP11B2 enzyme inhibitory activity, weak inhibitory effect on CYP11B1, excellent selectivity, and almost no effect on the synthesis of cortisol, and have better clinical safety; the compounds of the present invention also have good in vivo pharmacokinetic properties, high bioavailability, slow clearance in the body, long half-life, good oral absorption, and meet the requirements of once-a-day oral administration; the compounds of the present invention are highly permeable and low-efflux compounds, moderately bind to plasma proteins of different species, have a moderate proportion of plasma free drugs, and have good drugability; the compounds of the present invention show a low clearance rate in human liver microsomes, have good metabolic stability, have no inhibitory effect on CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and have an extremely low risk of drug-drug interactions.
[0272] Definition and Description
[0273] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.
[0274] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0275] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, which are prepared by reacting the compounds of the present invention with relatively nontoxic acids or bases, having specific substituents. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the compounds with a sufficient amount of base in neat solution or a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the compounds with a sufficient amount of acid in neat solution or a suitable inert solvent. Certain specific compounds of the present invention contain both basic and acidic functional groups and can be converted into either base or acid addition salts.
[0276] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of the two.
[0277] Unless otherwise indicated, the term "isomer" is intended to include geometric isomers, cis-trans isomers, stereoisomers, enantiomers, optical isomers, diastereomers and tautomers.
[0278] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are encompassed within the scope of the present invention.
[0279] Unless otherwise indicated, the term "enantiomer" or "optical isomer" refers to stereoisomers that are mirror images of one another.
[0280] Unless otherwise indicated, the term "cis-trans isomers" or "geometric isomers" arises from the inability to rotate freely about double bonds or single bonds forming ring carbon atoms.
[0281] Unless otherwise indicated, the term "diastereomer" refers to stereoisomers that have two or more chiral centers and that are not mirror images of each other.
[0282] Unless otherwise indicated, "(+)" indicates dextrorotatory, "(-)" indicates levorotatory, and "(±)" indicates racemic.
[0283] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicate the relative configuration of stereocenters with a wavy line Indicates a wedge-shaped solid key or dotted wedge key Or use a wavy line Indicates a straight solid bond or straight dashed key
[0284] Unless otherwise indicated, the terms "enriched in one isomer", "isomerically enriched", "enriched in one enantiomer" or "enantiomerically enriched" mean that the content of one isomer or enantiomer is less than 100%, and the content of that isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
[0285] Unless otherwise indicated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80%.
[0286] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are resolved by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).
[0287] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug biological half-life. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.
[0288] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0289] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced.
[0290] The term "optionally substituted" means that the group may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be any based on chemical feasibility.
[0291] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.
[0292] When the number of a linking group is 0, such as -(CRR)0-, it means that the linking group is a single bond.
[0293] When the number of a substituent is 0, it means that the substituent does not exist, for example, -A-(R)0 means that the structure is actually -A.
[0294] When a substituent is vacant, it means that the substituent does not exist. For example, when X in AX is vacant, it means that the structure is actually A.
[0295] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a single bond, it means that the structure is actually AZ.
[0296] When the linking group is listed without specifying its linking direction, its linking direction is arbitrary, for example, The connecting group L is -MW-, in which case -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form You can also connect ring A and ring B in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.
[0297] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection mode is non-positional and there are H atoms at the connectable sites, when the chemical bond is connected, the number of H atoms at the site will decrease accordingly with the number of connected chemical bonds, and become a group with a corresponding valence. The chemical bond connecting the site to other groups can be a straight solid bond. Straight dotted key or wavy lines For example, the straight solid bond in -OCH3 indicates that it is connected to other groups through the oxygen atom in the group; The straight dashed bond in the group indicates that the two ends of the nitrogen atom in the group are connected to other groups; The wavy line in the phenyl group indicates that it is connected to other groups through the carbon atoms at positions 1 and 2 in the phenyl group; Indicates that any linkable site on the piperidinyl group can be connected to other groups through a chemical bond, including at least In these four connection methods, even if an H atom is drawn on -N-, Still includes For groups connected in this way, when one chemical bond is connected, the H at that site will be reduced by one and become a corresponding monovalent piperidine group.
[0298] Unless otherwise specified, when ring A and ring B are fused, they share a bond, and the atom on the bond can be a C or N atom, for example, The atoms on the fused bond between A and B can be C or N, including but not limited to
[0299] Unless otherwise specified, the number of atoms in a ring is generally defined as the number of members of the ring, for example, a "5-7 membered ring" refers to a "ring" having 5-7 atoms arranged around it.
[0300]
[0046] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0301] Unless otherwise specified, the term “C 1-3 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 Alkyl groups include C 1-2 and C 2-3 Alkyl, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine). 1-3 Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
[0302] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to an alkyl group containing 1 to 3 carbon atoms which is linked to the rest of the molecule via an oxygen atom. It can be monovalent, divalent or polyvalent. 1-3 Alkoxy groups include C 1-2 、C 2-3 , C3 and C2 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
[0303] Unless otherwise specified, the term “C 1-3 "Alkylamino" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via a nitrogen atom. The C 1-3 Alkylamino groups include C 1-2 , C3 and C2 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.
[0304] Unless otherwise specified, the term “C 1-3 "Haloalkyl" means monohaloalkyl and polyhaloalkyl containing 1 to 3 carbon atoms. 1-3 Haloalkyl groups include C 1-2 、C 2-3 , C3, C2 and C1 haloalkyl, etc. 1-3 Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, pentachloroethyl, 3-bromopropyl, and the like.
[0305] Unless otherwise specified, the term “C 1-3 "Haloalkoxy" means monohaloalkoxy and polyhaloalkoxy containing 1 to 3 carbon atoms. 1-3 Haloalkoxy includes C 1-2 、C 2-3 , C3, C2 and C1 haloalkoxy, etc. 1-3 Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, pentachloroethoxy, 3-bromopropoxy, and the like.
[0306] Unless otherwise specified, “C 5-6 "Cycloalkyl" means a saturated or partially saturated cyclic hydrocarbon group consisting of 5 to 6 carbon atoms, which is a monocyclic system. 5-6 Cycloalkyl groups include C5 and C6 cycloalkyl groups, etc.; they may be monovalent, divalent, or polyvalent. 5-6 Examples of cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and the like.
[0307] Unless otherwise specified, “C 3-5 "Cycloalkyl" means a saturated or partially saturated cyclic hydrocarbon group consisting of 3 to 5 carbon atoms, which is a monocyclic system. 3-5 Cycloalkyl groups include C3, C4 and C5 cycloalkyl groups, etc.; they may be monovalent, divalent or polyvalent. 3-5 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, and the like.
[0308] Unless otherwise specified, the term "4-6 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group consisting of 4 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the carbon atoms are optionally oxo (i.e., C(O)), the nitrogen atoms are optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p, p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spirocyclic, fused and bridged rings. In addition, with respect to the "4-6 membered heterocycloalkyl", a heteroatom may occupy the position at which the heterocycloalkyl is connected to the rest of the molecule. The 4-6 membered heterocycloalkyl includes 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyls, etc. Examples of 4-6 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl or hexahydropyridazinyl, etc.
[0309] Unless otherwise specified, the term "5-6 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group consisting of 5 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the carbon atoms are optionally oxo (i.e., C(O)), the nitrogen atoms are optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spirocyclic, fused and bridged rings. In addition, with respect to the "4-6 membered heterocycloalkyl", a heteroatom may occupy the position at which the heterocycloalkyl is connected to the rest of the molecule. The 5-6 membered heterocycloalkyl includes 5-membered and 6-membered heterocycloalkyls, etc. Examples of 5-6 membered heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl or hexahydropyridazinyl, etc.
[0310] Unless otherwise specified, the terms "5-6 membered heteroaromatic ring" and "5-6 membered heteroaryl" are used interchangeably in the present invention. The term "5-6 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 6 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). 5-6 yuan of heteroaryl can be connected to the rest of the molecule through a heteroatom or a carbon atom. The 5-6 yuan of heteroaryl includes 5 yuan and 6 yuan of heteroaryl. The example of the 5-6 yuan of heteroaryl includes but is not limited to pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.).
[0311] Unless otherwise specified, the terms "5-membered heteroaromatic ring" and "5-membered heteroaryl" are used interchangeably in the present invention. The term "5-membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). The 5-membered heteroaryl group may be attached to the remainder of the molecule via a heteroatom or carbon atom. Examples of the 5-membered heteroaryl group include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1, 2, 3-triazolyl, 2 H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.),
[0312] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.
[0313] The structures of the compounds of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compounds, the absolute configuration can be confirmed by conventional techniques in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data on the cultured single crystal using a Bruker D8 venture diffractometer, using CuKα radiation as the light source and scanning mode: After scanning and collecting relevant data, the crystal structure is further analyzed using the direct method (Shelxs97) to confirm the absolute configuration.
[0314] The present invention uses the following abbreviations: eg represents equivalent, equal amount; DCM represents dichloromethane; PE represents petroleum ether; DMSO represents dimethyl sulfoxide; EtOAc represents ethyl acetate; EtOH represents ethanol; MeOH represents methanol; DMF represents N,N-dimethylformamide; Boc represents tert-butyloxycarbonyl, which is an amine protecting group; rt represents room temperature; TFA represents trifluoroacetic acid; Eaton's reagent represents 7.5% phosphorus pentoxide in methanesulfonic acid; PEG represents polyethylene glycol; solutol represents polyethylene glycol-15 hydroxystearate; C max is the maximum concentration; AUC is the oral exposure; T 1 / 2 is the half-life; V dss is the steady-state volume of distribution; CL is the clearance.
[0315] The solvent used in the present invention is commercially available.
[0316] Compounds are named according to the conventional nomenclature in the art or using Software naming, commercially available compounds use supplier catalog names. BRIEF DESCRIPTION OF THE DRAWINGS
[0317] Figure 1. Binding pattern of compound 1A and CYP11B2 protein.
[0318] Figure 2. Binding pattern of compound 2A and CYP11B2 protein.
[0319] Figure 3. Binding pattern of compound 3A and CYP11B2 protein. DETAILED DESCRIPTION
[0320] The present invention is described in detail below by examples, but it is not intended to limit the present invention in any way. The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement modes well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0321] Calculation Example 1
[0322] The molecular docking process was performed using Maestro ( The docking was performed using Glide SP[1] in version 2022-1) with default options. The co-crystal structure of CYP11B2 (PDBID: 4ZGX) was selected as the docking template. To prepare the protein, hydrogen atoms were added using the Protein Preparation Wizard module of Maestro[2], and the OPLS4 force field was used. For ligand preparation, the three-dimensional structure of the molecule was generated using the LigPrep module, and energy minimization was performed[3]. The small molecule conformation was searched using the ConfGen module[4]. The grid file required for docking was generated using the Receptor Grid Generation module in Glide, with the ligand in the crystal structure as the center of the docking box. The interaction type between the protein receptor and the ligand was analyzed, and then molecules with high potential were selected for synthesis testing based on the calculated docking score and binding mode. The binding mode diagrams of compounds 1A, 2A, and 3A are shown in Figures 1, 2, and 3.
[0323] [1] Glide, LLC, New York, NY, 2020.
[0324] [2] Maestro, LLC, New York, NY, 2020.
[0325] [3]LigPrep, LLC, New York, NY, 2020.
[0326] [4]ConfGen, LLC, New York, NY, 2020.
[0327] Conclusion: The compounds of the present invention have good binding to CYP11B2 protein.
[0328] Reference Example 1: Fragment A-1
[0329] Synthesis route:
[0330] Step 1: Synthesis of compound A-1-3
[0331] A-1-1 (19 g, 84.04 mmol) and tetrahydrofuran (250 mL) were added to the reaction flask, stirred and dissolved, and then A-1-2 (12.22 g, 100.85 mmol) was added, followed by dropwise addition of tetraethyl titanate (57.51 g, 252.13 mmol). The reaction was stirred at 75 ° C for 16 hours. 400 mL of ethyl acetate and 800 mL of saturated sodium bicarbonate aqueous solution were added, filtered, and the filter cake was washed three times with ethyl acetate (100 mL each time). The filtrate was collected, separated, and the aqueous phase was extracted twice with 400 mL of ethyl acetate, and the organic phases were combined. The organic phase was washed with 800 mL of saturated brine, the organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated to obtain the crude product of A-1-3. 1 H NMR (400MHz, CDCl3) δppm 9.19 (s, 1H), 8.71 (s, 1H), 3.25-3.35 (m, 1H), 3.10-3.18 (m, 1H), 2.83-2.99 (m, 2H), 1.96-2.16 (m, 2H), 1.34 (s, 9H).
[0332] Step 2: Synthesis of compound A-1-4
[0333] A-1-3 (11.13 g, 33.80 mmol) and tetrahydrofuran (100 mL) were added to the reaction flask, and the atmosphere was replaced with nitrogen. 9-Borabicyclo[3.3.1]nonane (0.5 M in tetrahydrofuran, 169.02 mL) was added dropwise at 0°C, and the temperature was slowly raised to 25°C for 16 hours. Saturated aqueous ammonium chloride (250 mL) and 250 mL of water were added to the reaction solution in sequence, and the aqueous phase was extracted three times with 500 mL of ethyl acetate. The combined organic phases were washed with saturated brine (1000 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 25% to 100%) to obtain A-1-4. 1 H NMR (400MHz, CDCl3) δppm 8.58 (d, J=8.78Hz, 2H), 4.60-4.70 (m, 1H), 3.18-3.31 (m, 1H), 2.81-2.92 (m, 1H), 2.62 (ddd, J=1 8.51, 9.60, 6.53Hz, 1H), 2.09-2.18(m, 1H), 1.93-2.07(m, 1H), 1.80-1.91(m, 2H), 1.23(s, 9H).
[0334] Step 3: Synthesis of compound A-1-5
[0335] A-1-4 (8.31 g, 25.09 mmol) was dissolved in ethyl acetate (50 mL). Hydrogen chloride / ethyl acetate (2 M, 160 mL) was added at 28°C and stirred for 16 hours. The reaction mixture was filtered and the filter cake was rinsed with 3 mL of ethyl acetate. The filter cake was collected and dried to obtain the crude hydrochloride salt of A-1-5. ESI-LCMS: m / z = 226.8, 228.9 [M+1] + .
[0336] Step 4: Synthesis of Compound A-1
[0337] The hydrochloride of A-1-5 (7.67 g), dichloromethane (150 mL), and triethylamine (8.83 g, 87.30 mmol) were added sequentially to a reaction flask. After stirring to dissolve, propionic anhydride (5.68 g, 43.65 mmol) was added and stirred at 28°C for 16 hours. 400 mL of saturated aqueous ammonium chloride solution was added, the layers were separated, and the aqueous phase was extracted three times with dichloromethane (200 mL each time). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 10%) to obtain A-1. 1 H NMR (400MHz, CDCl3) δppm 8.54 (s, 1H), 8.41 (s, 1H), 5.74 (br d, J=7.28Hz, 1H), 5.24-5.32 (m, 1H), 2.69-2.82 (m, 2H), 2.27 (q, J=7.53Hz, 2H), 1.98-2 .06 (m, 1H), 1.91 (dt, J=12.05, 6.02Hz, 2H), 1.78-1.86 (m, 1H), 1.21 (t, J=7.65Hz, 3H). [α] 20 D =+5.77 (c 1.0, MeOH).
[0338] Reference Example 2: Fragment A-2
[0339] Synthesis route:
[0340] Step 1: Synthesis of compound A-2
[0341] A-1 (70 mg, 247.21 μmol), triisopropyl borate (155.75 mg, 828.14 μmol), and tetrahydrofuran (3.5 mL) were added sequentially to the reaction flask. The atmosphere was replaced with nitrogen, and n-butyl lithium (2.5 M, 247.21 μL) was added dropwise at -78°C. The mixture was stirred at -78°C for 2 hours. Methanol (3.5 mL) was added dropwise to the reaction solution to obtain a methanol solution of A-2, which was used immediately. ESI-LCMS: m / z = 249.3 [M+H] + .
[0342] Example 1
[0343] Synthesis route:
[0344] Step 1: Synthesis of Compound 001-2
[0345] 001-1 (1 g, 4.16 mmol) and 1,2-dichloroethane (20 mL) were added to a reaction flask. After stirring to dissolve, N-bromosuccinimide (1.11 g, 6.25 mmol) and azobisisobutyronitrile (136.79 mg, 833.00 μmol) were added and the reaction was stirred at 80°C for 4 hours. 20 mL of water was added, the layers were separated, and the aqueous phase was extracted with dichloromethane three times (20 mL each time). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product 001-2. 1 H NMR (400MHz, CDCl3) δppm 7.73 (d, J=2.26Hz, 1H), 7.68 (dd, J=9.03, 2.26Hz, 1H), 7.62 (d, J=9.54Hz, 1H), 7.30 (d, J=2.51Hz, 1H), 6.78 (d, J=9.54Hz, 1H), 3.73 (s, 3H).
[0346] Step 2: Synthesis of Compound 001-3
[0347] 001-2 (1.6 g, 6.72 mmol), bis(trifluoromethyl)benzoate (2.56 g, 10.08 mmol), potassium acetate (1.98 g, 20.16 mmol), and 1,4-dioxane (10 mL) were added to a reaction flask. After nitrogen was replaced, [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (274.41 mg, 336.02 μmol) was added. The reaction was stirred at 80°C for 2 hours. 30 mL of ethyl acetate was added, stirred, and diluted. The mixture was filtered, and the filter cake was washed with 30 mL of ethyl acetate. The organic phase was collected and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate = 0%-20%) to obtain 001-3. ESI-LCMS: m / z = 286.1 [M+H] + .
[0348] Step 3: Synthesis of Compound 001
[0349] 001-3 (191.33 mg, 670.99 μmol), A-1 (190 mg, 670.99 μmol), and ethanol (2.5 mL) were added to a reaction flask, and sodium carbonate (142.50 mg, 1.34 mmol) and water (0.5 mL) were added after dissolution. After nitrogen was replaced, tetrakistriphenylphosphine palladium (38.77 mg, 33.55 μmol) was added. The reaction was stirred at 80 ° C for 16 hours. 20 mL of half-saturated brine was added to quench the reaction, and the mixture was extracted three times with ethyl acetate (10 mL each time). The combined organic phases were washed with 20 mL of saturated brine, the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane / methanol = 20:1), and then subjected to chiral separation [chiral column: DAICEL CHIRALCEL OD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; ethanol (0.1% ammonia water): 45%, isocratic elution] to obtain compound 001. 1 H NMR (400MHz, CDCl3) δppm 8.53 (s, 1H), 8.31 (s, 1H), 7.69 (d, J=9.29Hz, 1H), 7.43-7.52 (m, 3H), 6.77 (d, J=9.54Hz, 1H), 5.84 (br d, J=8.53Hz, 1H), 5.32-5.40 (m, 1H), 3.77 (s, 3H), 2.55-2.71 (m, 2H), 2.29 (q, J=7.53Hz, 2H ), 2.04-2.15(m, 1H), 1.82-1.90(m, 2H), 1.23(t, J=7.65Hz, 3H); ESI-LCMS: m / z=362.0[M+H] + SFC detection method: Column: Chiralcel OD-3, 150×4.6 mm ID, 3 μm; Mobile phase: A: CO2, B: ethanol (0.05% diethylamine), Gradient: B% = 5% to 40% (elution, 4 min), 40% (elution, 2 min), 5% (elution, 2 min); Flow rate: 2.5 mL / min; Column temperature: 35°C; Pressure: 1500 psi. EE = 99.52%, Retention time: 4.686 minutes.
[0350] Example 2
[0351] Synthesis route:
[0352] Step 1: Synthesis of Compound 002-2
[0353] To a reaction flask, a solution of 002-1 (6 g, 26.54 mmol) in 1,4-dioxane (60 mL) was added, along with Lawesson's reagent (7.51 g, 18.58 mmol). The atmosphere was purged with nitrogen, and the mixture was heated to 110°C and stirred for 2 hours. The reaction mixture was concentrated, and 10 mL of dichloromethane was added. The mixture was then concentrated under reduced pressure to afford the crude product. 12 mL of dichloromethane was added to the crude product, stirred for 0.5 hour, and filtered to afford 002-2. 1 H NMR (400MHz, CDCl3) δ = 9.84 (br s, 1H), 7.39-7.31 (m, 2H), 6.81-6.71 (m, 1H), 3.14-3.05 (m, 2H), 2.93-2.83 (m, 2H).
[0354] Step 2: Synthesis of Compound 002-4
[0355] To the reaction flask, 002-2 (540 mg, 2.23 mmol), 002-3 (198.26 mg, 2.68 mmol), and cyclohexanol (10.4 mL) were added. The atmosphere was replaced with nitrogen, and the temperature was raised to 120°C and stirred for 16 hours. 5 mL of water and 10 mL of ethyl acetate were added to the reaction solution for extraction. The organic phase was separated and collected, and the aqueous phase was extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed twice with saturated brine (10 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether: (ethyl acetate / methanol = 5 / 1) = 1:0 to 0:1) to obtain 002-4. 1 H NMR (400MHz, CDCl3) δ = 7.57-7.48 (m, 2H), 7.37 (d, J = 8.5Hz, 1H), 3.19-3.10 (m, 2H), 3.05-2.98 (m, 2H), 2.77 (s, 3H).
[0356] Step 3: Synthesis of Compound 002-5
[0357] To a reaction flask were added 002-4 (475 mg, 1.80 mmol), pinacol diboron (548.02 mg, 2.16 mmol), 1,4-dioxane (10 mL), potassium acetate (529.49 mg, 5.40 mmol), tris(dibenzylideneacetone)dipalladium (164.68 mg, 179.84 μmol), and tricyclohexylphosphine (100.87 mg, 359.68 μmol). After nitrogen displacement, the mixture was heated to 80°C and stirred for 12 hours. 10 mL of saturated brine and 20 mL of ethyl acetate were added to the reaction solution for extraction. The organic phase was separated and collected, and the aqueous phase was extracted three times with ethyl acetate (20 mL each). The organic phases were combined and washed three times with saturated brine (20 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography [petroleum ether: (ethyl acetate / methanol = 5 / 1) = 1:0 to 0:1] to give 002-5. 1 H NMR (400MHz, CD3OD) δ=7.84-7.78 (m, 2H), 7.68 (d, J=8.5Hz, 1H), 3.12-3.03 (m, 4H), 2.78 (s, 3H), 1.36 (s, 12H); ESI-LCMS: m / z=312.2[M+H] + .
[0358] Step 4: Synthesis of compounds 002 and 003
[0359] 002-5 (56.92 mg, 127.13 μmol), A-1 (30 mg, 105.95 μmol), ethanol (1.6 mL), and a solution of sodium carbonate (12.35 mg, 116.54 μmol) in water (0.3 mL) were added sequentially to a reaction flask. The atmosphere was purged with nitrogen, and tetrakis(triphenylphosphine)palladium (3.67 mg, 3.18 μmol) was added. The atmosphere was purged with nitrogen, and the mixture was heated to 85°C and stirred for 12 hours. The reaction solution was concentrated to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1). Chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm x 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; ethanol (0.1% ammonia water): 30%, isocratic elution) afforded 002 and 003. The ee value was then measured using the SFC detection method: chromatographic column: Chiralpak AD-3, 150×4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2 B: ethanol (0.2% 7 M ammonia in methanol; gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi).
[0360] Compound 002: ESI-LCMS: m / z = 388.3 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ = 8.55 (s, 1H), 8.32 (s, 1H), 7.57 (d, J = 9.0Hz, 1H), 7.32-7.29 (m, 2H), 5.73-5.66 (1m, 1H), 5.41 -5.34 (m, 1H), 3.22-3.16 (m, 2H), 3.10-3.04 (m, 2H), 2.82 (s, 3H), 2.71-2.55 (m, 2H), 2.30 (q, J=7.6Hz, 2H), 2.10 (br t, J = 5.1 Hz, 1H), 1.90-1.78 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H); ee = 100%, retention time: 3.778 min.
[0361] Compound 003: ESI-LCMS: m / z = 388.3 [M+H] + ; 1H NMR (400MHz, CDCl3) δ = 8.55 (s, 1H), 8.32 (s, 1H), 7.57 (d, J = 9.0Hz, 1H), 7.32-7.29 (m, 2H), 5.73-5.66 (m, 1H), 5.41 -5.34 (m, 1H), 3.22-3.16 (m, 2H), 3.10-3.04 (m, 2H), 2.82 (s, 3H), 2.71-2.55 (m, 2H), 2.30 (q, J=7.6Hz, 2H), 2.10 (br t, J = 5.1 Hz, 1H), 1.90-1.78 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H); ee = 99.86%, retention time: 4.024 min.
[0362] Example 3
[0363] Synthesis route:
[0364] Step 1: Synthesis of Compound 004-2
[0365] To a reaction flask, add 002-2 (2 g, 8.26 mmol), 004-1 (1.48 g, 12.39 mmol), silver acetate (2.76 g, 16.52 mmol, 846.06 μL), and acetonitrile (20 mL). Stir at 25°C for 12 hours. Filter the reaction mixture, and rinse the filter cake with 10 mL of acetonitrile. Collect the filtrate and concentrate to obtain crude 004-2. 1 H NMR (400MHz, CDCl3) δ=7.35 (br d, J=8.3Hz, 1H), 7.29 (br s, 1H), 7.13 (d, J=8.4Hz, 1H), 3.51 (s, 2H), 3.26 (s, 6H), 3.22 (s, 4H), 1.42 (s, 3H).
[0366] Step 2: Synthesis of Compound 004-3
[0367] 004-2 (3 g, 9.17 mmol), hydrochloric acid (12 M, 15 mL), and water (5 mL) were added to a reaction flask and stirred at 80°C for 5 hours. Saturated sodium bicarbonate solution was added dropwise to the reaction solution to adjust the pH to 7-8. The solution was extracted three times with dichloromethane (10 mL each time). The organic phase was separated and collected. The crude product was concentrated to obtain the product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 0:1) to obtain 004-3. 1H NMR (400MHz, CDCl3) δ=7.47 (d, J=2.0Hz, 1H), 7.46-7.41 (m, 1H), 7.38-7.33 (m, 1H), 6.79 (s, 1H), 3.07-2.91 (m, 4H), 2.51 (s, 3H).
[0368] Step 3: Synthesis of Compound 004-4
[0369] To a reaction flask were added 004-3 (230 mg, 874.08 μmol), pinacol diboronate (443.93 mg, 1.75 mmol), potassium acetate (257.35 mg, 2.62 mmol), tricyclohexylphosphine (49.02 mg, 174.82 μmol), tris(dibenzylideneacetone)dipalladium (80.04 mg, 87.41 μmol), and 1,4-dioxane (7.5 mL). After nitrogen displacement, the mixture was stirred at 80°C for 16 hours. Water (10 mL) and ethyl acetate (5 mL) were added to the reaction solution, which was filtered. The filtrate was extracted three times with ethyl acetate (5 mL each). The organic phases were separated, combined, washed with saturated brine (5 mL), and collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 004-4. ESI-LCMS: m / z = 311.4 [M+H] + .
[0370] Step 4: Synthesis of Compound 004
[0371] 004-4 (65.73 mg, 211.89 μmol), A-1 (40 mg, 141.26 μmol), ethanol (3.2 mL), and a solution of sodium carbonate (16.47 mg, 155.39 μmol) in water (0.52 mL) were added sequentially to a reaction flask. The atmosphere was purged with nitrogen, and then tetrakistriphenylphosphine palladium (4.90 mg, 4.24 μmol) was added. The atmosphere was purged with nitrogen, and the mixture was stirred at 85°C for 12 hours. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative thin-layer chromatography (ethyl acetate:methanol = 1:1) and then chiral separation (column: DAICEL CHIRALPAK AD (250 mm x 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 30% isopropanol (0.1% ammonia)) to obtain 004.
[0372] ESI-LCMS: m / z = 387.3 [M+H] + ; 1HNMR (400 MHz, CDCl3) δ = 8.53 (s, 1H), 8.33 (s, 1H), 7.57 (br d, J = 8.5 Hz, 1H), 7.26-7.22 (m, 2H), 6.84 (br s, 1H), 5.79-5.65 (m, 1H), 5.41-5.31 (m, 1H), 3.14-2.99 (m, 4H), 2.76-2.62 (m, 2H), 2.58 (s, 3H), 2.29 (q, J = 7.2 Hz, 2H), 2.14-2.06 (m, 1H), 1.86-1.78 (m, 3H), 1.23 (brt, J = 7.5 Hz, 3H); SFC detection method: Chromatographic column: Chiralpak AD-3, 150×4.6 mm ID, 3 μm; mobile phase: A: CO2B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B=90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi: ee=100%, retention time: 4.144 minutes.
[0373] Example 4
[0374] Synthesis route:
[0375] Step 1: Synthesis of Compound 005-1
[0376] A-1 (0.1 g, 353.15 μmol), methoxyamine hydrochloride (38.34 mg, 459.1 μmol), phosphorus oxychloride (119.12 mg, 776.94 μmol), and toluene (1 mL) were added to a reaction flask and stirred at 90°C for 10 hours. The reaction solution was concentrated, and the concentrate was slowly poured into water (2 mL). Saturated aqueous sodium carbonate solution was added dropwise to adjust the pH to 9-10. The product was extracted three times with dichloromethane (2 mL each). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 005-1. 1 H NMR (400MHz, CDCl3) δppm 8.56(s, 1H), 8.49(s, 1H), 5.31(s, 1H), 4.53-4.62(m, 1H), 3.75(s, 3H), 2.72-2.80(m, 2H), 2 .38 (qd, J=7.48, 3.69Hz, 2H), 1.97-2.07 (m, 2H), 1.77-1.91 (m, 2H), 1.28 (t, J=7.50Hz, 3H).
[0377] Step 2: Synthesis of compounds 005 and 006
[0378] 005-1 (100 mg, 320.30 μmol), 005-2 (110.37 mg, 384.36 μmol), ethanol (4.5 mL), water (1.5 mL), and sodium carbonate (37.34 mg, 352.33 μmol) were added sequentially to a reaction flask, and the atmosphere was replaced with nitrogen. Tetrakistriphenylphosphine palladium (11.10 mg, 9.61 μmol) was then added, and the atmosphere was replaced with nitrogen. The mixture was stirred at 85°C for 12 hours. The reaction mixture was filtered, the filter cake was rinsed with dichloromethane (5 mL), and the filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 0:1), preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase: [water (10mM ammonium bicarbonate)-acetonitrile]; gradient: acetonitrile%: 20%-50%), and chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250mm*30mm, 10μm); mobile phase: [A: supercritical carbon dioxide-B: isopropanol (0.1% ammonia water)]; isocratic elution: 35% B) to obtain 005 and 006. The SFC detection method was then used: (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: methanol [0.2% 7 M ammonia in methanol]; gradient: A:B=60:40; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi).
[0379] Compound 005: 1 H NMR (400MHz, CDCl3) δppm 8.62 (s, 1H), 8.33 (s, 1H), 7.14-7.25 (m, 1H), 7.00-7.14 (m, 2H), 5.34 (br d, J=10.13Hz, 1H), 4.66 (br s, 1H), 3.73-3.81 (m, 3H), 3.41 (s, 3H), 2.91-3.00 (m, 2H), 2.72 (br t, J=7.32Hz, 3H), 2.33-2.45 (m, 2H), 2.11 (br s, 1H), 1.89 (br d, J=7.00Hz, 1H), 1.74-1.87 (m, 3H), 1.30 (t, J=7.44Hz, 3H). ESI-LCMS: m / z=393.2[M+H] + ; ee=99.98%, retention time: 0.805 min.
[0380] Compound 006: 1H NMR (400MHz, CDCl3) δppm 8.59 (br s, 1H), 8.22-8.37 (m, 1H), 7.17-7.21 (m, 1H), 7.05-7.11 (m, 2H), 5.34 (br d, J=10.39Hz, 1H), 4.60-4.66 (m, 1H), 3.76 (s, 3H), 3.41 (s, 3H), 2.96 (t, J=7.42Hz, 2H), 2.69-2.75 (m, 3H), 2.36-2.42 (m, 2H), 2.08 (br dd, J=6.99, 1.92Hz, 1H), 1.85-1.89 (m, 1H), 1.74-1.83 (m, 3H), 1.29-1.32 (m, 3H); ESI-LCMS: m / z=393.2[M+H] + ; ee=100%, retention time: 0.510 min.
[0381] Example 5
[0382] Synthesis route:
[0383] Step 1: Synthesis of Compound 007-3
[0384] 007-1 (3 g, 12.49 mmol) and tetrahydrofuran (15 mL) were added to a reaction flask. The nitrogen atmosphere was purged, the temperature was lowered to 0°C, and lithium bis(trimethylsilyl)amide (1 M, 14.99 mL) was added dropwise. The mixture was stirred at 0°C for 1 hour. A solution of 007-2 (5.38 g, 37.48 mmol) in tetrahydrofuran (9 mL) was slowly added dropwise. The mixture was stirred at 0°C for 1 hour. The mixture was then heated to 25°C and stirred for 1 hour. Saturated aqueous ammonium chloride (30 mL) was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate (20 mL each). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 6:1) to obtain 007-3. 1 H NMR (400MHz, CDCl3) δ=7.39 (dd, J=2.2, 8.6Hz, 1H), 7.25-7.21 (m, 1H), 6.85 (d, J=8.6Hz, 1H), 3.34 (s, 3H), 2.79 (s, 2H), 1.33-1.28 (m, 2H), 0.76-0.68 (m, 2H).
[0385] Step 2: Synthesis of Compound 007-4
[0386] To the reaction flask were added 007-3 (190 mg, 713.93 μmol), bis(pinacolato)diboron (271.94 mg, 1.07 mmol), 1,4-dioxane (4 mL), and potassium acetate (140.13 mg, 1.43 mmol). The atmosphere was purged with nitrogen, and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride in dichloromethane (58.30 mg, 71.39 μmol) was added. The mixture was stirred at 80°C for 16 hours. Water (2 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (2 mL each). The organic phases were combined, washed with saturated brine (2 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 10:1) to obtain 007-4. 1 H NMR (400MHz, CDCl3) δ=7.73 (d, J=8.1Hz, 1H), 7.55 (s, 1H), 6.99 (d, J=8.1Hz, 1H) , 3.37(s, 3H), 2.81(s, 2H), 1.35(s, 12H), 1.31-1.27(m, 2H), 0.74-0.66(m, 2H).
[0387] Step 3: Synthesis of Compound 007
[0388] A-1 (100 mg, 353.15 μmol), 007-4 (132.73 mg, 423.78 μmol), ethanol (8.5 mL), and a solution of sodium carbonate (41.17 mg, 388.47 μmol) in water (1.42 mL) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (12.24 mg, 10.59 μmol) was added. The mixture was stirred at 85°C for 2 hours. Water (2 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (2 mL each). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (ethyl acetate:methanol=10:1) and chiral separation (chiral column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% aqueous ammonia)]; isocratic elution: 40% isopropanol (0.1% aqueous ammonia)) to obtain 007. 1H NMR (400MHz, CDCl3) δ=8.51 (s, 1H), 8.31 (s, 1H), 7.20 (dd, J=1.6, 8.4Hz, 1H), 7.08-7.01 (m, 2H), 5.85 (br d, J=8.3Hz, 1H), 5.39-5.29 (m, 1H), 3.40 (s, 3H), 2.86 (s, 2H), 2.69 (td, J=6.0, 15.7Hz, 2H), 2.30 (q, J=7.5 Hz, 2H), 2.16-2.05 (m, 1H), 1.92-1.83 (m, 3H), 1.38-1.31 (m, 2H), 1.23 (t, J=7.6Hz, 3H), 0.79-0.72 (m, 2H). ESI-LCMS: m / z=390.2[M+H] + SFC detection method: (Chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; Mobile phase: A: Co2, B: isopropanol [0.2% 7 M ammonia in methanol]; Gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); Flow rate: 3.4 mL / min; Column temperature: 35°C; Pressure: 1800 psi). ee = 100%, Retention time: 1.465 min.
[0389] Example 6
[0390] Synthesis route:
[0391] Step 1: Synthesis of Compound 008-3
[0392] To a reaction flask, 008-1 (0.2 g, 1.23 mmol), N,N-dimethylformamide (4 mL), cesium carbonate (1.09 g, 3.33 mmol), and potassium iodide (20.50 mg, 123.47 μmol) were added sequentially. 008-2 (206.19 mg, 1.23 mmol) was added dropwise to the reaction flask with stirring. The atmosphere was replaced with nitrogen and stirred at 20°C for 2 hours. Water (5 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL). The aqueous phase was collected. Aqueous citric acid solution was added to the aqueous phase to adjust the pH to 3-4, and ethyl acetate was added to extract the mixture three times (5 mL each). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 008-3. 1H NMR (400MHz, DMSO-d6) δ = 11.02-10.68 (m, 1H), 5.68 (s, 1H), 4.20 (t, J = 7.1Hz, 2H), 2.78 (t, J = 7.1Hz, 2H).
[0393] Step 2: Synthesis of Compound 008-4
[0394] To the reaction flask were added 008-3 (180 mg, 833.20 μmol), N,N-dimethylformamide (3 mL), cesium carbonate (325.77 mg, 999.84 μmol), and iodomethane (473.05 mg, 3.33 mmol) in sequence. The atmosphere was replaced with nitrogen, and the mixture was stirred at 25°C for 12 hours. 5 mL of water and 10 mL of ethyl acetate were added to the reaction solution, and the organic phase was separated and collected. The aqueous phase was extracted three times with ethyl acetate (30 mL each time). The organic phases were combined and washed twice with saturated brine (30 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 008-4. 1 H NMR (400MHz, CDCl3) δ=5.78 (s, 1H), 4.29 (t, J=7.1Hz, 2H), 3.24 (s, 3H), 2.94 (t, J=7.1Hz, 2H).
[0395] Step 3: Synthesis of Compound 008
[0396] To a reaction flask were added 008-4 (28.28 mg, 122.94 μmol), water (0.7 mL), acetonitrile (2.1 mL), methanol (0.7 mL), potassium carbonate (67.96 mg, 491.77 μmol), and 2-dicyclohexylphosphine-2′,6′-dimethoxybiphenyl (7.57 mg, 18.44 μmol). The atmosphere was purged with nitrogen. Bistriphenylphosphine palladium dichloride (4.31 mg, 6.15 μmol) and palladium acetate (1.38 mg, 6.15 μmol) were added. The atmosphere was purged with nitrogen. A solution of the crude product A-2 (prepared according to the synthesis method of Reference Example 2, used immediately, with the theoretical yield of 61 mg, 245.88 μmol) was added dropwise at 40°C and stirred at 75°C for 12 hours. The reaction solution was filtered, and the filtrate was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane: methanol = 3:1) and chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [A: supercritical carbon dioxide-B: methanol]; isocratic elution: 45% methanol) to obtain 008.
[0397] 1H NMR (400MHz, CDCl3) δ = 8.62-8.57 (m, 1H), 8.53-8.48 (m, 1H), 5.93 (s, 1H), 5.85-5.75 (m, 1 H), 5.39-5.27 (m, 1H), 4.40 (t, J=7.1Hz, 2H), 3.34 (s, 3H), 3.02 (t, J=7.1Hz, 3H), 2.30 (br d, J=7.6Hz, 2H), 2.22-2.00 (m, 2H), 1.87 (br s, 2H), 1.22 (br t, J=6.8Hz, 3H); ESI-LCMS: m / z 354.2[M+H] + SFC detection method: Column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; Mobile phase: A: supercritical CO2; B: methanol [0.2% 7 M ammonia in methanol]; Gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); Flow rate: 3.4 mL / min; Column temperature: 35°C; Pressure: 1800 psi. EE = 99.02%, Retention time: 1.532 minutes.
[0398] Example 7
[0399] Synthesis route:
[0400] Step 1: Synthesis of Compound 009-3
[0401] To a reaction flask, 009-1 (2 g, 7.04 mmol), 009-2 (2.44 g, 14.09 mmol), cesium carbonate (4.59 g, 14.09 mmol), toluene (20 mL), and 1,10-phenanthroline (253.91 mg, 1.41 mmol) were added sequentially. The atmosphere was purged with nitrogen, and cuprous iodide (134.17 mg, 704.49 μmol) was added. The mixture was stirred at 110°C for 24 hours. 20 mL of water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (50 mL each). The organic phases were combined and washed three times with saturated brine (50 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 009-3. 1H NMR (400MHz, CDCl3) δ=8.35 (d, J=1.8Hz, 1H), 8.11 (d, J=2.6Hz, 1H), 7.23 (t, J=2.2Hz, 1H), 4. 95-4.86 (m, 1H), 4.34 (ddd, J=0.8, 6.4, 9.8Hz, 2H), 4.02 (dd, J=3.9, 10.4Hz, 2H), 1.46 (s, 9H).
[0402] Step 2: Synthesis of Compound 009-4
[0403] 009-3 (60 mg, 182.27 μmol), dichloromethane (1 mL), and trifluoroacetic acid (5.38 mmol, 0.4 mL) were added to the reaction flask in sequence, and stirred at 20° C. for 1 hour. The reaction solution was concentrated to obtain 009-4. 1 H NMR (400MHz, CDCl3) δ = 8.56-8.33 (m, 2H), 8.04 (br s, 1H), 5.43 (br d, J = 1.3Hz, 1H), 4.71 (br s, 2H), 4.37 (br s, 2H), 3.49-3.41 (m, 1H).
[0404] Step 3: Synthesis of Compound 009-6
[0405] To the reaction flask were added 009-4 (60 mg, 261.92 μmol), 009-5 (50.52 mg, 392.89 μmol), dichloromethane (1 mL), and N,N-diisopropylethylamine (67.70 mg, 523.85 μmol) in sequence, and the mixture was stirred at 25°C for 12 hours. Water (1 mL) and dichloromethane (1 mL) were added to the reaction solution, and the mixture was separated. The organic phase was collected, and the aqueous phase was extracted three times with dichloromethane (1 mL each time). The combined organic phases were washed twice with saturated brine (1 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 009-6. 1 H NMR (400MHz, DMSO-d6) δ = 8.36 (d, J=1.5Hz, 1H), 8.27 (d, J=2.4Hz, 1H), 7.66 (t, J=2.1Hz, 1H), 5.23-5.13 (m, 1H), 4.33 (dd, J=6.5, 9.7Hz, 2H), 3.92 (dd, J=4.5, 9.8Hz, 2H), 3.22-3.14 (m, 2H), 1.23 (t, J=7.3Hz, 3H).
[0406] Step 4: Synthesis of Compound 009
[0407] To the reaction flask were added 002-5 (48.51 mg, 108.35 μmol), 009-6 (29 mg, 90.29 μmol), ethanol (2.4 mL), and an aqueous solution (0.39 mL) of sodium carbonate (10.53 mg, 99.32 μmol). The atmosphere was purged with nitrogen, and then tetrakistriphenylphosphine palladium (3.13 mg, 2.71 μmol) was added. The atmosphere was purged with nitrogen, and the mixture was stirred at 85°C for 12 hours. The reaction solution was concentrated to obtain a crude product. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 009. 1 H NMR (400MHz, CDCl3) δ = 8.54 (s, 1H), 8.18 (d, J = 2.3Hz, 1H), 7.63-7.59 (m, 1H), 7 .59-7.55(m, 2H), 7.29-7.27(m, 1H), 5.12-5.06(m, 1H), 4.36(dd, J=6.5, 9.4Hz , 2H), 4.19 (dd, J=4.8, 9.4Hz, 2H), 3.24-3.17 (m, 2H), 3.14-3.08 (m, 2H), 3.04 ( q, J=7.4Hz, 2H), 2.83 (s, 3H), 1.40 (t, J=7.4Hz, 3H); ESI-LCMS: m / z=426.1[M+H] + .
[0408] Example 8
[0409] Synthesis route:
[0410] Step 1: Synthesis of compound 010-2
[0411] To the reaction flask were added 010-1 (3 g, 13.16 mmol), pinacol diboronate (5.08 g, 20.02 mmol), potassium acetate (2.01 g, 20.45 mmol), and dioxane (90 mL) in sequence. The nitrogen atmosphere was replaced, and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride in dichloromethane (512.73 mg, 627.85 μmol) was added. The mixture was stirred at 100°C for 4 hours. 50 mL of water and 50 mL of dichloromethane were added to the reaction solution, and the mixture was extracted and separated. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain 010-2. ESI-LCMS: m / z = 276.1 [M+H] + Step 2: Synthesis of compound 010-3
[0412] To the reaction flask were added 010-2 (2.0 g, 7.27 mmol), N,N-dimethylformamide (15 mL), potassium carbonate (3.01 g, 21.81 mmol), and iodomethane (1.50 g, 10.54 mmol) in sequence, and stirred at 25°C for 16 hours. 10 mL of water and 15 mL of dichloromethane were added, and the mixture was extracted. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford 010-3. ESI-LCMS: m / z = 290.1 [M+H] + .
[0413] Step 3: Synthesis of compounds 010 and 011
[0414] To the reaction flask, crude 010-3 (0.1 g, 345.86 μmol), A-1 (97.94 mg, 345.86 μmol), ethanol (2 mL), water (0.4 mL), and sodium carbonate (36.66 mg, 345.86 μmol) were added in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (19.98 mg, 17.29 μmol) was added. The mixture was stirred at 80°C for 2 hours. 5 mL of water and 5 mL of dichloromethane were added to the reaction solution, and the mixture was extracted and separated. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (dichloromethane:methanol=20:1) followed by chiral separation (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: supercritical carbon dioxide-ethanol (0.1% aqueous ammonia)); isocratic elution: 45% ethanol (0.1% aqueous ammonia)) to afford 010 and 011. The ee value was then determined using SFC (column: Chiralpak AD-350×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: ethanol (0.05% diethylamine); gradient: 40% B; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1500 psi).
[0415] Compound 010: 1 H NMR (400MHz, CDCl3) δ = 8.43 (s, 1H), 8.21 (s, 1H), 7.03-6.93 (m, 1H), 6.92-6.82 (m, 2H), 5.65 (br d, J=8.5Hz, 1H), 5.39-5.11(m, 1H), 4.61(s, 2H), 3.34(s, 3H), 2.69-2.47(m, 2H), 2.29-2.14( q, J=7.7Hz, 2H), 2.06-1.92 (m, 1H), 1.84-1.69 (m, 3H), 1.19-1.07 (t, J=7.7Hz, 3H); ESI-LCMS: m / z=366.1[M+H]+ ; ee=96.72%, retention time: 0.582 min.
[0416] Compound 011: 1 H NMR (400MHz, CDCl3) δ = 8.41 (br s, 1H), 8.17 (br s, 1H), 7.04-6.70 (m, 3H), 5.87 (br s, 1H), 5.26 (br s, 1H), 4.59 (br s, 2H), 3.34 (s, 3H), 2.56 (br s, 2H), 2.20 (br s, 2H), 1.99 (br s, 4H), 1.14 (br s, 3H); ESI-LCMS: m / z=366.1[M+H] + ; ee=99.98%, retention time: 2.351 minutes.
[0417] Example 9
[0418] Synthesis route:
[0419] Step 1: Synthesis of Compound 012-2
[0420] To the reaction flask, 010-1 (2.0 g, 8.77 mmol) and toluene (100 mL) were added sequentially. The nitrogen atmosphere was replaced, and Lawesson's reagent (7.09 g, 17.54 mmol) was added. The mixture was stirred at 110°C for 16 hours. 50 mL of water and 50 mL of ethyl acetate were added to the reaction solution, and the mixture was extracted and separated. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. 012-2 was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 4:1) to obtain 012-2. 1 H NMR (400MHz, CDCl3) δ=9.61 (br s, 1H), 7.19 (s, 1H), 7.13 (dd, J=1.9, 8.4Hz, 1H), 6.77 (d, J=8.5Hz, 1H), 4.90 (s, 2H).
[0421] Step 2: Synthesis of Compound 012-4
[0422] To the reaction flask, 012-2 (1.0 g, 4.10 mmol), 002-3 (364.17 mg, 4.92 mmol), and cyclohexanol (5 mL) were added sequentially and stirred at 120°C for 16 hours. The reaction solution was concentrated to obtain a crude product, which was isolated and purified by column chromatography (dichloromethane:methanol = 20:1) to obtain 012-4.
[0423] Step 3: Synthesis of Compound 012-5
[0424] To the reaction flask, 012-4 (0.3 g, 1.13 mmol), pinacol diboron (429.44 mg, 1.69 mmol), and 1,4-dioxane (10 mL) were added sequentially. The nitrogen atmosphere was replaced, and potassium acetate (171.50 mg, 1.75 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium in dichloromethane (46.03 mg, 56.37 μmol) were added. The mixture was stirred at 100°C for 16 hours. The reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol=20:1) to obtain 012-5. ESI-LCMS: m / z=314.1 [M+H] + .
[0425] Step 4: Synthesis of compounds 012 and 013
[0426] To the reaction solution were added 012-5 (0.1 g, 319.33 μmol), A-1 (90.42 mg, 319.33 μmol), ethanol (5 mL), water (1 mL), and sodium carbonate (33.85 mg, 319.33 μmol) in sequence, the atmosphere was replaced with nitrogen, and tetrakistriphenylphosphine palladium (18.45 mg, 15.97 μmol) was added. The mixture was stirred at 80°C for 1 hour. The reaction solution was concentrated, and 50 mL of water and 50 mL of dichloromethane were added for extraction. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 20:1) followed by chiral separation (column: DAICEL CHIRALPAK IF (250 mm x 30 mm, 10 μm); mobile phase: [A: n-hexane, B: isopropanol / acetonitrile = 4:1]; isocratic elution with 100% B) to afford 012 and 013. The ee value was then determined using SFC (column: Chiralpak IF 100 x 4.6 mm, 3 μm; mobile phase: A: n-hexane (0.1% diethylamine), B: isopropanol / acetonitrile = 2:1, elution gradient: A / B = 20:8; flow rate: 1 mL / min, column temperature: 35°C).
[0427] Compound 012: ESI-LCMS: m / z = 390.1 [M+H] + ; 1H NMR (400 MHz, CDCl3) δ = 8.46 (s, 1H), 8.22 (s, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 1.8 Hz, 1H), 7.00 (dd, J = 2.0, 8.3 Hz, 1H), 5.77 (br d, J = 8.5 Hz, 1H), 5.28 (s, 3H), 2.77 (m, 3H), 2.65-2.44 (m, 2H), 2.22 (q, J = 7.7 Hz, 2H), 2.08-1.96 (m, 1H), 1.84-1.76 (m, 3H), 1.15 (t, J = 7.5 Hz, 3H); ee = 99.87%, retention time: 3.245 minutes.
[0428] Compound 013: 1 H NMR (400MHz, CDCl3) δ=8.48 (s, 1H), 8.24 (s, 1H), 7.53 (d, J=8.3Hz, 1H), 7.07 (d, J=1.8Hz, 1H), 7.03-6.94 (m, 1H), 5.65 (br d, J=8.0Hz, 1H), 5.29 (s, 3H), 2.77 (s, 3H), 2.68-2.47 (m, 2H), 2.22 (q, J=7.5Hz, 2H), 2.09-1.89 (m, 1H), 1.85-1.69 (m, 3H), 0.77 (br s, 3H); ESI-LCMS: m / z=390.1[M+H] + ; ee=98.44%, retention time: 2.328 minutes.
[0429] Example 10
[0430] Synthesis route:
[0431] Step 1: Synthesis of Compound 014-2
[0432] 014-1 (120.00 mg, 761.64 μmol), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (196.15 mg, 1.52 mmol), and 2-(7-azobenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (577.06 mg, 1.52 mmol) were added sequentially to a reaction flask. After stirring at 25°C for 5 minutes, the hydrochloride salt of A-1-5 (200 mg) was added and stirred at 25°C for 16 hours. 25 mL of water was added to the reaction solution, which was transferred to a separatory funnel and extracted three times with 20 mL of ethyl acetate. The organic phases were combined, washed with saturated brine, collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 014-2. 1 H NMR (400MHz, CDCl3) δppm 8.58 (s, 1H), 8.53 (s, 1H), 8.43 (d, J=3.26Hz, 1H), 8.18 (br s, 1H), 7.86 (d, J=8.28Hz, 1H), 7.39 (dd, J=8.16, 4.39Hz, 1H), 5.40-5.48 (m, 1H), 2.72-2.92 (m, 2H), 1.95-2.17 (m, 4H).
[0433] Step 2: Synthesis of Compound 014
[0434] 014-2 (204 mg, 556.40 μmol), 001-3 (317.32 mg, 1112.8 μmol), ethanol (10 mL), sodium carbonate (117.95 mg, 1.11 mmol), and water (2 mL) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (64.3 mg, 55.64 μmol) was added. The reaction solution was stirred at 80°C for 20 hours. 40 mL of semi-saturated brine was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed with 40 mL of saturated brine. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (dichloromethane:methanol=20:1) and chiral separation [chromatographic column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; isocratic elution: 30% ethanol (0.1% ammonia water)] to afford 014, which was then detected by SFC (chromatographic column: Chiralcel OJ-350*4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2, B: ethanol (0.05% diethylamine); gradient (B%): 5%-40% (0-2 min), 40% (hold 1.2 min), 5% (hold 0.8 min); flow rate: 3 mL / min; column temperature: 35°C; column pressure: 1500 psi): ee=100%, retention time 1.834 min. ESI-LCMS: m / z = 445.0 [M+H] + ; 1 H NMR (400MHz, CDCl3) δppm 8.64 (s, 1H), 8.44 (dd, J=4.52, 1.26Hz, 1H), 8.35 (s, 1H), 8.21 (br d, J=8.53Hz, 1H), 7.87 (dd, J=8.16, 1.38Hz, 1H), 7.71 (d, J=9.54Hz, 1H), 7.50-7.55 (m, 2H), 7.44-7.50 (m, 1H), 7.40 (dd, J=8.03, 4.52Hz, 1H), 6.79 (d, J = 9.54Hz, 1H), 5.49-5.56 (m, 1H), 3.78 (s, 3H), 2.60-2.77 (m, 2H), 2.16-2.25 (m, 1H), 1.99-2.08 (m, 1H), 1.82-1.93 (m, 2H).
[0435] Example 11
[0436] Synthesis route:
[0437] Step 1: Synthesis of compound 015-2
[0438] 015-1 (192.76 mg, 1.37 mmol), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (514.89 mg, 3.98 mmol), 1-hydroxybenzotriazole (76.90 mg, 569.13 μmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (109.10 mg, 569.13 μmol) were added sequentially to a reaction flask. The mixture was stirred at 25°C for 5 minutes, and the hydrochloride salt of A-1-5 (300 mg) was added. The reaction solution was stirred at 25°C for 16 hours. 25 mL of water was added to the reaction solution, which was transferred to a separatory funnel and extracted three times with 20 mL of ethyl acetate. The organic phases were combined and washed sequentially with semi-saturated brine and saturated brine (40 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 015-2.
[0439] Step 2: Synthesis of Compound 015
[0440] To the reaction flask, 015-2 (124 mg, 354.07 μmol), 001-3 (201.92 mg, 708.15 μmol), ethanol (5 mL), sodium carbonate (112.58 mg, 1.06 mmol), water (1 mL) were added in sequence, nitrogen was replaced, tetrakistriphenylphosphine palladium (40.92 mg, 35.41 μmol) was added, and the reaction solution was stirred at 85 ° C for 16 hours. 20 mL of semi-saturated brine was added to the reaction solution, the reaction solution was transferred to a separatory funnel, and extracted with ethyl acetate three times (10 mL each time). The organic phases were combined, washed with 20 mL of saturated brine, collected, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol=20:1) and chiral separation (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; isocratic elution: 45% ethanol (0.1% ammonia water)) to obtain 015, which was detected by SFC (chromatographic column: Chiralpak AS-350*4.6 mm ID, 3 μm; mobile phase: A: CO2B:ethanol (0.05% diethylamine); gradient (B%): 5%-40% (0-2 min), 40% (hold 1.2 min), 5% (hold 0.8 min); flow rate: 3 mL / min; column temperature: 35°C; column pressure: 1500 psi): ee=100%, retention time 2.383 min. ESI-LCMS: m / z = 429.1 [M+H] + ;1 H NMR (400MHz, CDCl3) δppm 8.60 (s, 1H), 8.34 (s, 1H), 7.69 (d, J=9.54Hz, 1H), 7.42-7.56 (m, 3H), 6.75 (d, J=9.54Hz, 1H), 6.02 (br d, J=8.28Hz, 1H), 5.46-5.57 (m, 1H), 3.76 (s, 3H), 2.58-2.74 (m, 5H), 2.43 (s, 3H), 2.15-2.25 (m, 1H), 1.83-2.01 (m, 3H).
[0441] Example 12
[0442] Synthesis route:
[0443] Step 1: Synthesis of Compound 016
[0444] To the reaction flask were added 009-6 (217 mg, 675.61 μmol), 010-3 (195.34 mg, 675.61 μmol), ethanol (10 mL), sodium carbonate (143.22 mg, 1.35 mmol), and water (2 mL) in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (39.04 mg, 33.78 μmol) was added. The reaction solution was stirred at 80°C for 16 hours. 40 mL of semi-saturated brine was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined, washed with 40 mL of saturated brine, and the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol=20:1) and preparative high-performance liquid chromatography [column: C18 100×40 mm; mobile phase: [water (0.075% trifluoroacetic acid)-acetonitrile]; gradient: 7%-37% acetonitrile] to obtain 016. ESI-LCMS: m / z=404.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δppm 8.55 (s, 1H), 8.18 (d, J=2.26Hz, 1H), 7.22-7.35 (m, 3H), 7.13 (d, J=8.28Hz, 1H), 5.11 (quin, J=5.58Hz, 1H), 4.73 (s, 2H), 4 .34-4.45 (m, 2H), 4.22 (dd, J=9.16, 4.64Hz, 2H), 3.47 (s, 3H), 3.09 (q, J=7.45Hz, 2H), 1.45 (t, J=7.40Hz, 3H).
[0445] Example 13
[0446] Synthesis route:
[0447] Step 1: Synthesis of compound 017-3
[0448] Palladium acetate (480.24 mg, 2.14 mmol), 2-di-tert-butylphosphino-2', 4', 6'-triisopropylbiphenyl (2.04 g, 4.28 mmol) and N, N-dimethylformamide (89 mL) were added to the reaction flask in sequence to replace nitrogen. Then, 017-1 (8.9 g, 42.78 mmol), triethylamine (34.63 g, 342.25 mmol, 47.64 mL) and 017-2 (41.63 g, 256.69 mmol) were added and nitrogen was replaced again. The reaction solution was stirred at 80 ° C for 12 hours. 10 mL of water was added to the reaction solution, which was transferred to a separatory funnel and 20 mL of ethyl acetate was added. The mixture was separated and the aqueous phase was extracted three times with 30 mL of ethyl acetate each time. The organic phases were combined and washed twice with brine (30 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 017-3. 1 H NMR (400MHz, CDCl3) δ=8.49 (d, J=16.1Hz, 1H), 7.48 (d, J=5.6Hz, 1H), 7.46-7.34 (m, 5H), 7.29 (d, J=5.7Hz, 1H), 6.52 (d, J=16.1Hz, 1H), 5.29 (s, 2H).
[0449] Step 2: Synthesis of Compound 017-4
[0450] To the reaction flask, 017-3 (5 g, 17.28 mmol), methanol (175 mL), ammonium chloride (1.02 g, 19.01 mmol), and water (50 mL) were added in sequence. The nitrogen atmosphere was replaced, and iron powder (4.83 g, 86.41 mmol) was slowly added. The reaction solution was stirred at 60 ° C for 2 hours. The reaction solution was cooled to room temperature, water (100 mL) was added, and the reaction solution was transferred to a separatory funnel. 100 mL of dichloromethane was added, extracted, and separated. The organic phase was collected and the aqueous phase was extracted three times with dichloromethane (100 mL each time). The combined organic phases were washed twice with saturated brine (100 mL each time), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 017-4, which was used directly in the next step without further purification. ESI-LCMS: m / z = 260.1 [M+H] + .
[0451] Step 3: Synthesis of Compound 017-5
[0452] To the reaction flask, 017-4 (4 g, 15.42 mmol), tributylphosphine (9.36 g, 46.27 mmol), and methanol (70 mL) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 70°C for 2 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 017-5. 1 H NMR (400MHz, CDCl3) δ=7.88 (d, J=9.3Hz, 1H), 7.11-7.08 (m, 1H), 7.07-7.04 (m, 1H), 6.68 (d, J=9.3Hz, 1H). ESI-LCMS: m / z=152.1[M+H] + .
[0453] Step: 4: Synthesis of compound 017-6
[0454] To a reaction flask, 017-5 (1 g, 6.61 mmol), N,N-dimethylformamide (20 mL), cesium carbonate (2.59 g, 7.94 mmol), and iodomethane (3.76 g, 26.46 mmol) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 25°C for 2 hours. Water (30 mL) was added to the reaction mixture, which was then transferred to a separatory funnel and ethyl acetate (30 mL) was added. Extraction was performed, and the layers were separated. The organic phase was collected, and the aqueous phase was extracted three times with ethyl acetate (30 mL each). The combined organic phases were washed twice with saturated brine (30 mL each), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 017-6. 1 H NMR (400MHz, CD3OD) δ=7.91 (d, J=9.3Hz, 1H), 7.22 (q, J=5.6Hz, 2H), 6.53 (d, J=9.3Hz, 1H), 3.72 (s, 3H).
[0455] Step 5: Synthesis of Compound 017-7
[0456] 017-6 (30 mg, 181.58 μmol) and tetrahydrofuran (0.5 mL) were added sequentially to a reaction flask. The nitrogen atmosphere was replaced three times, the temperature was cooled to -78°C, and lithium tri(2-butyl)borohydride (1 M solution in tetrahydrofuran, 297.80 μL) was added dropwise. The reaction solution was stirred at -78°C for 1 hour, then slowly warmed to 25°C and stirred for 12 hours. Water (1 mL) was added to the reaction solution, which was transferred to a separatory funnel and extracted with 1 mL of dichloromethane. The layers were separated, and the aqueous phase was extracted three times with dichloromethane (1 mL each). The organic phases were combined and washed twice with saturated brine (1 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 017-7. 1 H NMR (400MHz, CDCl3) δ = 6.80-6.77 (m, 1H), 6.76-6.73 (m, 1H), 3.32 (d, J = 2.3Hz, 3H), 2.87-2.81 (m, 2H), 2.75-2.67 (m, 2H).
[0457] Step 6: Synthesis of Compound 017-8
[0458] To the reaction flask, 017-7 (10 mg, 59.80 μmol) and dichloromethane (0.2 mL) were added sequentially. The nitrogen atmosphere was replaced, the reaction temperature was lowered to 0°C, and N-bromosuccinimide (11.71 mg, 65.78 μmol) was added. The reaction solution was stirred at 0°C for 0.5 hours. Water (1 mL) was added to the reaction solution, which was transferred to a separatory funnel and 1 mL of dichloromethane was added. The mixture was separated and the organic phase was collected. The aqueous phase was extracted three times with dichloromethane (1 mL each time). The organic phases were combined and washed twice with saturated brine (1 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 017-8. 1 H NMR (400MHz, CDCl3) δ=6.73 (s, 1H), 3.25 (s, 3H), 2.83-2.75 (m, 2H), 2.70 (d, J=7.6Hz, 2H).
[0459] Step 7: Synthesis of Compound 017
[0460] To the reaction flask were added 017-8 (20 mg, 81.26 μmol), potassium carbonate (44.92 mg, 325.04 μmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (5.00 mg, 12.19 μmol), water (0.4 mL), acetonitrile (1.2 mL), methanol (0.4 mL), and nitrogen was replaced. Bistriphenylphosphine palladium dichloride (2.85 mg, 4.06 μmol) and palladium acetate (912.17 μg, 4.06 μmol) were added in sequence. The nitrogen was replaced and the reaction solution was brought to 40°C. The crude product solution of A-2 (prepared and used according to the synthetic method of Reference Example 2, added according to the theoretical yield, the theoretical yield is 40.32 mg, 162.52 μmol) was added dropwise. After the addition was completed, the reaction solution was heated to 75°C and stirred for 12 hours. The reaction solution was filtered through celite and anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin layer chromatography (developing solvent: ethyl acetate: dichloromethane: methanol = 3:1:0.3) to obtain 017. 1 H NMR (400MHz, CDCl3) δ = 8.59-8.52 (m, 1H), 8.48-8.42 (m, 1H), 6.89 (s, 1H), 6. 40-6.22(m, 1H), 5.37-5.21(m, 1H), 3.35(s, 3H), 3.10-2.99(m, 2H), 2.90(br d, J=8.0Hz, 2H), 2.79(br d, J=7.8Hz, 2H), 2.34(br d, J=7.4Hz, 2H), 2.18(br d, J=2.9Hz, 2H), 1.94-1.90 (m, 2H), 1.23-1.20 (m, 3H); ESI-LCMS: m / z=370.2[M+H] + SFC analysis (method: chromatographic column: (S,S)-WHELK-O1, 100×4.6 mm ID, 3.5 μm; mobile phase: A: CO2, B: ethanol [0.2% 7 M ammonia in methanol]; isocratic: A / B = 40:60; flow rate: 4 mL / min; column temperature: 35°C; pressure: 2000 psi) ee = 94.22%, retention time 2.467 minutes.
[0461] Example 14
[0462] Synthesis route:
[0463] Step 1: Synthesis of compound 018-3
[0464] To the reaction flask were added 018-1 (10 g, 52.63 mmol), dichloromethane (200 mL), and pyridine (5.00 g, 63.15 mmol) in sequence. The nitrogen atmosphere was replaced, and 018-2 (7.79 g, 57.89 mmol) was added. The reaction solution was stirred at 25°C for 3 hours. The reaction solution was concentrated to obtain a crude product, which was then isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 018-3. 1 H NMR (400MHz, CDCl3) δ = 8.30 (t, J = 8.7Hz, 1H), 7.66 (d, J = 12.0Hz, 1H), 7.27-7.23 (m, 2H), 7.10 (br s, 1H), 5.34 (d, J=12.1Hz, 1H), 3.97 (q, J=7.0Hz, 2H), 1.37 (t, J=7.1Hz, 3H).
[0465] Step 2: Synthesis of Compound 018-4
[0466] 98% concentrated sulfuric acid (5 mL) was added to the reaction flask, followed by 018-3 (500 mg, 1.74 mmol). The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 25°C for 3 hours. The temperature was then raised to 80°C and stirred for 1 hour. The reaction mixture was poured into ice water and filtered. The filter cake was washed with water and dried under reduced pressure to obtain crude 018-4. This was used directly in the next reaction without further purification.
[0467] Step 3: Synthesis of Compound 018-5
[0468] To a reaction flask, 018-4 (0.2 g, 826.30 μmol), N,N-dimethylformamide (0.5 mL), and cesium carbonate (538.45 mg, 1.65 mmol) were added sequentially. The atmosphere was replaced with nitrogen. The reaction solution was placed at 0°C, and iodomethane (469.13 mg, 3.31 mmol) was slowly added dropwise. The atmosphere was replaced with nitrogen, and the mixture was stirred at 25°C for 2 hours. 2 mL of water was added to the reaction solution, which was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each). The organic phases were combined and washed three times with saturated brine (3 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 018-5. 1 H NMR (400MHz, CDCl3) δ=7.55 (d, J=9.5Hz, 1H), 7.50-7.37 (m, 2H), 6.76 (d, J=9.5Hz, 1H), 3.90 (d, J=8.4Hz, 3H).
[0469] Step 4: Synthesis of Compound 018-6
[0470] To the reaction flask were added 018-5 (100 mg, 390.52 μmol), dioxane (2 mL), bis-naphthalene boronate (148.75 mg, 585.78 μmol), potassium acetate (114.98 mg, 1.17 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane (15.95 mg, 19.53 μmol) in sequence. The atmosphere was replaced with nitrogen and the reaction solution was stirred at 80°C for 16 hours. The reaction solution was filtered, rinsed with ethyl acetate, and the filtrate was collected and concentrated to give the crude product 018-6, which was used directly in the next step without purification. ESI-LCMS: m / z = 304.2 [M+H] + .
[0471] Step 5: Synthesis of Compound 018
[0472] To the reaction flask were added A-1 (0.05 g, 176.58 μmol), potassium carbonate (97.62 mg, 706.31 μmol), 2-dicyclohexylphosphine-2′, 6′-dimethoxybiphenyl (10.87 mg, 26.49 μmol), bistriphenylphosphine palladium dichloride (6.20 mg, 8.83 μmol), palladium acetate (1.98 mg, 8.83 μmol), water (1.2 mL), acetonitrile (3.6 mL), and methanol (1.2 mL) in sequence. The atmosphere was replaced with nitrogen, and the reaction solution was placed at 40°C. A solution of 018-6 (107.05 mg, 353.15 μmol) in tetrahydrofuran (1.2 mL) was added dropwise, and the reaction solution was heated to 75°C and stirred for 2 hours. The reaction mixture was returned to room temperature, 20 mL of water was added, and the mixture was transferred to a separatory funnel and extracted three times with dichloromethane (30 mL each time). The organic phases were combined and washed three times with saturated brine (30 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was subsequently purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 1:1:0.1) and chiral SFC separation (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical CO2-methanol (0.1% ammonia)]; isocratic elution: 45% methanol (0.1% ammonia)) to obtain 018. 1H NMR (400MHz, CD3OD) δ = 8.41 (s, 1H), 8.26 (s, 1H), 7.95 (dd, J = 1.5, 9.5Hz, 1H), 7.51 ( d, J=1.7Hz, 1H), 7.46 (dd, J=1.9, 15.3Hz, 1H), 6.76 (d, J=9.4Hz, 1H), 5.22 (t, J=5.7 Hz, 1H), 3.96 (d, J=8.0Hz, 3H), 2.83-2.63 (m, 2H), 2.29 (dq, J=1.9, 7.6Hz, 2H), 2.13 -2.00 (m, 1H), 1.94-1.72 (m, 3H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=380.2[M+H] + ; SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6mm ID, 3μm; mobile phase: A: CO2 B: methanol [0.2% 7M ammonia in methanol]; gradient: A / B=95 / 5 (0min), 95 / 5 (0.2min), 50 / 50 (1.2min), 50 / 50 (2.2min), 95 / 5 (2.6min), 95 / 5 (3.0min); flow rate: 3.4mL / min; column temperature: 35℃; column pressure: 1800psi), ee=100%, retention time 1.504 minutes.
[0473] Example 15
[0474] Synthesis route:
[0475] Step 1: Synthesis of compound 019-2
[0476] To the reaction flask, 019-1 (0.96 g, 5.81 mmol) and N,N-dimethylformamide (10 mL) were added. The nitrogen atmosphere was replaced, and the reaction solution was cooled to 0°C. N-bromosuccinimide (1.24 g, 6.97 mmol) was added. After the addition was complete, the reaction solution was stirred at 25°C for 8 hours. Water (20 mL) and saturated aqueous sodium thiosulfate solution (2 mL) were added to the reaction solution, stirred for 10 minutes, filtered, and the filter cake was collected. Dichloromethane (20 mL) was added, and the mixture was transferred to a separatory funnel and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product 019-2, which was used directly in the next reaction without further purification. 1H NMR (400MHz, CDCl3) δppm 8.32 (br s, 1H), 7.34 (d, J=7.03Hz, 1H), 6.61 (d, J=8.94Hz, 1H), 2.95 (t, J=7.57Hz, 2H), 2.59-2.69 (m, 2H).
[0477] Step 2: Synthesis of compound 019-3
[0478] To the reaction flask, 019-2 (1.3 g, 5.33 mmol), N,N-dimethylformamide (13 mL), and cesium carbonate (3.47 g, 10.65 mmol) were added in sequence. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, iodomethane (2.27 g, 15.98 mmol) was added dropwise, and the reaction solution was stirred at 25°C for 1 hour. Water (20 mL) was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined, washed twice with saturated brine (20 mL each time), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product of 019-3, which was directly subjected to the next step without further purification.
[0479] Step 3: Synthesis of Compound 019-4
[0480] To a reaction flask, 019-3 (1.3 g, 5.04 mmol), dichloroethane (26 mL), N-bromosuccinimide (1.34 g, 7.56 mmol), and 2,2-azobisisobutyronitrile (165.42 mg, 1.01 mmol) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 80°C for 2 hours. Water (30 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted with ethyl acetate (30 mL x 2). The organic phases were separated, combined, washed with saturated brine (30 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 30:1 to 3:1) to obtain 019-4. 1 H NMR (400MHz, CDCl3) δppm 7.76 (d, J=7.25Hz, 1H), 7.58 (d, J=9.51Hz, 1H), 7.13 (d, J=10.38Hz, 1H), 6.69 (d, J=9.51Hz, 1H), 3.67 (s, 3H).
[0481] Step 4: Synthesis of Compound 019-5
[0482] To a reaction flask were added 019-4 (500 mg, 1.95 mmol), 1,4-dioxane (20 mL), bis(triisopropyl)-1,1′-biphenylyl)-1,4′-dioxane (743.75 mg, 2.93 mmol), potassium acetate (574.88 mg, 5.86 mmol), and methanesulfonic acid (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenylyl)(2′-amino-1,1′-biphenyl-2-yl) palladium(II) (82.64 mg, 97.63 μmol). The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate:methanol = 10:1 (10 mL). The filtrate was collected and concentrated to give the crude product 019-5, which was directly used in the next step without further purification.
[0483] Step 5: Synthesis of Compound 019
[0484] A-1 (100 mg, 353.15 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), potassium carbonate (195.23 mg, 1.41 mmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (21.75 mg, 52.97 μmol) were added to the reaction flask in sequence, and the nitrogen atmosphere was replaced. Bistriphenylphosphine palladium dichloride (12.39 mg, 17.66 μmol) and palladium acetate (3.96 mg, 17.66 μmol) were added and the nitrogen atmosphere was replaced. The reaction solution was placed at 40°C, and a solution of the crude product of 019-5 (156.09 mg, 706.31 μmol) in tetrahydrofuran (2 mL) was added dropwise. The reaction solution was placed at 75°C and stirred for 2 hours. The reaction mixture was returned to room temperature, and anhydrous sodium sulfate (5 g) was added to the reaction mixture. The mixture was filtered through celite, and the filter cake was washed with ethyl acetate (10 mL). The filtrate was collected and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 1:1:0.1) and chiral separation by SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-methanol (0.1% ammonia)]; isocratic elution: 50% methanol (0.1% ammonia)) to obtain 019. 1H NMR (400 MHz, CD3OD) δ ppm 8.44 (s, 1H), 8.25 (s, 1H), 7.95 (d, J = 9.51Hz, 1H), 7.69 (d, J = 7.88Hz, 1H), 7.52 (d, J=11.88Hz, 1H), 6.69 (d, J=9.38Hz, 1H), 5.24 (t, J=5.75Hz, 1H), 3. 76(s, 3H), 2.54-2.70(m, 2H), 2.29(qd, J=7.61, 2.19Hz, 2H), 2.01-2.10(m, 1H), 1.78-1.95 (m, 3H), 1.20 (t, J=7.63Hz, 3H); ESI-LCMS: m / z=380.2[M+H] + SFC analysis (chromatographic column: Chiralpak AD-3, 150×4.6 mm, ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 50:50; flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi)) ee = 100%, retention time 1.797 minutes.
[0485] Example 16
[0486] Synthesis route:
[0487] Step 1: Synthesis of compound 020-2
[0488] To the reaction solution were added A-1-1 (0.2 g, 880.67 μmol), dichloromethane (10 mL), and N,N-diisopropylethylamine (682.92 mg, 5.28 mmol) in sequence. The atmosphere was replaced with nitrogen, and then 020-1 (140.53 mg, 880.67 μmol) was added. The reaction solution was stirred at 25°C for 1 hour. Water (10 mL) was added to the reaction solution, which was transferred to a separatory funnel and extracted with dichloromethane twice (10 mL each time). The organic phases were separated, combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 3:1) to obtain 020-2. 1 H NMR (400MHz, CDCl3) δppm 8.41-8.71 (m, 2H), 5.97 (br d, J==6.31Hz, 1H), 5.39-5.53 (m, 1H), 2.80-2.86 (m, 2H), 2.63 (s, 3H), 2.42 (s, 3H), 2.12-2.18 (m, 1H), 1.90-1.96 (m, 3H).
[0489] Step 2: Synthesis of Compound 020
[0490] Compound 020-2 (50 mg, 142.77 μmol), water (0.6 mL), acetonitrile (1.8 mL), methanol (0.6 mL), potassium carbonate (78.93 mg, 571.09 μmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (8.79 mg, 21.42 μmol) were added to the reaction flask in sequence, and the nitrogen atmosphere was replaced. Bistriphenylphosphine palladium dichloride (5.01 mg, 7.14 μmol) and palladium acetate (1.60 mg, 7.14 μmol) were added and the nitrogen atmosphere was replaced. The reaction solution was placed at 40°C, and a solution of 019-5 (63.10 mg, 285.54 μmol) in tetrahydrofuran (1 mL) was added dropwise. The reaction solution was raised to 75°C and stirred for 2 hours. The reaction mixture was returned to room temperature, and anhydrous sodium sulfate (5 g) was added to the reaction mixture. The mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate (10 mL). The filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate = 1:1) and chiral SFC separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-methanol (0.1% ammonia)]; isocratic elution: 50% methanol (0.1% ammonia)) to obtain 020. 1 H NMR (400MHz, CD3OD) δppm 8.58 (s, 1H), 8.29 (s, 1H), 7.95 (d, J=9.51Hz, 1H), 7.70 (d, J=7.88Hz, 1H), 7.53 (d, J=11.88Hz, 1H), 6.69 (d, J=9.51Hz, 1H), 5.43 (t, J=6 .50Hz, 1H), 3.76 (s, 3H), 2.60-2.72 (m, 2H), 2.54 (s, 3H), 2.38 (s, 3H), 2.12-2.23 (m, 1H), 1.85-2.02 (m, 3H); ESI-LCMS: m / z=447.3[M+H] + SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%, retention time 1.566 minutes.
[0491] Example 17
[0492] Synthesis route:
[0493] Step 1: Synthesis of compound 021-2
[0494] To a reaction flask, 021-1 (0.3 g, 1.03 mmol), potassium carbonate (283.93 mg, 2.05 mmol), and N,N-dimethylformamide (6 mL) were added sequentially. The nitrogen atmosphere was replaced, and the reaction solution was cooled to 0°C. Methyl iodide (583.21 mg, 4.11 mmol) was added, and the reaction solution was heated to 25°C and stirred for 3 hours. Water (30 mL) was added to the reaction solution, and the solution was extracted three times with ethyl acetate (10 mL each time). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 021-2. 1 H NMR (400MHz, CDCl3) δ=7.97 (s, 1H), 7.76 (dd, J=1.8, 9.0Hz, 1H), 7.34 (d, J=9.0Hz, 1H), 7.14 (s, 1H), 3.74 (s, 3H).
[0495] Step 2: Synthesis of compound 021-3
[0496] To the reaction flask were added 021-2 (100 mg, 326.71 μmol), bis-naphthalene boronate (124.45 mg, 490.07 μmol), potassium acetate (96.19 mg, 980.14 μmol), and 1,4-dioxane (2 mL). The atmosphere was purged of nitrogen, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (26.68 mg, 32.67 μmol) was added. The reaction mixture was stirred at 80°C for 3 hours. The reaction mixture was concentrated to give the crude product 021-3, which was directly carried out in the next step without further purification.
[0497] Step 3: Synthesis of Compound 021
[0498] To the reaction flask were added crude 021-3 (109.75 mg, 310.77 μmol), A-1 (80 mg, 282.52 μmol), sodium carbonate (59.89 mg, 565.04 μmol), water (0.3 mL), and ethanol (1.8 mL) in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (32.65 mg, 28.25 μmol) was added. The reaction solution was stirred at 85 ° C for 2.5 hours. The reaction solution was concentrated to obtain a crude product, which was then separated and purified by preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 5:5:1) and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia aqueous solution)]; isocratic elution: 30% isopropanol (0.1% ammonia aqueous solution)) to obtain 021. 1 H NMR (400MHz, CD3OD) δ = 8.42 (s, 1H), 8.25 (s, 1H), 7.89-7.82 (m, 1H), 7.80-7.73 (m, 2H), 7.17 (s, 1H), 5.24 (t, J = 5.9Hz, 1H), 3.84 (s, 3H), 2.78-2.60 (m, 2H), 2.28 (dq, J=2.0, 7.6Hz, 2H), 2.12-2.00 (m, 1H), 1.95-1.76 (m, 3H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=430.2[M+H] + SFC analysis and detection (chromatographic column: Chiralpak AD-3, 150×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 100%, retention time 3.591 minutes.
[0499] Example 18
[0500] Synthesis route:
[0501] Step 1: Synthesis of compound 022-2
[0502] To the reaction flask were added 022-1 (0.4 g, 1.78 mmol), N,N-dimethylformamide (8 mL), and cesium carbonate (694.95 mg, 2.13 mmol) in sequence. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, and iodomethane (1.01 g, 7.11 mmol) was added dropwise. The reaction solution was stirred at 0°C for 1 hour. Water (10 mL) was added to the reaction solution, and the reaction solution was transferred to a separatory funnel. 10 mL of ethyl acetate was added, and the mixture was extracted. The organic phase was separated and the aqueous phase was collected. The aqueous phase was extracted three times with ethyl acetate (15 mL each time). The organic phases were combined and washed twice with saturated brine (10 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product of 022-2, which was directly used in the next step without further purification. 1 H NMR (400MHz, CDCl3) δ=8.63 (d, J=2.4Hz, 1H), 7.99 (d, J=2.4Hz, 1H), 7.58 (d, J=9.5Hz, 1H), 6.81 (d, J=9.5Hz, 1H), 3.81 (s, 3H).
[0503] Step 2: Synthesis of compound 022-3
[0504] To the reaction flask were added crude 022-2 (0.32 g, 1.34 mmol), 1,4-dioxane (12.8 mL), bis(tris(2-amino-1,1'-biphenyl-2-yl)palladium(II)) (56.65 mg, 66.93 μmol) in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered, the filter cake was rinsed with ethyl acetate, and the filtrate was collected and concentrated to give crude 022-3, which was directly used in the next step without further purification. ESI-LCMS: m / z = 205.1 [M+H] + .
[0505] Step 3: Synthesis of Compound 022
[0506] To a reaction flask were added A-1 (0.14 g, 494.41 μmol), water (1.6 mL), acetonitrile (4.8 mL), methanol (1.6 mL), potassium carbonate (273.33 mg, 1.98 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (30.45 mg, 74.16 μmol). The atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (17.35 mg, 24.72 μmol) and palladium acetate (5.55 mg, 24.72 μmol) were added. The atmosphere was replaced with nitrogen. The reaction mixture was heated to 40°C, and a solution of 022-3 (201.71 mg, 988.83 μmol) in tetrahydrofuran (2.8 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was returned to room temperature, anhydrous sodium sulfate was added, and the mixture was filtered. The filtrate was collected and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 1:1:0.1) and chiral separation by SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol]; isocratic: 55% isopropanol) to obtain 022. 1 H NMR (400MHz, CDCl3) δ=8.61 (s, 1H), 8.56 (d, J=2.3Hz, 1H), 8.35 (s, 1H), 7.82 (d, J=2.3Hz, 1H), 7.69 (d, J=9.5Hz, 1H), 6.85 (d, J=9.4Hz, 1H), 5.83 (br d, J=8.5Hz, 1H), 5.44-5.31 (m, 1H), 3.89 (s, 3H), 2.76-2.60 (m, 2H), 2.31 (q, J=7.5Hz, 2H), 2.17-2.09 (m, 1H), 1.93 (br s, 6H), 1.24 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=363.2[M+H] + ; SFC analysis and detection: (chromatographic column: Chiralpak IG-3, 50×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B=95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee=100%, retention time 2.145 minutes.
[0507] Example 19
[0508] Synthesis route:
[0509] Step 1: Synthesis of Compound 023-1
[0510] To the reaction flask, 017-6 (75 mg, 410.36 μmol) and tetrahydrofuran (3 mL) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. N-bromosuccinimide (58.43 mg, 328.29 μmol) was added, and the reaction mixture was stirred at 0°C for 0.5 hours. A semi-saturated aqueous sodium thiosulfate solution (3 mL) was added to the reaction mixture, and the mixture was stirred at 25°C for 5 minutes. The reaction mixture was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each). The organic phases were combined, washed with saturated brine (3 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 3:1) to obtain 023-1. 1 H NMR (400MHz, CDCl3) δ=7.58 (d, J=9.4Hz, 1H), 7.10 (s, 1H), 6.55 (d, J=9.4Hz, 1H), 3.64 (s, 3H).
[0511] Step 2: Synthesis of Compound 023
[0512] To the reaction flask were added 023-1 (70 mg, 286.76 μmol), potassium carbonate (158.53 mg, 1.15 mmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (17.66 mg, 43.01 μmol), water (1.4 mL), acetonitrile (4.2 mL), methanol (0.4 mL), nitrogen was replaced, bistriphenylphosphine palladium dichloride (10.06 mg, 14.34 μmol), palladium acetate (3.22 mg, 14.34 μmol), nitrogen was replaced, the reaction solution was placed at 40 ° C, A-2 crude product solution was added (according to the synthesis method of Reference Example 2, prepared immediately, according to the theoretical yield, the theoretical yield is 142.28 mg, 573.52 μmol), the reaction solution was raised to 75 ° C and stirred for 12 hours. The reaction solution was filtered through celite and anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 3:1:0.3) and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to obtain 023. 1H NMR (400MHz, CDCl3) δ = 8.58-8.37 (m, 2H), 7.69 (d, J = 9.4Hz, 1H), 7.05 (s, 1H), 6.61 (d, J = 9.4Hz, 1H), 5.81 (br d, J = 8.4Hz, 1H), 5.35 (br d, J=7.8Hz, 1H), 3.71 (s, 3H), 2.95-2.78 (m, 2H), 2.30 (q, J=7.5Hz, 2H), 2.10 (br dd, J=5.5, 8.6Hz, 1H), 1.88 (brdd, J=3.6, 5.8Hz, 3H), 1.23 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=368.2[M+H] + SFC analysis (chromatographic column: (Chiralpak IG-3100 × 4.6 mm ID, 3 μm); mobile phase: A: supercritical carbon dioxide; B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B = 60:40; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi)) ee = 100%, retention time 2.762 minutes.
[0513] Example 20
[0514] Synthesis route:
[0515] Step 1: Synthesis of compound 024-2
[0516] To the reaction flask, 024-1 (500 mg, 2.51 mmol) and hydrogen chloride / ethyl acetate (4 M, 7.50 mL) were added sequentially, and the reaction solution was stirred at 25°C for 1 hour. The reaction solution was concentrated to obtain 024-2 hydrochloride, which was directly used for the next step without further purification. 1 H NMR (400MHz, CDCl3) δ=3.62-3.50 (m, 4H), 2.89 (t, J=6.4Hz, 4H).
[0517] Step 2: Synthesis of Compound 024-3
[0518] 024-2 hydrochloride (260 mg) and dichloromethane (2.6 mL) were added to the reaction flask in sequence. The reaction solution was cooled to 0°C, and N,N-diisopropylethylamine (1.02 g, 7.87 mmol) and propionyl chloride (364.01 mg, 3.93 mmol) were added. The reaction solution was stirred at 0°C for 1 hour. Water (2 mL) was added to the reaction solution, which was transferred to a separatory funnel and extracted three times with ethyl acetate (2 mL each). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 6:1) to obtain 024-3. 1 H NMR (400MHz, CDCl3) δ=3.99-3.66 (m, 4H), 2.56-2.33 (m, 6H), 1.21 (t, J=7.4Hz, 3H).
[0519] Step 3: Synthesis of Compound 024-4
[0520] A-1-5 hydrochloride (140 mg), triethylamine (161.25 mg, 1.59 mmol), and methanol (1.4 mL) were added to the reaction flask in sequence. The reaction solution was stirred at 25°C, and then 024-3 (123.66 mg, 796.78 μmol) and acetic acid (76.56 mg, 1.27 mmol) were added. After 10 minutes, sodium cyanoborohydride (100.14 mg, 1.59 mmol) was added, and the reaction solution was stirred at 25°C for 1 hour. Saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to 8-9. The reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (2 mL each time). The organic phases were combined, washed with saturated brine (2 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (dichloromethane: methanol = 1:0 to 15:1) to obtain 024-4. 1 H NMR (400MHz, CDCl3) δ = 8.53 (br s, 2H), 4.59-4.36 (m, 1H), 4.18-4.03 (m, 1H), 3.75 (br d, J=16.9Hz, 1H), 3.60-3.41(m, 1H), 3.27-3.15(m, 1H), 2.98(br s, 1H), 2.85(br d, J=14.3Hz, 1H), 2.69-2.58 (m, 1H), 2.39-2.36 (m, 2H), 2.17-1.94 (m, 4H), 1.87 (br d, J=4.4Hz, 3H), 1.60 (br s, 2H), 1.18-1.15 (m, 3H).
[0521] Step 4: Synthesis of Compound 024
[0522] To a reaction flask were added 024-4 (60 mg, 163.80 μmol), water (0.2 mL), acetonitrile (0.6 mL), methanol (0.2 mL), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (10.09 mg, 24.57 μmolq), and potassium carbonate (90.56 mg, 655.21 μmol) in sequence. The atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (5.75 mg, 8.19 μmol) and palladium acetate (1.84 mg, 8.19 μmol) were added. The atmosphere was replaced with nitrogen. The reaction mixture was placed at 40°C. A solution of 001-3 (56.05 mg, 196.56 μmol) in tetrahydrofuran (1.2 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was sequentially subjected to preparative thin-layer chromatography (petroleum ether: ethyl acetate: methanol = 1:1:0.1), preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; gradient: 15%-55% acetonitrile) and SFC chiral separation (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [supercritical carbon dioxide-methanol (0.1% ammonia water)]; isocratic elution: 50% methanol (0.1% ammonia water)) to obtain 024. 1 H NMR (400MHz, CDCl3) δ=8.62 (br s, 1H), 8.30 (s, 1H), 7.69 (br d, J=9.5Hz, 1H), 7.55-7.41 (m, 3H), 6.78 (br d, J=9.5Hz, 1H), 4.56-4.34 (m, 1H), 4.05 (br d, J=13.0Hz, 1H), 3.93-3.82 (m, 1H), 3.16 (brt, J=11.6Hz, 1H), 3.06-2.97 (m, 1H), 2 .96-2.85(m, 1H), 2.76-2.63(m, 1H), 2.61-2.50(m, 1H), 2.44-2.33(m, 2H), 2.05(br s, 1H), 1.90 (br s, 4H), 1.79-1.30 (m, 7H), 1.17 (brt, J=6.6Hz, 3H); ESI-LCMS: m / z=445.3[M+H] +; SFC analysis and detection (chromatographic column: Chiralpak IH-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 2.051 minutes.
[0523] Example 21
[0524] Synthesis route:
[0525] Step 1: Synthesis of compound 025-1
[0526] Tetrahydrofuran (2 mL) and trimethylsulfoxide iodide (554.62 mg, 2.52 mmol) were added sequentially to the reaction flask. The nitrogen atmosphere was replaced, and the reaction mixture was cooled to 0°C. A 2.5 M solution of n-butyllithium in n-hexane (940.86 μL) was added. The reaction mixture was stirred at 0°C for 0.5 hours. A solution of 001-2 (200 mg, 840.05 μmol) in tetrahydrofuran (1 mL) was added dropwise. The reaction mixture was heated to 25°C and stirred for 15.5 hours. Water (2 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted twice with ethyl acetate (2 mL each). The organic phases were combined, washed with saturated brine (2 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 5:1) to afford 025-1. 1 H NMR (400MHz, CDCl3) δ=7.49 (d, J=2.4Hz, 1H), 7.33 (dd, J=2.4, 8.8Hz, 1H), 6.82 (d, J=8.8Hz, 1H), 3.31 (s, 3H ), 2.49 (dt, J=5.2, 8.0Hz, 1H), 2.32 (ddd, J=4.8, 7.6, 9.5Hz, 1H), 1.65-1.61 (m, 1H), 0.64 (q, J=4.8Hz, 1H).
[0527] Step 2: Synthesis of 025-2
[0528] To a reaction flask, 025-1 (140 mg, 555.32 μmol), 1,4-dioxane (2.8 mL), bispinacolato boronate (211.53 mg, 832.98 μmol), potassium acetate (163.50 mg, 1.67 mmol), and [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride in dichloromethane (22.67 mg, 27.77 μmol) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was allowed to return to room temperature, and 4 mL of water was poured into the reaction mixture. The reaction mixture was transferred to a separatory funnel and washed with ethyl acetate three times (3 mL each). The organic phases were combined and washed three times with saturated brine (3 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 025-2. 1 H NMR (400MHz, CDCl3) δ=7.81 (d, J=1.3Hz, 1H), 7.67 (dd, J=1.4, 8.2Hz, 1H), 6.95 (d, J=8.2Hz, 1H) , 3.34 (s, 3H), 2.56 (dt, J=5.2, 8.0Hz, 1H), 2.38-2.26 (m, 2H), 1.58-1.53 (m, 1H), 1.36 (s, 12H).
[0529] Step 3: Synthesis of 025 and 026
[0530] To the reaction flask were added A-1 (75 mg, 264.86 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), potassium carbonate (146.43 mg, 1.06 mmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (16.31 mg, 39.73 μmol) in sequence, the nitrogen atmosphere was replaced, bistriphenylphosphine palladium dichloride (9.30 mg, 13.24 μmol) and palladium acetate (2.97 mg, 13.24 μmol) were added, the nitrogen atmosphere was replaced, the reaction solution was heated to 40°C, a solution of 025-2 (95.09 mg, 317.84 μmol) in tetrahydrofuran (1.2 mL) was added, the reaction solution was heated to 75°C and stirred for 2 hours. The reaction solution was returned to room temperature, 2 mL of water was poured into the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted three times with dichloromethane (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=1:1:0.3) and chiral SFC separation (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; isocratic elution; 35% ethanol (0.1% ammonia water)) to obtain 025 and 026. The ee value was then measured by SFC analysis (chromatographic column: Chiralpak IH-3, 100×4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2, B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.2 min), 50 / 50 (2.4 min), 50 / 50 (3.4 min), 90 / 10 (4.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 2000 psi).
[0531] Compound 025: 1 H NMR (400MHz, CD3OD) δppm 8.35 (s, 1H) 8.20 (s, 1H) 7.40 (d, J = 1.43Hz, 1H) 7.18-7.25 (m, 2H) 5.22 (t, J = 5.84Hz, 1H) 3.37 (s, 3H) 2.62-2.82 (m, 3H) 2.22-2.37 (m, 3H) 1.99-2.08 (m, 1H) 1.76-1.92 (m, 3H) 1.69 (td, J = 9.00, 4.29Hz, 1H) 1.19 (t, J = 7.63Hz, 3H) 0.62 (q, J = 4.65Hz, 1H); ESI-LCMS: m / z=376.2[M+H] +; ee=99.90%, retention time: 2.458 minutes.
[0532] Compound 026: 1 H NMR (400MHz, CD3OD) δppm 8.35 (s, 1H) 8.20 (s, 1H) 7.40 (d, J = 1.43Hz, 1H) 7.18-7.26 (m, 2H) 5.22 (t, J = 5.84Hz, 1H) 3.37 (s, 3H) 2.60-2.82 (m, 3H) 2.21-2.36 (m, 3H) 1. 98-2.10 (m, 1H) 1.74-1.95 (m, 3H) 1.69 (td, J = 9.00, 4.29Hz, 1H) 1.19 (t, J = 7.63Hz, 3H) 0.62 (q, d== 4.81Hz, 1H); ESI-LCMS: m / z = 376.2 [M+H] + ; ee=99.88%, retention time: 2.804 minutes.
[0533] Example 22
[0534] Synthesis route:
[0535] Step 1: Synthesis of Compound 027-2
[0536] To the reaction flask, 027-1 (300 mg, 1.26 mmol), N,N-dimethylformamide (3 mL), and cesium carbonate (821.12 mg, 2.52 mmol) were added sequentially. The nitrogen atmosphere was purged, the reaction mixture was cooled to 0°C, and iodomethane (715.41 mg, 5.04 mmol) was added. The reaction mixture was stirred at 25°C for 1 hour. Water (15 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with ethyl acetate (5 mL each). The organic phases were combined and washed twice with saturated brine (5 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 6:1) to obtain 027-2. 1 H NMR (400MHz, CDCl3) δ=7.81 (d, J=2.1Hz, 1H), 7.66 (dd, J=2.3, 9.0Hz, 1H), 7.24 (s, 1H), 6.63 (s, 1H), 3.69 (s, 3H), 2.45 (s, 3H).
[0537] Step 2: Synthesis of Compound 027-3
[0538] To the reaction flask were added 027-2 (210 mg, 832.98 μmol), bispinacolato boronate (423.05 mg, 1.67 mmol), 1,4-dioxane (8.4 mL), and potassium acetate (245.25 mg, 2.50 mmol). The atmosphere was purged with nitrogen, and methanesulfonic acid (2-dicyclohexylphosphino-2′,4′,6′-tri-isopropyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl) palladium(II) (35.25 mg, 41.65 μmol) was added. The reaction mixture was stirred at 80°C for 16 hours to obtain the reaction mixture of 027-3, which was used directly in the next reaction without post-treatment. ESI-LCMS: m / z = 300.0 [M+H] + .
[0539] Step 3 Synthesis of Compound 027
[0540] To a reaction flask were added A-1 (58.68 mg, 207.24 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (114.57 mg, 828.96 μmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (12.76 mg, 31.09 μmol). The atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (7.27 mg, 10.36 μmol) and palladium acetate (2.33 mg, 10.36 μmol) were added. The atmosphere was replaced with nitrogen. The reaction mixture was heated to 40°C, and the reaction mixture of 027-3 was added. The reaction mixture was heated to 75°C and stirred for 4 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (petroleum ether: ethyl acetate: methanol = 1:1:0.1) and chiral separation (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia aqueous solution)]; isocratic elution: 50% ethanol (0.1% ammonia aqueous solution)) to obtain 027. 1 H NMR (400MHz, CD3OD) δ = 8.40 (s, 1H), 8.27 (s, 1H), 7.79 (d, J = 1.9Hz, 1H), 7.74-7.70 (m , 1H), 7.67-7.63 (m, 1H), 6.65 (d, J=1.1Hz, 1H), 5.23 (t, J=6.0Hz, 1H), 4.58 (s, 3H), 3 .79 (s, 3H), 2.80-2.59 (m, 2H), 2.54 (d, J=1.1Hz, 3H), 2.29 (dq, J=2.0, 7.6Hz, 2H), 2. 12-1.98 (m, 1H), 1.91-1.87 (m, 1H), 1.20 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=376.2[M+H]+ ; SFC analysis and detection (chromatographic column: Chiralpak IG-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2; B: ethanol [0.2% 7 M ammonia in methanol]; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 2.133 minutes.
[0541] Example 23
[0542] Synthesis route:
[0543] Step 1: Synthesis of Compound 028-2
[0544] To a reaction flask, 028-1 (2 g, 11.59 mmol) and diethyl oxalate (16.94 g, 115.90 mmol) were added sequentially. The atmosphere was purged with nitrogen, and 1,8-diazabicyclo[5.4.0]undec-7-ene (2.03 g, 13.33 mmol) was added. The reaction mixture was stirred at 25°C for 15 hours. The reaction mixture was poured into ice water (20 mL), 1 M hydrochloric acid (15 mL) was added, and the mixture was filtered to collect the filter cake. The filter cake was added to anhydrous methanol (10 mL), stirred for 10 minutes, and filtered to collect the filter cake to obtain 028-2. 1 H NMR (400MHz, CDCl3) δ=8.96 (s, 1H), 8.26 (s, 1H), 7.26 (d, J=1.3Hz, 1H), 6.97 (d, J=0.9Hz, 1H), 4.45 (q, J=7.1Hz, 2H), 1.43 (t, J=7.1Hz, 3H).
[0545] Step 2: Synthesis of Compound 028-3
[0546] To a reaction flask, 028-2 (1.7 g, 6.24 mmol), water (3 mL), and tetrahydrofuran (12 mL) were added sequentially. The nitrogen atmosphere was replaced, and the reaction mixture was cooled to 0°C. Sodium borohydride (259.49 mg, 6.86 mmol) was added portionwise. The reaction mixture was stirred at 0°C for 0.5 hours. Ice water (5 mL) and saturated aqueous ammonium chloride (5 mL) were added to the reaction mixture. The reaction mixture was transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each). The organic phases were combined, washed with saturated brine (10 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 4:1) to obtain 028-3. 1 H NMR (400MHz, CDCl3) δ=8.97 (s, 1H), 7.48 (s, 1H), 4.50 (td, J=4.2, 8.4Hz, 1H), 4.30 (dq, J=3.6, 7.1Hz, 2H) , 3.60 (dd, J=3.9, 14.0Hz, 1H), 3.24 (dd, J=8.4, 13.9Hz, 1H), 3.01 (d, J=4.8Hz, 1H), 1.33 (t, J=7.2Hz, 3H).
[0547] Step 3: Synthesis of Compound 028-4
[0548] To the reaction flask were added 028-3 (0.8 g, 2.91 mmol), iron powder (650.70 mg, 11.65 mmol), and acetic acid (12 mL) in sequence. The nitrogen atmosphere was replaced, and the reaction solution was stirred at 70°C for 0.5 hours. 1,4-dioxane (8 mL) and hydrochloric acid (6 M, 5.83 mL) were added, and the reaction solution was raised to 90°C and stirred for 3.5 hours. The reaction solution was lowered to 25°C and poured into saturated aqueous sodium bicarbonate solution (200 mL). The mixture was stirred for 0.5 hours and filtered to collect the filter cake. 028-4 was obtained and used directly in the next step without purification. ESI-LCMS: m / z = 181.0 [M+H] + .
[0549] Step 5: Synthesis of Compound 028-5
[0550] To the reaction flask were added 028-4 (0.2 g, 1.11 mmol), cesium carbonate (541.25 mg, 1.66 mmol), and N,N-dimethylformamide (4 mL) in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. Methyl iodide (628.77 mg, 4.43 mmol) was added, and the reaction mixture was stirred at 0°C for 1 hour. Water (20 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 028-5. 1 H NMR (400MHz, CDCl3) δ=8.58 (s, 1H), 7.60 (d, J=9.6Hz, 1H), 7.48 (s, 1H), 6.95 (d, J=9.6Hz, 1H), 3.77 (s, 3H).
[0551] Step 4: Synthesis of Compound 028
[0552] 028-5 (60 mg, 308.30 μmol), sodium carbonate (98.03 mg, 924.89 μmol), water (0.3 mL), 1,4-dioxane (1.8 mL) were added to the reaction flask in sequence, and nitrogen was replaced. Methanesulfonic acid (2-dicyclohexylphosphino-2′, 4′, 6′-tri-isopropyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl) palladium (II) (26. 10 mg, 30.83 μmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (29.39 mg, 61.66 μmol, 0.2 eq), the reaction solution was heated to 85 ° C, and the crude product solution of A-2 (prepared according to the synthesis method of Reference Example 2, added according to the theoretical yield, the theoretical yield is 114.73 mg, 462.45 μmol) was added. The reaction solution was stirred at 85 ° C for 0.5 hours. The reaction solution was cooled to room temperature, water (2 mL) was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted with dichloromethane three times (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=5:5:1) and chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia aqueous solution)]; isocratic elution: 50% isopropanol (0.1% ammonia aqueous solution)) to obtain 028. 1H NMR (400MHz, CD3OD) δ = 9.05 (s, 1H), 8.44 (s, 1H), 8.40 (s, 1H), 8.00 (d, J = 9.5H z, 1H), 7.83 (s, 1H), 6.97 (d, J=9.5Hz, 1H), 5.24 (t, J=6.1Hz, 1H), 3.86 (s, 3H) , 2.96-2.85 (m, 1H), 2.82-2.71 (m, 1H), 2.29 (dq, J=2.1, 7.6Hz, 2H), 2.13-2.0 0 (m, 1H), 1.96-1.76 (m, 3H), 1.20 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=363.2[M+H] + ; SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2; B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B=95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee=100%, retention time 1.827 minutes.
[0553] Example 24
[0554] Synthesis route:
[0555] Step 1: Synthesis of Compound 029-2
[0556] To the reaction flask were added 029-1 (0.45 g, 1.99 mmol), acetic acid (956.25 mg, 15.92 mmol), and isopropanol (4 mL) in sequence. The atmosphere was replaced with nitrogen, and sodium cyanoborohydride (375.26 mg, 5.97 mmol) was added portionwise. The reaction solution was stirred at 75°C for 14 hours. Saturated aqueous sodium bicarbonate solution was added to the reaction solution to adjust the pH to 7-8. The reaction solution was transferred to a separatory funnel and extracted three times with dichloromethane (5 mL each). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 029-2. This product was used directly in the next step without purification. 1 H NMR (400MHz, CDCl3) δ=8.60 (s, 1H), 8.57 (s, 1H), 4.88 (t, J=4.9Hz, 1H), 2.88-2.83 (m, 1H), 2.72-2.65 (m, 1H), 2.10-1.79 (m, 5H).
[0557] Step 2: Synthesis of Compound 029-3
[0558] 029-2 (0.4 g, 1.75 mmol) and dichloromethane (4 mL) were added to the reaction flask in sequence, the nitrogen was replaced, the reaction solution was cooled to 0°C, thionyl chloride (312.96 mg, 2.63 mmol) was added, and the reaction solution was stirred at 0°C for 1 hour. The reaction solution was raised to 25°C and stirred for 1.5 hours. The reaction solution was concentrated to obtain the crude product of 029-3, which was used directly in the next step without purification. 1 H NMR (400MHz, CDCl3) δ = 8.83 (s, 1H), 8.74 (s, 1H), 5.52-5.36 (m, 1H), 3.15 (td, J=4.5, 19.6Hz, 1H), 2.93-2.80 (m, 1H), 2.40-2.22 (m, 3H), 2.15-2.05 (m, 1H).
[0559] Step 3: Synthesis of Compound 029-5
[0560] To a reaction flask were added 029-3 (0.36 g, 1.46 mmol), 029-4 (350.95 mg, 1.75 mmol), N,N-diisopropylethylamine (566.19 mg, 4.38 mmol), potassium iodide (242.41 mg, 1.46 mmol), and acetonitrile (5 mL) in sequence. The atmosphere was replaced with nitrogen. The reaction solution was stirred at 40°C for 2 hours, then raised to 80°C and stirred for 16 hours. The reaction solution was cooled to room temperature and concentrated to obtain a crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 029-5. 1 H NMR (400MHz, CDCl3) δ = 8.79 (s, 1H), 8.51 (s, 1H), 4.49 (br s, 1H), 3.88 (br d, J = 2.5Hz, 1H), 3.47 (br d, J = 1.3Hz, 1H), 2.81 (br d, J=17.3Hz, 2H), 2.73-2.52 (m, 3H), 2.22 (br d, J=7.5Hz, 1H), 2.11 (br d, J=9.3Hz, 1H), 1.99 (br dd, J=5.1, 9.3Hz, 2H), 1.87 (br d, J=9.9Hz, 1H), 1.59-1.32 (m, 13H).
[0561] Step 4: Synthesis of Compound 029-6
[0562] To the reaction flask, 029-5 (0.2 g, 487.39 μmol) and hydrogen chloride / ethyl acetate (4 M, 10.00 mL) were added sequentially, the atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 25°C for 0.5 h. The reaction mixture was concentrated to obtain the hydrochloride salt of 029-6, which was used directly in the next step without purification. 1 H NMR (400MHz, DMSO-d6) δ = 8.98 (s, 1H), 8.75 (s, 1H), 4.69 (br s, 1H), 3.43-3.19 (m, 4H), 3.18-3.04 (m, 1H), 2.91-2.66 (m, 2H), 2.36- 2.22(m, 2H), 2.19-1.99(m, 4H), 1.97-1.92(m, 1H), 1.86-1.73(m, 1H).
[0563] Step 5: Synthesis of Compound 029-7
[0564] To the reaction flask were added the hydrochloride salt of 029-6 (220 mg), N,N-diisopropylethylamine (410.07 mg, 3.17 mmol), and dichloromethane (5 mL) in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. Propionic anhydride (99.10 mg, 761.48 μmol) was added, and the reaction mixture was stirred at 0°C for 1 hour. Water (2 mL) was added to the reaction mixture, and the mixture was extracted three times with dichloromethane (2 mL each time). The organic phases were combined, washed with saturated brine (2 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 029-7. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 5:5:1) to afford 029-7. 1 H NMR (400MHz, CDCl3) δ = 8.80 (s, 1H), 8.51 (s, 1H), 5.34 (br d, J=4.6Hz, 1H), 3.97-3.73 (m, 2H), 2.90-2.70 (m, 3H), 2.66-2.49 (m, 2H), 2.32-2.24 (m, 1H), 2.20 (q, J=7.7Hz, 2H), 2.11 (br d, J=5.0Hz, 1H), 2.04-1.95(m, 2H), 1.90-1.82(m, 1H), 1.67(br s, 1H), 1.59-1.53 (m, 2H), 1.46 (d, J=6.6Hz, 1H), 1.17-1.12 (m, 3H).
[0565] Step 6: Synthesis of compounds 029 and 030
[0566] To the reaction flask, 029-7 (0.1 g, 273.00 μmol), 001-3 (93.41 mg, 327.60 μmol), sodium carbonate (57.87 mg, 546.01 μmol), water (0.7 mL), and ethanol (2 mL) were added in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (31.55 mg, 27.30 μmol) was added. The reaction solution was placed at 85°C and stirred for 2 hours. The reaction solution was returned to room temperature, water (5 mL) was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted three times with dichloromethane (5 mL each time). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=3:3:1) and chiral separation by SFC (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: ethanol (0.2% 7 M ammonia in methanol), flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) to obtain 029 and 030. The product was then analyzed and detected by SFC: (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: carbon dioxide, B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi).
[0567] Compound 029: 1H NMR (400MHz, CD3OD) δ=8.83 (s, 1H), 8.21 (s, 1H), 7.97 (d, J=9.5Hz, 1H), 7.73-7.68 (m, 2H), 7.67-7.63 (m, 1H), 6.74 (d, J=9.5Hz, 1H), 4.03 (br dd, J=5.5, 9.6Hz, 1H), 3.80 (s, 3H), 3.73-3.61 (m, 1H), 3.00-2.90 (m, 1H) , 2.80-2.68(m, 2H), 2.64-2.52(m, 2H), 2.38-2.28(m, 1H), 2.19(q, J=7.5 Hz, 2H), 2.06-1.90 (m, 3H), 1.87-1.76 (m, 2H), 1.71-1.58 (m, 2H), 1.44 (d q, J=3.7, 11.6Hz, 1H), 1.13 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=445.3[M+H] + ; ee=100%, retention time: 1.489 minutes.
[0568] Compound 030: 1 H NMR (400MHz, CD3OD) δ=8.83 (s, 1H), 8.21 (s, 1H), 7.97 (d, J=9.5Hz, 1H), 7.73-7.69 (m, 2H), 7.67-7.63 (m, 1H), 6.74 (d, J=9.5Hz, 1H), 4.03 (br dd, J=5.6, 9.5Hz, 1H), 3.80 (s, 3H), 3.72-3.61 (m, 1H), 2.95 (br d, J=11.3Hz, 1H), 2.82-2.68 (m, 2H), 2.65-2.51 (m, 2H), 2.32 (dt, J=2.1, 11.4Hz, 1H), 2.19 (q, J=7.6Hz, 2H), 2.09-1.90 (m, 3H), 1.88-1.76 (m, 2H), 1.72-1.57 (m, 2H), 1.44 (dq, J=3.9, 11.6Hz, 1H), 1.12 (t, J=7.7Hz, 3H); ESI-LCMS: m / z=445.3[M+H] + ; ee=100%, retention time: 1.806 minutes.
[0569] Example 25
[0570] Synthesis route:
[0571] Step 1: Synthesis of compound 031-2
[0572] To a reaction flask, 031-1 (0.3 g, 1.46 mmol), potassium carbonate (402.52 mg, 2.91 mmol), and N,N-dimethylformamide (3 mL) were added sequentially. The nitrogen atmosphere was replaced, and chloroacetyl chloride (180.92 mg, 1.60 mmol) was added. The reaction solution was stirred at 80°C for 2 hours. The reaction solution was returned to room temperature, and water (30 mL) was added. The reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 031-2. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 4:1) to afford 031-2. 1 H NMR (400MHz, DMSO-d6) δ=11.01 (br s, 1H), 7.22 (dd, J=2.0, 9.8Hz, 1H), 7.08 (t, J=1.7Hz, 1H), 4.64 (s, 2H).
[0573] Step 2: Synthesis of compound 031-3
[0574] To the reaction flask, 031-2 (0.1 g, 406.45 μmol), cesium carbonate (198.64 mg, 609.67 μmol), and N,N-dimethylformamide (2 mL) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. Methyl iodide (230.76 mg, 1.63 mmol) was added, and the reaction mixture was stirred at 0°C for 1 hour. Water (10 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined, washed with saturated brine (5 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 031-3. 1 H NMR (400MHz, DMSO-d6) δ=7.34 (dd, J=1.9, 12.1Hz, 1H), 7.19 (s, 1H), 4.67 (s, 2H), 3.33 (br s, 3H).
[0575] Step 3: Synthesis of compound 031-4
[0576] To the reaction flask were added 031-3 (100 mg, 384.53 μmol), bispinacolato borate (146.47 mg, 576.79 μmol), potassium acetate (113.21 mg, 1.15 mmol), and 1,4-dioxane (2 mL) in sequence. The atmosphere was replaced with nitrogen, and [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (28.14 mg, 38.45 μmol) was added. The reaction solution was stirred at 80°C for 4 hours. The reaction solution was returned to room temperature and concentrated to give the crude product of 031-4, which was used directly in the next step without purification.
[0577] Step 4: Synthesis of Compound 031
[0578] To the reaction flask were added A-1 (100 mg, 353.15 μmol), 031-4 (108.46 mg, 353.15 μmol), sodium carbonate (74.86 mg, 706.31 μmol), water (0.5 mL), and ethanol (3 mL) in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (40.81 mg, 35.32 μmol) was added. The reaction solution was stirred at 85 ° C for 1 hour. The reaction solution was returned to room temperature, diluted with water (5 mL), extracted with dichloromethane (5 mL x 3), and the organic phases were combined, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (ethyl acetate: methanol = 1:0 to 10:1) and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia water)]; isocratic elution: 50% isopropanol (0.1% ammonia water)) to obtain 031. 1 H NMR (400MHz, CD3OD) δ=8.37 (s, 1H), 8.19 (s, 1H), 6.93 (dd, J=1.8, 13.1Hz, 1H), 6.88 (d, J=1.3Hz, 1H), 5.20 (t, J=5.8Hz, 1H), 4.64 (s, 2H), 3.51 (d, J= 5.9Hz, 3H), 2.78-2.62(m, 2H), 2.27(dq, J=1.7, 7.6Hz, 2H), 2.07-1.98(m, 1H), 1.92-1.76 (m, 3H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=384.2[M+H] +SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol [0.2% 7 M ammonia in methanol]; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.479 minutes.
[0579] Example 26
[0580] Synthesis route:
[0581] Step 1: Synthesis of compound 032-2
[0582] To a reaction flask, 032-1 (0.3 g, 1.46 mmol), potassium carbonate (402.53 mg, 2.91 mmol), and N,N-dimethylformamide (3 mL) were added sequentially. The atmosphere was replaced with nitrogen, and chloroacetyl chloride (180.92 mg, 1.60 mmol) was added. The reaction solution was stirred at 80°C for 2 hours. The reaction solution was returned to room temperature, and water (30 mL) was added. The reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 4:1) to obtain 032-2. 1 H NMR (400MHz, DMSO-d6) δ = 10.88 (br s, 1H), 7.31 (d, J = 6.4Hz, 1H), 6.83 (d, J = 9.2Hz, 1H), 4.59 (s, 2H).
[0583] Step 2: Synthesis of compound 032-3
[0584] To the reaction flask were added 032-2 (100 mg, 406.45 μmol), cesium carbonate (198.64 mg, 609.67 μmol), and N,N-dimethylformamide (1.5 mL) in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. Methyl iodide (230.76 mg, 1.63 mmol) was added, and the reaction mixture was stirred at 0°C for 1 hour. Water (10 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with ethyl acetate (5 mL each). The organic phases were combined, washed with saturated brine (10 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 032-3. 1 H NMR (400MHz, DMSO-d6) δ=7.36 (d, J=6.5Hz, 1H), 7.30 (d, J=10.1Hz, 1H), 4.67 (s, 2H), 3.24 (s, 3H).
[0585] Step 3: Synthesis of Compound 032-4
[0586] To the reaction flask were added 032-3 (120 mg, 461.43 μmol), bispinacolato boronate (175.76 mg, 692.15 μmol), potassium acetate (135.86 mg, 1.38 mmol), and 1,4-dioxane (3 mL) in sequence. The atmosphere was replaced with nitrogen, and [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (33.76 mg, 46.14 μmol) was added. The reaction mixture was placed at 85°C and stirred for 16 hours. The reaction mixture was returned to room temperature and concentrated to give the crude product of 032-4, which was used directly in the next step without purification.
[0587] Step 4: Synthesis of Compound 032
[0588] A-1 (120 mg, 423.78 μmol), 032-4 (130.15 mg, 423.78 μmol), sodium carbonate (89.83 mg, 847.57 μmol), water (0.5 mL), and ethanol (3 mL) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, and tetrakistriphenylphosphine palladium (48.97 mg, 42.38 μmol) was added. The reaction solution was stirred at 85°C for 1 hour. The reaction solution was returned to room temperature, and water (5 mL) was added to the reaction solution. The solution was extracted three times with dichloromethane (5 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially subjected to column chromatography (ethyl acetate:methanol=1:0 to 10:1) and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia water)]; isocratic elution: 50% isopropanol (0.1% ammonia water)) to obtain 032. 1 H NMR (400MHz, CD3OD) δ = 8.39 (s, 1H), 8.18 (s, 1H), 7.11 (d, J = 10.6Hz, 1H), 6.92 (d, J = 6.6Hz, 1H), 5.22 (brt, J = 5.8Hz, 1H), 4.66 (s, 2H), 3.39 (s , 3H), 2.73-2.51 (m, 2H), 2.27 (dq, J=2.0, 7.6Hz, 2H), 2.11-1.97 (m, 1H), 1.94-1.75 (m, 3H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=384.2[M+H] + ; SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6mm ID, 3um; mobile phase: A: CO2 B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.795 minutes.
[0589] Example 27
[0590] Synthesis route:
[0591] Step 1: Synthesis of Compound 033-2
[0592] 033-1 hydrochloride (2 g, 16.45 mmol), dichloromethane (20 mL), and N,N-diisopropylethylamine (5.32 g, 41.13 mmol) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, and a solution of propionic anhydride (3.00 g, 23.03 mmol) in dichloromethane (10 mL) was added. The reaction solution was stirred at 0°C for 1 hour. Water (10 mL) was added to the reaction solution, and the reaction solution was transferred to a separatory funnel and extracted with 10 mL of dichloromethane. The layers were separated, and the organic phase was collected. The aqueous phase was further extracted with a mixed solvent (dichloromethane: methanol = 10:1) three times (10 mL each time). The organic phases were combined and washed twice with saturated brine (10 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to dichloromethane: methanol = 20:1) to obtain 033-2. 1 H NMR (400MHz, CDCl3) δ=3.94-3.85 (m, 4H), 2.70 (t, J=7.9Hz, 1H), 2.62 (t, J=7.9Hz, 1H), 2.41-2.34 (m, 1H), 2.27 (q, J=7.4Hz, 1H), 1.21-1.16 (m, 3H).
[0593] Step 2: Synthesis of compound 033-3
[0594] To a reaction flask were added A-1-5 hydrochloride (0.7 g), methanol (7 mL), triethylamine (631.53 mg, 6.24 mmol), 033-2 (734.19 mg, 5.20 mmol), and acetic acid (249.85 mg, 4.16 mmol) in sequence. The mixture was stirred for 15 minutes, and sodium cyanoborohydride (653.64 mg, 10.40 mmol) was added. The reaction solution was stirred at 25°C for 1 hour. Saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to 8-9. The reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 033-3. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to dichloromethane:methanol = 20:1) to afford 033-3. 1H NMR (400MHz, CDCl3) δ = 8.53 (d, J = 3.4Hz, 1H), 8.51-8.47 (m, 1H), 3.98-3.83 (m, 1H), 3.73-3.57 (m, 3H), 3.52-3.44 (m, 1H) ), 3.12(s, 2H), 2.88-2.78(m, 1H), 2.70-2.59(m, 1H), 2.31-2.25(m, 2H), 2.19-2.10(m, 1H), 2.02-1.96(m, 1H), 1.92(br d, J=4.0Hz, 1H), 1.89-1.82 (m, 2H), 1.38 (s, 3H).
[0595] Step 3: Synthesis of compounds 033 and 034
[0596] To a reaction flask were added 001-3 (553.67 mg, 1.94 mmol), potassium carbonate (894.51 mg, 6.47 mmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (99.64 mg, 242.71 μmol), bistriphenylphosphine palladium dichloride (56.79 mg, 80.90 μmol), palladium acetate (18.16 mg, 80.90 μmol), water (5.5 mL), acetonitrile (16.5 mL), and methanol (5.5 mL) in sequence. The atmosphere was replaced with nitrogen. The reaction mixture was placed at 40°C, and a solution of 033-3 (0.57 g, 1.62 mmol) in tetrahydrofuran (5.5 mL) was added. The reaction mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was returned to room temperature, filtered through anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 1:1:0.3) and SFC chiral separation (ChiralPak IH column, 250 x 30 mm, 10 μm; mobile phase: supercritical carbon dioxide-ethanol: acetonitrile = 1:1 (0.1% ammonia solution); isocratic elution: 50% ethanol: acetonitrile = 1:1 (0.1% ammonia solution)) to afford 033 and 034. SFC analysis was then performed (Chiralpak IH-3 column, 50 x 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol: acetonitrile (0.1% 7 M ammonia in methanol); gradient: A / B = 65:35; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi) to determine the ee value.
[0597] Compound 033: 1H NMR (400MHz, CD3OD) δ=8.58 (d, J=10.6Hz, 1H), 8.21 (d, J=3.1Hz, 1H), 7.97 (d, J=9.5Hz , 1H), 7.75-7.61 (m, 3H), 6.74 (d, J=9.5Hz, 1H), 4.03-3.95 (m, 1H), 3.80 (s, 3H), 3.79- 3.50(m, 4H), 3.49-3.33(m, 2H), 2.81-2.71(m, 1H), 2.68-2.57(m, 1H), 2.43-2.31(m, 2H), 2.28-2.13(m, 1H), 2.02(br d, J=12.1Hz, 1H), 1.98-1.79 (m, 3H), 1.79-1.68 (m, 1H), 1.15 (dt, J=0.8, 7.5Hz, 3H); ESI-LCMS: m / z=431.3[M+H] + ; ee=100%, retention time 2.289 minutes.
[0598] Compound 034: 1 H NMR (400MHz, CD3OD) δ=8.60 (s, 1H), 8.22 (d, J=2.3Hz, 1H), 7.97 (d, J=9.5Hz, 1H), 7.72 -7.60 (m, 3H), 6.74 (d, J=9.4Hz, 1H), 4.03 (td, J=4.8, 9.6Hz, 1H), 3.80 (s, 3H), 3.77 (br d, J=3.1Hz, 4H), 3.45 (td, J=7.5, 12.2Hz, 1H), 3.29-3.22 (m, 1H), 2.79-2.71 (m, 1H), 2.68 -2.58(m, 1H), 2.36(qd, J=7.5, 11.7Hz, 2H), 2.25-2.15(m, 1H), 2.05-1.90(m, 4H), 1.73(br dd, J=2.1, 5.7Hz, 1H), 1.13 (dt, J=3.5, 7.5Hz, 3H); ESI-LCMS: m / z=431.2[M+H] + ; ee=100%, retention time 3.580 minutes.
[0599] Example 28
[0600] Synthesis route:
[0601] Step 1: Synthesis of compound 035-3
[0602] To the reaction flask, 035-1 (2.2 g, 11.82 mmol) and dichloromethane (34 mL) were added sequentially. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, and a solution of 035-2 (1.94 g, 14.19 mmol) in dichloromethane (34 mL) was added. The reaction solution was heated to 25°C and stirred for 12 hours. Water (10 mL) was added to the reaction solution, which was transferred to a separatory funnel and extracted three times with dichloromethane (30 mL each). The mixture was separated, and the organic phases were combined and washed twice with saturated brine (20 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was then isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 035-3. 1 H NMR (400MHz, CDCl3) δppm 7.57 (d, J=8.50Hz, 2H) 7.13 (d, J=8.63Hz, 2H) 3.69 (s, 3H) 3.29 (s, 3H) 3.23 (s, 2H).
[0603] Step 2: Synthesis of compound 035-4
[0604] To a reaction flask, 035-3 (3.3 g, 11.53 mmol), tetrahydrofuran (33 mL), and an aqueous solution (33 mL) of lithium hydroxide monohydrate (967.98 mg, 23.07 mmol) were added in sequence. The reaction solution was stirred at 25°C for 12 hours. 12M hydrochloric acid was added to the reaction solution to adjust the pH to 1-2. Water (15 mL) was added to the reaction solution, and the solution was extracted twice with ethyl acetate (30 mL each). The organic phases were combined, washed with saturated brine (30 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. 25 mL of a mixed solvent (petroleum ether:ethyl acetate = 10:1) was added to the crude product, stirred for 0.5 hour, filtered, and the filter cake was collected and dried to obtain 035-4. 1 H NMR (400MHz, DMSO-d6) δppm 7.66 (br d, J=7.63Hz, 2H) 7.32 (br d, J=7.63Hz, 2H) 3.17 (br s, 3H) 3.11 (br s, 2H).
[0605] Step 3: Synthesis of Compound 035-5
[0606] To the reaction flask, 035-4 (2.8 g, 10.29 mmol) and Eaton's reagent (30.30 g, 127.28 mmol) were added sequentially. The nitrogen atmosphere was replaced, and the reaction solution was stirred at 70°C for 12 hours. The reaction solution was added to ice water (100 mL), stirred at 0°C for 0.5 hours, filtered, and the filter cake was collected. The filter cake was added to acetonitrile (28 mL), stirred at 25°C for 1 hour, filtered, and the filter cake was collected to obtain 035-5. 1 H NMR (400MHz, DMSO-d6) δppm 11.59 (s, 1H) 7.95 (d, J=2.38Hz, 1H) 7.76 (dd, J=9.01, 2.38Hz, 1H) 7.44 (d, J=9.01Hz, 1H) 5.89 (s, 1H) 3.51 (s, 3H).
[0607] Step 4: Synthesis of Compound 035-6
[0608] To a reaction flask, 035-5 (0.4 g, 1.57 mmol) and N,N-dimethylformamide (10 mL) were added sequentially. The atmosphere was purged of nitrogen, followed by the addition of sodium carbonate (166.86 mg, 1.57 mmol). The reaction mixture was cooled to 0°C, and iodomethane (335.18 mg, 2.36 mmol) was added. The reaction mixture was stirred at 0°C for 2 hours, then raised to 25°C and stirred for 10 hours. 10 mL of water was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with ethyl acetate (30 mL each). The organic phases were combined and washed twice with saturated brine (30 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was then isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 035-6. 1 H NMR (400MHz, DMSO-d6) δ=7.95 (d, J=2.1Hz, 1H), 7.79 (dd, J=2.2, 9.1Hz, 1H), 7.48 (d, J=9.1Hz, 1H), 6.09 (s, 1H), 3.94 (s, 3H), 3.54 (s, 3H).
[0609] Step 5: Synthesis of Compound 035-7
[0610] To the reaction flask were added 035-6 (0.16 g, 596.78 μmol), 1,4-dioxane (7 mL), bispinacolato boronate (227.32 mg, 895.17 μmol), potassium acetate (175.70 mg, 1.79 mmol), and methanesulfonic acid (2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl) palladium(II) (25.26 mg, 29.84 μmol). The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 80°C for 6 hours. The reaction mixture was filtered, the filter cake was rinsed with ethyl acetate, and the filtrate was concentrated to obtain the crude product of 035-7. The product was used directly in the next step without purification. ESI-LCMS: m / z = 316.2 [M+H] + .
[0611] Step 6: Synthesis of Compound 035
[0612] To a reaction flask were added A-1 (80 mg, 282.52 μmol), water (1.7 mL), acetonitrile (5.1 mL), methanol (1.7 mL), potassium carbonate (156.18 mg, 1.13 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (17.40 mg, 42.38 μmol). The atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (9.92 mg, 14.13 μmol) and palladium acetate (3.17 mg, 14.13 μmol) were added. The atmosphere was replaced with nitrogen. The reaction mixture was heated to 40°C. A solution of 035-7 (178.09 mg, 565.04 μmol) in tetrahydrofuran (2.6 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 1:1:0.3) and chiral separation by SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-methanol (0.1% ammonia)]; isocratic: 50% methanol (0.1% ammonia)) to afford 035. 1H NMR (400MHz, CDCl3) δ=8.54 (br s, 1H), 8.33 (br s, 1H), 7.91 (d, J=1.9Hz, 1H), 7.51 (dd, J=2.0, 8.6Hz, 1H), 7.42 (d, J=8.8Hz, 1H), 6.09 (s, 1H), 5.81 (br d, J=8.6Hz, 1H), 5.40-5.33 (m, 1H), 3.96 (s, 3H), 3.72 (s, 3H), 2.74-2.54 (m, 2H), 2.30 (q, J=7.5 Hz, 2H), 2.15-2.07 (m, 1H), 1.87-1.80 (m, 3H), 1.23 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=392.2[M+H] + SFC analysis (chromatographic column: Chiralpak IG-3, 100×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 50:50; flow rate: 4 mL / min; column temperature: 35°C; pressure: 2000 psi)) ee = 100%, retention time 2.119 minutes.
[0613] Example 29
[0614] Synthesis route:
[0615] Step 1: Synthesis of Compound 036-2
[0616] To the reaction flask, 036-1 hydrochloride (2 g, 18.60 mmol), dichloromethane (20 mL), and N,N-diisopropylethylamine (4.49 g, 34.72 mmol) were added sequentially. The nitrogen atmosphere was replaced, and the reaction solution was cooled to 0°C. A dichloromethane solution (5 mL) of propionic anhydride (2.53 g, 19.44 mmol) was added, and the reaction solution was stirred at 0°C for 1 hour. The reaction solution was poured into 2 mL of water, separated, and the organic phase was collected and concentrated to obtain the crude product of 036-2, which was used directly in the next step without purification. 1 H NMR (400MHz, CDCl3) δ=4.81 (br d, J=13.8Hz, 4H), 2.31 (q, J=7.5Hz, 2H), 1.19 (t, J=7.6Hz, 3H).
[0617] Step 2: Synthesis of Compound 036-3
[0618] To a reaction flask were added A-1-5 hydrochloride (0.5 g), methanol (5 mL), triethylamine (451.09 mg, 4.46 mmol), 036-2 (472.31 mg, 3.71 mmol), and acetic acid (178.46 mg, 2.97 mmol) in sequence. The reaction solution was stirred at 25°C for 0.5 hours. Sodium cyanoborohydride (466.89 mg, 7.43 mmol) was added, the atmosphere was replaced with nitrogen, and the mixture was stirred at 25°C for 15.5 hours. The reaction solution was poured into 5 mL of saturated sodium bicarbonate aqueous solution and extracted three times with dichloromethane (5 mL each). The organic phases were combined and washed three times with saturated brine (5 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 1:1:0.1) to obtain 036-3. ESI-LCMS: m / z = 338.0 [M+H] + .
[0619] Step 3: Synthesis of Compound 036
[0620] To the reaction flask were added 001-3 (50.58 mg, 177.39 μmol), potassium carbonate (81.72 mg, 591.29 μmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (9.10 mg, 22.17 μmol), bistriphenylphosphine palladium dichloride (5.19 mg, 7.39 μmol), palladium acetate (1.66 mg, 7.39 μmol), water (0.4 mL), acetonitrile (1.2 mL), and methanol (0.4 mL) in sequence. The atmosphere was replaced with nitrogen, the reaction solution was heated to 40° C., a solution of 036-3 (50 mg, 147.82 μmol) in tetrahydrofuran (0.4 mL) was added, and the reaction solution was heated to 75° C. and stirred for 1 hour. The reaction solution was returned to room temperature and added with 2 mL of water. The reaction solution was transferred to a separatory funnel and extracted with dichloromethane three times (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=1:1:0.3), preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (10mM ammonium bicarbonate)-acetonitrile]; gradient: 5%-45% 10mM ammonium bicarbonate), and SFC chiral separation (chromatographic column: REGIS (S,S) WHELK-O1 (250mm*25mm, 10μm); mobile phase: [supercritical carbon dioxide-isopropanol:acetonitrile=1:1 (0.1% ammonia water)]; isocratic: 50% isopropanol:acetonitrile=1:1 (0.1% ammonia water)) to obtain 036. 1H NMR (400MHz, CD3OD) δ=8.56 (d, J=3.8Hz, 1H), 8.24 (s, 1H), 7.97 (d, J=9.4Hz, 1H), 7.75-7.68 (m, 2H), 7.6 7-7.61 (m, 1H), 6.74 (d, J=9.4Hz, 1H), 4.47-4.33 (m, 1H), 4.27-4.13 (m, 1H), 4.01-3.87 (m, 3H), 3.78 (br s, 3H), 3.78-3.68 (m, 1H), 2.83-2.70 (m, 1H), 2.69-2.58 (m, 1H), 2.17 (q, J=7.5Hz, 2H), 2.00-1.83(m, 3H), 1.78-1.68(m, 1H), 1.10(t, J=7.6Hz, 3H); ESI-LCMS: m / z=417.3[M+H] + ; SFC analysis and detection (chromatographic column: (S,S)-WHELK-O1, 50×4.6 mm ID, 3.5 μm; mobile phase: A: CO2 B: 0.1% isopropylamine (isopropanol:acetonitrile = 1:1); gradient: A / B = 55:45 flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 99.62%, retention time 2.720 minutes.
[0621] Example 30
[0622] Synthesis route:
[0623] Step 1: Synthesis of Compound 037-3
[0624] To a reaction flask, 037-2 (26.43 g, 366.51 mmol) and tetrahydrofuran (450 mL) were added sequentially. The nitrogen atmosphere was replaced, and the reaction mixture was cooled to 0°C. Potassium tert-butoxide (38.38 g, 342.07 mmol) was added and stirred at 0°C for 30 minutes. A solution of 037-1 (43 g, 244.34 mmol) in tetrahydrofuran (22.5 mL) was added and stirred at 0°C for 10 minutes. The reaction mixture was diluted with aqueous ammonium chloride (300 mL) and transferred to a separatory funnel. Extraction was performed three times with ethyl acetate (300 mL each). The organic phases were combined, washed with saturated brine (300 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 6:1) to obtain 037-3. 1H NMR (400MHz, CDCl3) δ=8.57 (s, 1H), 8.36 (d, J=5.6Hz, 1H), 6.79 (d, J=5.6Hz, 1 H), 5.91 (tdd, J=6.8, 10.3, 17.1Hz, 1H), 5.25-5.12 (m, 2H), 4.13 (t, J=6.6Hz, 2H), 2.62 (q, J=6.6Hz, 2H).
[0625] Step 2: Synthesis of Compound 037-4
[0626] To a reaction flask, 037-3 (28.1 g, 123.20 mmol) and N,N-dimethylformamide (281 mL) were added sequentially. The atmosphere was purged of nitrogen, followed by acetic acid (60.46 g, 616.00 mmol), 1,2-bis(diphenylphosphino)ethane (9.82 g, 24.64 mmol), and palladium acetate (2.77 g, 12.32 mmol). The atmosphere was purged of nitrogen, and the reaction solution was stirred at 100°C for 2 hours. The reaction solution was allowed to return to room temperature, and water (1.4 L) was added. The reaction solution was transferred to a separatory funnel and extracted three times with ethyl acetate (500 mL each). The organic phases were combined and washed twice with saturated brine (500 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was then isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 037-4. 1 H NMR (400MHz, CDCl3) δ=8.72 (s, 1H), 8.26 (d, J=5.7Hz, 1H), 6.76 (d, J=5.7Hz, 1H), 5.62 (s, 1H), 5.00 (s, 1H), 4.37-4.26 (m, 2H), 2.69 (t, J=5.7Hz, 2H).
[0627] Step 3: Synthesis of Compound 037-5
[0628] To a reaction flask, 037-4 (2 g, 13.59 mmol), tert-butanol (10 mL), acetonitrile (10 mL), and water (10 mL) were added sequentially. The atmosphere was purged of nitrogen, and osmium tetroxide (345.48 mg, 1.36 mmol) was added. The reaction solution was stirred at 25°C for 0.5 hours. Sodium periodate (5.81 g, 27.18 mmol) was added and stirred at 25°C for 4 hours. Water (20 mL) was added to the reaction solution, which was transferred to a separatory funnel and extracted twice with a mixed solvent (ethyl acetate:ethanol = 5:1) (20 mL each). The organic phases were combined, washed with saturated brine (50 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 2:1) to yield 037-5.1 H NMR (400MHz, CDCl3) δ=9.02 (s, 1H), 8.53 (d, J=5.9Hz, 1H), 6.91 (d, J=5.9Hz, 1H), 4.70-4.56 (m, 2H), 2.93-2.79 (m, 2H).
[0629] Step 4: Synthesis of Compound 037-6
[0630] To a reaction flask were added 037-5 (400 mg, 2.68 mmol), tetrahydrofuran (4 mL), A-1-2 (325.05 mg, 2.68 mmol), and tetraethyl titanate (1.84 g, 8.05 mmol) in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 50°C for 16 hours. The reaction mixture was allowed to return to room temperature, and ethyl acetate (4 mL) was added, followed by an aqueous sodium glycolate solution (3.4 mL). The mixture was stirred at 25°C for 30 minutes. The layers were separated, and the aqueous phase was extracted twice with ethyl acetate (2 mL each). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 037-6. 1 H NMR (400MHz, CDCl3) δ=9.10 (s, 1H), 8.44 (d, J=5.8Hz, 1H), 6.86 (d, J=5.8Hz , 1H), 4.53-4.35(m, 2H), 3.62-3.50(m, 1H), 3.45-3.33(m, 1H), 1.34(s, 9H).
[0631] Step 5: Synthesis of Compound 037-7
[0632] 037-6 (420 mg, 1.66 mmol) and tetrahydrofuran (4.2 mL) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, the reaction mixture was cooled to 0°C, and 9-borabicyclo[3.3.1]nonane (0.5 M, 9.99 mL) was added. The reaction mixture was heated to 25°C and stirred for 1 hour. 20% aqueous citric acid (23 mL) was added to the reaction mixture, followed by saturated aqueous sodium bicarbonate solution to adjust the pH to 8-9. The reaction mixture was transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each). The organic phases were combined, washed with saturated brine (20 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (dichloromethane:methanol = 1:0 to 20:1) to obtain 037-7. 1H NMR (400MHz, CDCl3) δ = 8.51 (s, 1H), 8.33 (d, J = 5.8Hz, 1H), 6.79 (d, J = 5.8Hz, 1H), 5 .31 (s, 1H), 4.73-4.61 (m, 1H), 4.40-4.31 (m, 2H), 2.25-2.10 (m, 2H), 1.25 (s, 9H).
[0633] Step 6: Synthesis of Compound 037-8
[0634] 037-7 (270 mg, 1.06 mmol) and ethanol (5.4 mL) were added to the reaction flask in sequence. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, and trimethylsilyl chloride (230.66 mg, 2.12 mmol) was added. The reaction solution was stirred at 25°C for 1 hour. The reaction solution was concentrated to obtain crude 037-8, which was used directly in the next step without purification. ESI-LCMS: m / z = 151.3 [M+H] + .
[0635] Step 7: Synthesis of Compound 037-9
[0636] To the reaction flask, crude 037-8, dichloromethane (2 mL), and N,N-diisopropylethylamine (289.16 mg, 2.24 mmol) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to 0°C. A solution of propionic anhydride (194.11 mg, 1.49 mmol) in dichloromethane (1 mL) was added, and the mixture was stirred at 0°C for 1 hour. Water (5 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted three times with dichloromethane (2 mL each). The organic phases were combined and washed with saturated brine (2 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford the crude product, which was then isolated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to afford 037-9. ESI-LCMS: m / z = 207.1 [M+H] + .
[0637] Step 8: Synthesis of Compound 037-10
[0638] 037-9 (95 mg, 460.63 μmol) and sulfuric acid (1 mL) were added sequentially to the reaction flask. The nitrogen atmosphere was replaced, and the reaction solution was cooled to 0°C. N-bromosuccinimide (163.96 mg, 921.25 μmol) was added. The reaction solution was heated to 25°C and stirred for 19 hours. The reaction solution was added to a saturated aqueous sodium bicarbonate solution (ice-water mixture), the pH adjusted to 7-8, and extracted three times with ethyl acetate (5 mL each). The organic phases were combined, washed with saturated brine (5 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 037-10. 1 H NMR (400MHz, CD3OD) δppm 8.40 (s, 1H), 8.21 (s, 1H), 5.18 (t, J=5.63Hz, 1H), 4.41-4.55 (m, 2H), 2.23-2.32 (m, 2H), 2.05-2.22 (m, 2H), 1.16 (t, J=7.63Hz, 3H).
[0639] Step 9: Synthesis of Compound 037
[0640] To a reaction flask were added 005-2 (58.01 mg, 202.01 μmol), 037-10 (48 mg, 168.34 μmol), ethanol (3 mL), and a solution of sodium carbonate (19.63 mg, 185.17 μmol) in water (0.5 mL). The atmosphere was replaced with nitrogen. Methanesulfonic acid (2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl) palladium (II) (4.27 mg, 5.05 μmol) was added. The atmosphere was replaced with nitrogen. The reaction solution was stirred at 85°C for 2 hours and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 30:1) to obtain 037. 1 H NMR (400MHz, CD3OD) δ=8.24 (d, J=3.2Hz, 2H), 7.44 (dd, J=1.6, 8.4Hz, 1H), 7. 40 (s, 1H), 7.19 (d, J=8.3Hz, 1H), 5.21 (t, J=5.5Hz, 1H), 4.47-4.28 (m, 2H), 3. 39 (s, 3H), 2.97 (t, J = 7.4Hz, 2H), 2.66 (t, J = 7.4Hz, 2H), 2.28 (dq, J = 2.3, 7.6 Hz, 2H), 2.24-2.04 (m, 2H), 1.18 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=366.2[M+H] +SFC analysis and detection (chromatographic column: Chiralpak IG-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 98.96%, retention time 2.179 minutes.
[0641] Example 31
[0642] Synthesis route:
[0643] Step 1: Synthesis of Compound 038-3
[0644] To a reaction flask, 038-2 (18.72 g, 77.29 mmol) and tetrahydrofuran (140 mL) were added sequentially. The nitrogen atmosphere was replaced, and triethylamine (15.64 g, 154.57 mmol) and magnesium bromide (14.23 g, 77.29 mmol) were added. A solution of 038-1 (14 g, 77.29 mmol) in tetrahydrofuran (70 mL) was then added, and the mixture was stirred at 25°C for 2 hours. The reaction solution was poured into 20 mL of water and extracted three times with dichloromethane (30 mL each). The organic phases were combined and washed three times with saturated brine (30 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was then isolated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 038-3. 1 H NMR (400MHz, CDCl3) δ=8.22 (d, J=9.2Hz, 1H), 7.24 (d, J=17.6Hz, 1H), 6.97 (dd, J=2.8, 9.1H z, 1H), 6.84 (d, J=2.6Hz, 1H), 4.13 (q, J=7.2Hz, 2H), 3.90 (s, 3H), 1.13 (t, J=7.2Hz, 3H).
[0645] Step 2: Synthesis of Compound 038-4
[0646] To the reaction flask were added 038-3 (1 g, 3.71 mmol), methanol (35 mL), a solution of ammonium chloride (218.55 mg, 4.09 mmol) in water (10 mL), and iron powder (1.04 g, 18.57 mmol) in sequence. The reaction mixture was heated to 60°C and stirred for 2 hours. The reaction mixture was returned to room temperature and filtered. The filter cake was collected to obtain the crude product 038-4, which was directly carried to the next step without purification. ESI-LCMS: m / z = 194.1 [M+H] + .
[0647] Step 3: Synthesis of Compound 038-5
[0648] To the reaction flask, 038-4 (0.4 g, 2.07 mmol) and N,N-dimethylformamide (5 mL) were added sequentially. The nitrogen atmosphere was replaced, and cesium carbonate (1.35 g, 4.14 mmol) was added. The nitrogen atmosphere was replaced, and the reaction solution was cooled to 0°C. Methyl iodide (1.18 g, 8.28 mmol) was added and stirred at 0°C for 1 hour, then raised to 30°C and stirred for 2 hours. 5 mL of water was added to the reaction solution, and the reaction solution was filtered through celite. The filtrate was collected and transferred to a separatory funnel and extracted three times with ethyl acetate (30 mL each). The organic phases were combined and washed twice with saturated brine (30 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 038-5. ESI-LCMS: m / z = 208.0 [M+H] + .
[0649] Step 4: Synthesis of Compound 038-6
[0650] To the reaction flask, 038-5 (564.51 mg, 2.72 mmol) and dichloromethane (4 mL) were added sequentially. The nitrogen atmosphere was replaced, the reaction solution was cooled to 0°C, and boron tribromide (2M, 5.45 mL) was added. The mixture was stirred at 0°C for 1 hour. The reaction solution was poured into ice water, concentrated to remove dichloromethane, and filtered to collect the filter cake to obtain crude 038-6, which was directly carried to the next step without purification. 1 H NMR (400MHz, CD3OD) δ=7.59 (d, J=9.9Hz, 1H), 7.45 (d, J=9.1Hz, 1H), 7.13 (dd, J=2.6, 9.1Hz, 1H), 7.03 (d, J=2.7Hz, 1H), 3.76 (s, 3H).
[0651] Step 5: Synthesis of Compound 038-7
[0652] 038-6 (197.93 mg, 1.02 mmol) and dichloromethane (2 mL) were added to the reaction flask in sequence. The atmosphere was replaced with nitrogen, and the reaction mixture was cooled to -20°C. Pyridine (129.68 mg, 1.64 mmol) and trifluoromethanesulfonic anhydride (346.91 mg, 1.23 mmol) were added. The mixture was stirred at -20°C for 0.5 hours, then raised to 0°C and stirred for 2 hours. Water (10 mL) was added to the reaction mixture, which was transferred to a separatory funnel and extracted four times with dichloromethane (10 mL each). The organic phases were combined and washed twice with saturated brine (10 mL each). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 038-7. ESI-LCMS: m / z = 325.9 [M+H] + .
[0653] Step 6: Synthesis of Compound 038-8
[0654] To the reaction flask were added 038-7 (90 mg, 276.72 μmol), 1,4-dioxane (1 mL), bispinacol boronate (105.41 mg, 415.08 μmol), [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (30.37 mg, 41.51 μmol), and potassium acetate (81.47 mg, 830.17 μmol, 3 eq). The atmosphere was replaced with nitrogen, and the reaction mixture was stirred at 100°C for 3 hours. The reaction mixture was filtered, the filtrate was collected, and concentrated to give the crude product 038-8, which was used directly in the next step without purification. ESI-LCMS: m / z = 304.0 [M+H] + .
[0655] Step 7: Synthesis of Compound 038
[0656] To a reaction flask were added A-1 (50 mg, 176.58 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (97.62 mg, 706.31 μmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (10.87 mg, 26.49 μmol). The atmosphere was replaced with nitrogen. [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (6.20 mg, 8.83 μmol) and palladium acetate (1.98 mg, 8.83 μmol) were added. The atmosphere was replaced with nitrogen. The reaction mixture was heated to 40°C, and a solution of the crude product of 038-8 (80.29 mg, 264.86 μmol) in tetrahydrofuran (1.5 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was returned to room temperature, filtered through anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain the crude product. The crude product was subjected to preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 1:1:0.5) and chiral separation by SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to afford 038. 1 H NMR (400MHz, CD3OD) δ = 8.40 (s, 1H), 8.25 (s, 1H), 7.79 (d, J = 9.5Hz, 1H), 7.74-7.68 (m, 2H), 7.66-7.59 (m, 1H), 5.23 (br t, J=5.8Hz, 1H), 3.86 (s, 3H), 2.78-2.63 (m, 2H), 2.29 (dq, J=2.2, 7.6Hz, 2H), 2.09 -2.00 (m, 1H), 1.94-1.77 (m, 3H), 1.20 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=380.1[M+H] + SFC analysis (Chromatographic column: Chiralpak IG-3, 50×4.6 mm ID, 3 μm mobile phase: A: CO2, B: ethanol (0.2% 7 M ammonia in methanol); isocratic gradient: 50%), flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.345 minutes.
[0657] Example 32
[0658] Synthesis route:
[0659] Step 1: Synthesis of Compound 039-3
[0660] To the reaction flask, 039-1 (0.5 g, 2.69 mmol) and 039-2 (892.90 mg, 5.37 mmol) were added sequentially. The atmosphere was replaced with nitrogen, and the reaction mixture was heated to 130°C and stirred for 12 hours. The reaction mixture was returned to room temperature and concentrated to afford crude 039-3. This product was used directly in the next step without purification.
[0661] Step 2: Synthesis of Compound 039-4
[0662] To the reaction flask, 039-3 (822.6 mg, 2.69 mmol) and sulfuric acid (4.60 g, 45.96 mmol) were added sequentially. The nitrogen atmosphere was replaced, and the reaction solution was heated to 95°C and stirred for 1 hour. The reaction solution was returned to room temperature, and water (7.5 mL) was added. The reaction solution was transferred to a separatory funnel and extracted twice with ethyl acetate (7.5 mL each). The organic phases were combined and washed with saturated brine (7.5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 20:1 to 5:1) to obtain 039-4. 1 H NMR (400MHz, CDCl3) δppm 7.98 (s, 1H), 7.74 (dd, J=8.97, 2.17Hz, 1H), 7.33 (d, J=9.16Hz, 1H), 6.97 (s, 1H), 6.64-6.93 (m, 1H), 3.73 (s, 3H).
[0663] Step 3: Synthesis of Compound 039-5
[0664] To the reaction flask were added 039-4 (0.33 g, 1.15 mmol), 1,4-dioxane (6 mL), bispinacol boronate (436.32 mg, 1.72 mmol), potassium acetate (337.25 mg, 3.44 mmol), and [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (83.82 mg, 114.54 μmol). The atmosphere was replaced with nitrogen, and the reaction solution was stirred at 80°C for 18 hours. The reaction solution was returned to room temperature and filtered through celite. The filter cake was rinsed with ethyl acetate (5 mL), and the filtrate was collected and concentrated to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 3:1) to obtain 039-5. ESI-LCMS: m / z = 336.0 [M+H] + .
[0665] Step 4: Synthesis of Compound 039
[0666] To the reaction flask, A-1 (100 mg, 353.15 μmol), 039-5 (177.54 mg, 529.73 μmol), ethanol (5 mL), and sodium carbonate (74.86 mg, 706.31 μmol) were added in sequence. The atmosphere was replaced with nitrogen. Tetrakistriphenylphosphine palladium (40.81 mg, 35.32 μmol) was added and the atmosphere was replaced with nitrogen. The reaction solution was heated to 85°C and stirred for 2 hours. The reaction solution was returned to room temperature, anhydrous sodium sulfate (5 g) was added to the reaction solution, and the mixture was filtered through celite. The filter cake was rinsed with ethyl acetate (10 mL), and the filtrate was collected and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.1) and chiral separation (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia aqueous solution)]; isocratic elution: 50% isopropanol (0.1% ammonia aqueous solution)) to obtain 039. 1 H NMR (400MHz, CD3OD) δppm 8.41 (s, 1H), 8.26 (s, 1H), 7.87 (s, 1H), 7.80 (d, J=8.80Hz, 1H), 7.73 (br d, J=8.80Hz, 1H), 7.05-7.33(m, 1H), 6.99(s, 1H), 5.24(brt, J=5.56Hz, 1H), 3.83(s, 3H), 2.62-2.76(m, 2H), 2.24-2.31(m, 2H), 2.03(br) d, J=11.98Hz, 1H), 1.78-1.91 (m, 3H), 1.20 (t, J=7.64Hz, 3H). ESI-LCMS: m / z=412.2[M+H] + SFC analysis and detection (chromatographic column: Chiralpak IG-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.808 minutes.
[0667] Example 33
[0668] Synthesis route:
[0669] Step 1: Synthesis of Compound 040-2
[0670] To a reaction flask, 040-1 (5 g, 36.45 mmol), triethylamine (4.06 g, 40.09 mmol), and dichloromethane (100 mL) were added sequentially. The nitrogen atmosphere was replaced, and a solution of 035-2 (5.47 g, 40.09 mmol) in dichloromethane (7.5 mL) was added. The mixture was stirred at 25°C for 10 minutes. The reaction solution was spin-dried and dissolved in ethyl acetate (100 mL). The mixture was washed once with 1N citric acid (50 mL) and saturated brine (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 040-2, which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ = 7.19-7.11 (m, 2H), 6.97-6.88 (m, 2H), 3.83 (s, 3H), 3.68 (s, 3H), 3.27 (s, 3H), 3.22 (s, 2H).
[0671] Step 2: Synthesis of Compound 040-3
[0672] To the reaction flask, crude 040-2 (8.5 g), aqueous sodium hydroxide solution (1 M, 42.50 mL), and methanol (42.5 mL) were added sequentially, the nitrogen atmosphere was replaced, and the mixture was stirred at 25°C for 2 hours. The reaction solution was concentrated and extracted once with ethyl acetate (30 mL). The aqueous phase was collected, the pH was adjusted to 3-4 with 1N hydrochloric acid, and extracted three times with ethyl acetate (50 mL each). The organic phases were combined and washed with saturated brine (50 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 040-3, which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ=7.14-7.07(m, 2H), 7.00-6.94(m, 2H), 3.85(s, 3H), 3.32(s, 3H), 3.13(s, 2H).
[0673] Step 3: Synthesis of Compound 040-4
[0674] To the reaction flask, crude 040-3 (8 g) and Eaton's reagent (60.60 g, 254.57 mmol) were added sequentially. The atmosphere was replaced with nitrogen and stirred at 70°C for 3 hours. The reaction mixture was cooled to 25°C and poured into ice water (250 mL). The mixture was filtered and the filter cake was collected. Acetonitrile (100 mL) was added and stirred for 0.5 hours. The mixture was filtered and the filter cake was collected to obtain 040-4. 1H NMR (400MHz, DMSO-d6) δ = 11.52 (br s, 1H), 7.46 (d, J=9.3Hz, 1H), 7.34 (d, J=3.0Hz, 1H), 7.27 (dd, J=3.0, 9.1Hz, 1H), 5.95 (s, 1H), 3.81 (s, 3H), 3.54 (s, 3H).
[0675] Step 4: Synthesis of Compound 040-5
[0676] Phosphorus oxybromide (8.59 g, 29.97 mmol) and N,N-dimethylformamide (41 mL) were added sequentially to the reaction flask. The atmosphere was replaced with nitrogen, and 040-4 (4.1 g, 19.98 mmol) was added portionwise. The mixture was stirred at 80°C for 3 hours. The reaction mixture was cooled to 25°C, poured into ice water (200 mL), filtered, and the filter cake was collected and dried to obtain 040-5, which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ=7.44 (d, J=2.9Hz, 1H), 7.34-7.31 (m, 1H), 7.26-7.22 (m, 1H), 7.17 (s, 1H), 3.92 (s, 3H), 3.71 (s, 3H).
[0677] Step 5 Synthesis of Compound 040-6
[0678] 040-5 (1 g, 3.73 mmol), N-fluorobisbenzenesulfonamide (2.35 g, 7.46 mmol), and tetrahydrofuran (30 mL) were added to a reaction flask in sequence. After replacing the nitrogen atmosphere, the temperature was lowered to -78°C, and n-butyllithium (2.5 M, 4.48 mL) was added. The mixture was stirred at -78°C for 1 hour. The reaction solution was diluted with water (10 mL) and extracted three times with ethyl acetate (10 mL each). The organic phases were combined, washed with saturated brine (10 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 040-6. 1 H NMR (400MHz, CDCl3) δ=7.38-7.32 (m, 1H), 7.28 (d, J=2.9Hz, 1H), 7.26-7.24 (m, 1H), 6.43 (d, J=11.3Hz, 1H), 3.90 (s, 3H), 3.70 (s, 3H).
[0679] Step 6: Synthesis of Compound 040-7
[0680] To the reaction flask, 040-6 (170 mg, 820.46 μmol) and dichloromethane (4 mL) were added sequentially. The nitrogen atmosphere was replaced, the temperature was lowered to 0°C, and boron tribromide (2 M in dichloromethane, 1.64 mL) was added. The mixture was stirred at 0°C for 1 hour. The reaction solution was concentrated to obtain 040-7, which was used directly in the next step.
[0681] Step 7: Synthesis of Compound 040-8
[0682] To a reaction flask, crude 040-7 (0.16 g) and dichloromethane (6 mL) were added sequentially. After nitrogen was replaced, the mixture was placed at 0°C, and pyridine (196.55 mg, 2.48 mmol) and trifluoromethanesulfonic anhydride (467.37 mg, 1.66 mmol) were added. The mixture was stirred at 0°C for 0.5 hours. Water (2 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane three times (2 mL each time). The organic phases were combined, washed with saturated brine (5 mL), collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 040-8. 1 H NMR (400MHz, CDCl3) δ=7.75 (d, J=2.8Hz, 1H), 7.61-7.55 (m, 1H), 7.51-7.46 (m, 1H), 6.52 (d, J=10.9Hz, 1H), 3.72 (s, 3H).
[0683] Step 8: Synthesis of Compound 040-9
[0684] To the reaction flask were added 040-8 (150 mg, 461.20 μmol), pinacol borate (175.68 mg, 691.81 μmol), potassium acetate (135.79 mg, 1.38 mmol), and 1,4-dioxane (3 mL) in sequence. The atmosphere was replaced with nitrogen, and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (33.75 mg, 46.12 μmol) was added. The mixture was stirred at 90° C. for 4 hours. The reaction solution was concentrated to obtain the crude product 040-9, which was used directly in the next step.
[0685] Step 9: Synthesis of Compound 040
[0686] To a reaction flask, crude 040-9 (135.42 mg), A-1 (115 mg, 406.13 μmol), sodium carbonate (86.09 mg, 812.25 μmol), water (0.5 mL), and ethanol (3 mL) were added sequentially. After nitrogen was replaced, tetrakistriphenylphosphine palladium (46.93 mg, 40.61 μmol) was added and stirred at 85°C for 1 hour. The reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (ethyl acetate: methanol = 1:0 to 20:1), preparative thin layer chromatography (dichloromethane: ethyl acetate: methanol = 5:5:1), preparative high performance liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM ammonium bicarbonate)-acetonitrile]; gradient: 20%-50% acetonitrile), and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250mm*30mm, 10μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia water)]; isocratic elution: 50% isopropanol (0.1% ammonia water)) to obtain 040. 1 H NMR (400MHz, CDCl3) δ = 8.56 (s, 1H), 8.33 (s, 1H), 7.76 (d, J = 1.7Hz, 1H), 7.64-7.56 (m, 1H), 7.53-7.46 (m, 1H), 6.46 (d, J = 11.0Hz, 1H), 5.80 (br d, J=8.7Hz, 1H), 5.46-5.32 (m, 1H), 3.75 (s, 3H), 2.74-2.55 (m, 2H), 2.30 (q, J=7.6Hz, 2H) , 2.15-2.08 (m, 1H), 1.91-1.76 (m, 3H), 1.23 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=380.2[M+H] + SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: [A: supercritical carbon dioxide B: isopropanol [0.2% 7 M ammonia in methanol]; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%, retention time 1.484 minutes.
[0687] Example 34
[0688] Synthesis route:
[0689] Step 1: Synthesis of compound 041-2
[0690] To the reaction flask, 041-1 (0.85 g, 4.98 mmol) and sodium methoxide (5.4 M in methanol, 8.5 mL) were added sequentially and stirred at 80°C for 1 hour. The reaction mixture was returned to 25°C, and water (5 mL) was added. Extraction was performed with 10 mL of dichloromethane, and the organic phase was collected. The aqueous phase was extracted with dichloromethane (10 mL x 3). The organic phases were combined and washed with saturated brine (10 mL x 2). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude 041-2, which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ=8.88 (s, 1H), 8.21 (d, J=8.9Hz, 1H), 6.91 (d, J=8.9Hz, 1H), 4.03 (s, 3H).
[0691] Step 2: Synthesis of compound 041-3
[0692] To the reaction flask, crude 041-2 (0.26 g) and hydrobromic acid (58.70 g, 239.40 mmol) were added sequentially, the atmosphere was replaced with nitrogen, and the mixture was stirred at 130°C for 2 hours. The reaction mixture was returned to 25°C and concentrated to obtain crude 041-3, which was used directly in the next step. 1 H NMR (400MHz, DMSO-d6) δ=9.10 (s, 1H), 8.21 (d, J=9.0Hz, 1H), 6.72 (d, J=9.0Hz, 1H).
[0693] Step 3: Synthesis of compound 041-4
[0694] To the reaction flask, crude 041-3 (0.38 g), N,N-dimethylformamide (8 mL), and potassium carbonate (690.26 mg, 4.99 mmol) were added sequentially. The nitrogen atmosphere was replaced, the temperature was lowered to 0°C, and iodomethane (1.42 g, 9.99 mmol) was added dropwise. The mixture was stirred at 0°C for 2 hours. 10 mL of water was added to the reaction solution, and 10 mL of ethyl acetate was added for extraction. The layers were separated, and the organic phase was collected. The aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (30 mL × 2), and the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:0) to obtain 041-4. 1 H NMR (400MHz, CDCl3) δ=8.58 (s, 1H), 8.00 (d, J=9.7Hz, 1H), 6.68 (d, J=9.5Hz, 1H), 3.74 (s, 3H).
[0695] Step 4: Synthesis of Compound 041-5
[0696] To the reaction flask, 041-4 (50 mg, 300.84 μmol) and tetrahydrofuran (1 mL) were added sequentially. The atmosphere was replaced with nitrogen, and zinc chloride (0.7 M in tetrahydrofuran, 429.77 μL) was added. The temperature was lowered to -5°C, and lithium bistrimethylsilylamide (1 M in tetrahydrofuran, 601.68 μL) was added dropwise. The temperature was raised to 10°C and stirred for 1 hour. The resulting reaction solution of 041-5 was used directly in the next step without further treatment.
[0697] Step 5: Synthesis of Compound 041
[0698] A-1 (85.15 mg, 300.71 μmol) and N,N-dimethylformamide (3 mL) were added to the reaction flask in sequence. The atmosphere was replaced with nitrogen. Methanesulfonic acid (2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl) palladium (II) (7.04 mg, 9.02 μmol) was added. The atmosphere was replaced with nitrogen. The temperature was raised to 100° C. The reaction mixture of 041-5 was added, and the mixture was stirred at 100° C. for 12 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (ethyl acetate: dichloromethane: methanol = 1:1:0.3) and SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-methanol (0.1% ammonia)]; gradient: 45%-54% methanol (0.1% ammonia)) to obtain 041. 1 H NMR (400MHz, CD3OD) δ = 8.71 (s, 1H), 8.48 (s, 1H), 8.13 (d, J = 9.5Hz, 1H), 6.69 (d, J = 9.5Hz, 1H), 5.24 (br s, 1H), 3.80 (s, 3H), 3.18 (br s, 1H), 3.15-3.10 (m, 1H), 2.29 (dq, J=1.5, 7.6Hz, 2H), 2.09-1.84 (m, 5H), 1.19 (t, J=7.7Hz, 3H); ESI-LCMS: m / z=369.1[M+H] +SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: methanol [0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.968 minutes.
[0699] Example 35
[0700] Synthesis route:
[0701] Step 1: Synthesis of compound 042-3
[0702] To a reaction flask, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (530.70 mg, 1.11 mmol), palladium acetate (124.97 mg, 556.62 μmol), and N,N-dimethylformamide (74 mL) were added sequentially. The atmosphere was purged with nitrogen. 042-1 (3.7 g, 11.13 mmol), triethylamine (9.01 g, 89.06 mmol), and 042-2 (10.83 g, 66.79 mmol) were added, and the atmosphere was purged with nitrogen. The mixture was stirred at 100°C for 16 hours. The reaction solution was cooled to 25°C, water (370 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was collected and washed with saturated brine (100 mL × 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 5:1) to obtain 042-3. 1 H NMR (400MHz, DMSO-d6) δ=7.71 (d, J=16.5Hz, 1H), 7.47-7.33 (m, 6H), 6.68 (d, J=8.9Hz, 1H), 6.48 (d, J=16.4Hz, 1H), 5.85 (s, 2H), 5.24 (s, 2H).
[0703] Step 2: Synthesis of Compound 042-4
[0704] To the reaction flask were added 042-3 (2.18 g, 5.95 mmol), methanol (22 mL), and tributylphosphine (3.61 g, 17.84 mmol) in sequence, and stirred at 70° C. for 1.5 hours. The reaction solution was directly concentrated to obtain crude 042-4, which was used directly in the next step. 1H NMR (400MHz, DMSO-d6) δ=12.14 (br s, 1H), 8.10 (d, J=9.9Hz, 1H), 7.82 (d, J=8.9Hz, 1H), 7.31 (s, 1H), 6.66 (d, J=9.8Hz, 1H).
[0705] Step 3: Synthesis of Compound 042-5
[0706] To a reaction flask, crude 042-4 (5.5 g), N,N-dimethylformamide (55 mL), and potassium carbonate (5.88 g, 42.55 mmol) were added sequentially. The nitrogen atmosphere was replaced, and iodomethane (12.08 g, 85.11 mmol) was added. The mixture was stirred at 25°C for 16 hours. Water (50 mL) was added to the reaction solution, which was filtered and the filter cake was collected to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 3:1) to obtain 042-5. 1 H NMR (400MHz, DMSO-d6) δ=8.14 (d, J=9.9Hz, 1H), 7.93 (d, J=9.1Hz, 1H), 7.49 (d, J=9.3Hz, 1H), 6.78 (d, J=9.9Hz, 1H), 3.61 (s, 3H).
[0707] Step 4: Synthesis of Compound 042-6
[0708] To the reaction flask were added 042-5 (200 mg, 733.88 μmol), pinacol borate (279.54 mg, 1.10 mmol), 1,4-dioxane (4 mL), and potassium acetate (144.05 mg, 1.47 mmol) in sequence. The atmosphere was replaced with nitrogen, and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (53.70 mg, 73.39 μmol) was added. The atmosphere was replaced with nitrogen, and the mixture was stirred at 80°C for 16 hours. The reaction solution was cooled to 25°C and filtered. The filter cake was rinsed with dichloromethane, and the filtrate was collected and concentrated under reduced pressure to obtain the crude product 042-6, which was used directly in the next step.
[0709] Step 5: Synthesis of Compound 042
[0710] To a reaction flask, A-1 (141.76 mg, 500.64 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), potassium carbonate (276.77 mg, 2.00 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (30.83 mg, 75.10 μmol) were added in sequence. The atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (17.57 mg, 25.03 μmol) and palladium acetate (5.62 mg, 25.03 μmol) were added. The temperature was raised to 40°C. A solution of the crude product of 042-6 (240 mg) in tetrahydrofuran (7.2 mL) was added. The atmosphere was replaced with nitrogen. The temperature was raised to 75°C and stirred for 2 hours. The reaction solution was filtered, rinsed with dichloromethane, and the filtrate was collected and concentrated under reduced pressure. 042 was isolated and purified by preparative high performance liquid chromatography (chromatographic column: 2_Phenomenex Gemini C18 75*40mm*3μm; mobile phase: [water (10mM ammonium bicarbonate)-acetonitrile]; gradient: 10%-40% acetonitrile). 1 H NMR (400MHz, DMSO-d6) δ = 8.41 (s, 1H), 8.38-8.25 (m, 1H), 8.25-8.17 (m, 2H), 7.70-7.63 (m, 1H), 7.62-7.46 (m, 1H), 6.82 (d, J = 9.9Hz, 1H), 5.11 (br d, J=6.3Hz, 1H), 3.69 (s, 3H), 2.40-2.31 (m, 2H), 2.23-2.13 (m, 2H), 1.92-1.65 (m, 4H), 1.07 (dt, J=3.8, 7.6Hz, 3H); ESI-LCMS: m / z=396.1[M+H] + .
[0711] Example 36
[0712] Synthesis route:
[0713] Step 1: Synthesis of Compound 043-3
[0714] To the reaction flask were added 043-1 (500 mg, 1.97 mmol), dichloromethane (5 mL), and pyridine (187.19 mg, 2.37 mmol) in sequence. The atmosphere was replaced with nitrogen, and 043-2 (291.91 mg, 2.17 mmol) was added. The mixture was stirred at 20°C for 3 hours. The reaction solution was concentrated to obtain a crude product, which was then isolated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1 to 1:1) to obtain 043-3. 1H NMR (400MHz, CDCl3) δ=7.74-7.57 (m, 3H), 7.42 (dd, J=1.8, 8.2Hz, 1H), 5.29 (d, J=12.0Hz, 1H), 3.96 (q, J=7.0Hz, 2H), 1.36 (s, 15H).
[0715] Step 2: Synthesis of Compound 043-4
[0716] To the reaction flask were added 043-3 (149.02 mg, 423.78 μmol), potassium carbonate (195.24 mg, 1.41 mmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (21.75 mg, 52.97 μmol), bistriphenylphosphine palladium dichloride (12.39 mg, 17.66 μmol), palladium acetate (3.96 mg, 17.66 μmol), water (1.6 mL), acetonitrile (4.8 mL), methanol (1.6 mL) in sequence, the atmosphere was replaced with nitrogen, the temperature was raised to 45 ° C, a solution of A-1 (100 mg, 353.15 μmol) in tetrahydrofuran (1.6 mL) was added, and the temperature was continued to rise to 75 ° C and stirred for 2 hours. 2 mL of water was added to the reaction solution, and the mixture was extracted with dichloromethane (3 mL × 3). The organic phases were combined and washed with saturated brine (3 mL × 3). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=1:1:0.3) to obtain 043-4. 1 H NMR (400MHz, CDCl3) δ = 8.57 (br d, J=2.1Hz, 1H), 8.41-8.09 (m, 1H), 7.69 (dd, J=3.1, 12.0Hz, 1H), 7.62-7.49 (m, 1H), 7.40-7.32 (m, 1H), 5.54-5.42 (m, 1H), 5.40-5.32(m, 1H), 5.31-5.23(m, 1H), 4.14-3.91(m, 2H), 3.02-2.91(m, 2H), 2.44-2.28(m, 4H), 2.21-2.12(m, 2H), 1.39(br t, J=6.7Hz, 3H), 1.23-1.19 (m, 3H).
[0717] Step 3: Synthesis of Compound 043-5
[0718] Concentrated sulfuric acid (1.5 mL) was added to the reaction flask in sequence, the temperature was lowered to 0°C, 043-4 (90 mg, 210.32 μmol) was added, the nitrogen atmosphere was replaced, and the mixture was stirred at 25°C for 2 hours. Water was added to the reaction solution, and the pH of the reaction solution was adjusted to 7-8 with saturated sodium bicarbonate aqueous solution. Ethyl acetate was added for extraction (3 mL × 3), and the organic phases were combined and washed with saturated brine (3 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product of 043-5, which was used directly in the next step. 1 H NMR (400MHz, CD3OD) δ = 8.44 (s, 1H), 8.25 (d, J = 4.5Hz, 1H), 8.17 (s, 1H), 7.97 (d, J = 9.6Hz, 1H), 7.66-7.58 (m, 1H), 7.18 (d, J=5.4Hz, 1H), 5.31-5.18(m, 1H), 2.88-2.79(m, 2H), 2.56-2.47(m, 2H), 2.27-2.22(m, 2H), 2.05-1.99(m, 2H), 1.18(s, 3H).
[0719] Step 4: Synthesis of Compound 043
[0720] To the reaction flask, crude 043-5 (40 mg), N,N-dimethylformamide (0.5 mL), and cesium carbonate (68.26 mg, 209.50 μmol) were added in sequence. The temperature was lowered to 0°C, and iodomethane (22.30 mg, 157.13 μmol) was added to replace the nitrogen atmosphere. The mixture was stirred at 0°C for 1 hour. The reaction solution was poured into 2 mL of water and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol=1:1:0.3) and SFC chiral separation (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain 043. 1H NMR (400MHz, DMSO-d6) δ = 8.41 (s, 1H), 8.39-8.25 (m, 1H), 8.21 (s, 1H), 7.93 (dd, J=9.7, 18.6Hz, 1H), 7.82-7.61(m, 2H), 6.74-6.62(m, 1H), 5.18-5.04(m , 1H), 3.65(s, 3H), 2.42-2.33(m, 2H), 2.25-2.10(m, 2H), 1.95-1.74(m, 2H) , 1.74-1.61 (m, 2H), 1.07 (dt, J=3.4, 7.5Hz, 3H); ESI-LCMS: m / z=396.1[M+H] + SFC analysis (chromatographic column: Chiralpak IH-3, 100×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide; B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.2 min), 50 / 50 (2.4 min), 50 / 50 (3.4 min), 90 / 10 (4.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 2000 psi)) ee = 93.92%, retention time 3.194 minutes.
[0721] Example 37
[0722] Synthesis route:
[0723] Step 1: Synthesis of Compound 044
[0724] To the reaction flask were added 001-3 (120.00 mg, 420.85 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (193.89 mg, 1.40 mmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (21.60 mg, 52.61 μmol) in sequence, the nitrogen atmosphere was replaced, bistriphenylphosphine palladium dichloride (12.31 mg, 17.54 μmol) and palladium acetate (3.94 mg, 17.54 μmol) were added, the nitrogen atmosphere was replaced, the temperature was raised to 45°C, a solution of 037-10 (100 mg, 350.71 μmol) in tetrahydrofuran (6 mL) was added, the temperature was raised to 75°C and stirred for 16 hours. The reaction solution was concentrated to obtain a crude product, which was subjected to preparative thin-layer chromatography (petroleum ether:ethyl acetate=0:1), a second preparative thin-layer chromatography (dichloromethane:methanol=10:1), and chiral separation by SFC (chromatographic column: DAICELCHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia aqueous solution)]; isocratic elution: 40% isopropanol (0.1% ammonia aqueous solution)) to obtain 044. 1 H NMR (400MHz, CD3OD) δ=8.31 (d, J=15.0Hz, 2H), 7.98 (d, J=9.5Hz, 1H), 7.90-7.84 (m, 2H), 7.68 (s, 1H), 6.72 (d, J=9.5Hz, 1H), 5.24 (s, 1H), 4.53-4.28 (m, 2H), 3.79 (s, 3H), 2.33-2.26 (m, 2H), 2.25-2.07 (m, 2H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=364.2[M+H] + SFC analysis and detection (chromatographic column: Chiralcel AD-3, 150×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi) ee = 100%, retention time 3.894 minutes.
[0725] Example 38
[0726] Synthesis route:
[0727] Step 1: Synthesis of Compound 045-1
[0728] To a reaction flask, 023-1 (120 mg, 491.59 μmol), triisopropyl borate (309.72 mg, 1.65 mmol), and tetrahydrofuran (1.2 mL) were added sequentially. The atmosphere was replaced with nitrogen, and the temperature was lowered to -5°C. Isopropylmagnesium chloride-lithium chloride (1.3 M, 567.21 μL) was added, and the mixture was stirred at -5°C for 0.5 h. Isopropylmagnesium chloride-lithium chloride complex (1.3 M solution in tetrahydrofuran, 378.14 μL) was added, and the mixture was stirred at -5°C for 1 h. Isopropylmagnesium chloride-lithium chloride complex (1.3 M solution in tetrahydrofuran, 567.21 μL) and triisopropyl borate (92.45 mg, 491.59 μmol) were further added, and the mixture was stirred at 0°C for 0.5 h. 0.9 mL of methanol was added to the reaction solution, and the resulting reaction solution containing 045-1 was used directly in the next step.
[0729] Step 2: Synthesis of Compound 045
[0730] To the reaction flask were added 037-10 (69.57 mg, 243.98 μmol), tetrahydrofuran (0.9 mL), water (0.3 mL), acetonitrile (0.3 mL), potassium carbonate (134.88 mg, 975.94 μmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (15.02 mg, 36.60 μmol) in sequence, and the atmosphere was replaced with nitrogen. Bistriphenylphosphine palladium dichloride (8.56 mg, 12.20 μmol) and palladium acetate (2.74 mg, 12.20 μmol) were added, and the atmosphere was replaced with nitrogen. The reaction solution of the above 045-1 was added at 45°C, and the temperature was raised to 75°C and stirred for 16 hours. The reaction solution was concentrated to obtain a crude product, which was then separated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 0:1), a second preparative thin-layer chromatography (dichloromethane:methanol = 10:1), and preparative high-performance liquid chromatography (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; gradient: 10%-43% acetonitrile) to obtain 045. 1 H NMR (400MHz, CD3OD) δ = 8.67 (s, 1H), 8.28-8.19 (m, 1H), 7.97-7.90 (m, 1H), 7.74 (s, 1H), 6.5 6(d, J=9.3Hz, 1H), 5.23(s, 1H), 4.66-4.46(m, 2H), 3.76(s, 3H), 2.32-2.27(m, 2H), 2.26(br s, 2H), 1.19 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=370.1[M+H] +SFC detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: 0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee = 100%, retention time 1.479 minutes.
[0731] Example 39
[0732] Synthesis route:
[0733] Step 1: Synthesis of Compound 046-1
[0734] To the reaction flask, 017-8 (0.25 g, 1.02 mmol) and tetrahydrofuran (6.25 mL) were added sequentially. The atmosphere was purged with nitrogen and the temperature was lowered to -15 to -20°C. Isopropylmagnesium chloride-lithium chloride complex (1.3 M solution in tetrahydrofuran, 1.95 mL) was added dropwise. The mixture was stirred at -15 to -20°C for 0.5 hour. Triisopropyl borate (353.59 mg, 3.40 mmol) was added and stirring continued for 0.5 hour. 0.5 mL of methanol was added to the reaction solution, and the resulting reaction solution of 046-1 was used directly in the next step.
[0735] Step 2: Synthesis of Compound 046
[0736] To the reaction flask, 037-10 (0.13 g, 455.92 μmol), potassium phosphate (193.56 mg, 911.84 μmol), isopropanol (7.2 mL), and water (1.2 mL) were added sequentially. The atmosphere was replaced with nitrogen and dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium(II) (32.28 mg, 45.59 μmol) was added. The atmosphere was replaced with nitrogen again and the temperature was raised to 45°C. The reaction solution of 046-1 was added dropwise. After the addition was complete, the temperature was raised to 75°C and stirred for 2 hours. The reaction solution was filtered through anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to dichloromethane:methanol = 1:1) and preparative high-performance liquid chromatography (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; 15%-50% acetonitrile isocratic gradient) to obtain 046. 1H NMR (400MHz, CD3OD) δ = 8.57 (br s, 1H), 8.14 (br s, 1H), 7.36 (s, 1H), 5.19 (t, J=5.5Hz, 1H), 4.64-4.42 (m, 2H), 3.34 (s, 3H), 2.93-2.84 (m, 2 H), 2.77-2.66 (m, 2H), 2.34-2.08 (m, 4H), 1.18 (t, J=7.6Hz, 3H); ESI-LCMS: m / z=372.2[M+H] + ; SFC analysis and detection (chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm mobile phase: A: supercritical carbon dioxide B: 0.2% 7 M ammonia in methanol); gradient: A / B=95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) ee=100%, retention time 1.431 minutes.
[0737] Example 40
[0738] Synthesis route:
[0739] Step 1: Synthesis of Compound 047-2
[0740] To the reaction flask, 047-1 (350 mg, 2.06 mmol), methanol (7 mL), and sodium methoxide (5.4 M in methanol, 2 mL) were added sequentially. The mixture was placed in a microwave reactor and heated to 100°C with stirring for 5 hours. Three batches of the same scale were carried out in parallel and combined for post-processing. The combined reaction mixtures were concentrated, and 20 mL of water and 20 mL of ethyl acetate were added. The aqueous phase was collected and extracted with ethyl acetate (10 mL x 2). The organic phases were combined, washed with saturated brine, and the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product of 047-2. 1 H NMR (400MHz, CDCl3) δppm 8.00 (d, J=8.53Hz, 1H), 7.67 (d, J=5.52Hz, 1H), 7.41 (d, J=5.52Hz, 1H), 6.77 (d, J=8.53Hz, 1H), 4.02 (s, 3H).
[0741] Step 2: Synthesis of Compound 047-3
[0742] 047-2 (0.9 g), acetic acid (9 mL), and hydrobromic acid (9 mL, 66.29 mmol, 40% concentration) were added to the reaction flask in sequence. After nitrogen replacement, the mixture was stirred at 85°C for 18 hours. The reaction solution was concentrated under reduced pressure to obtain crude 047-3. 1 H NMR (400MHz, CD3OD) δppm 8.73 (d, J=9.29Hz, 1H), 8.32 (d, J=5.52Hz, 1H), 7.44 (d, J=5.52Hz, 1H), 7.07 (d, J=9.03Hz, 1H).
[0743] Step 3: Synthesis of Compound 047-4
[0744] To the reaction flask, 047-3 (1.43 g) and N,N-dimethylformamide (30 mL) were added sequentially, followed by potassium tert-butoxide (3.18 g, 28.38 mmol) at 0°C. After stirring at 0°C for 15 minutes, iodomethane (1.47 mL, 23.65 mmol) was added dropwise, and the temperature was raised to 20°C and stirred for 18 hours. The mixture was diluted with 40 mL of ethyl acetate, and 80 mL of hydrochloric acid (1 M) was added for extraction. The layers were separated, and the aqueous phase was extracted with ethyl acetate (40 mL x 5). The organic phases were combined, washed with saturated brine (140 mL x 3), and the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was isolated and purified by column chromatography (ethyl acetate:petroleum ether = 10-100%) to obtain 047-4. 1 H NMR (400MHz, CD3OD) δppm 7.97 (d, J=9.29Hz, 1H), 7.89 (d, J=5.52Hz, 1H), 7.32 (d, J=5.52Hz, 1H), 6.55 (d, J=9.29Hz, 1H), 3.75 (s, 3H).
[0745] Step 4: Synthesis of Compound 047-5
[0746] To the reaction flask, 047-4 (213 mg, 1.29 mmol) and tetrahydrofuran (12 mL) were added sequentially. The nitrogen atmosphere was replaced, the temperature was lowered to 0°C, and a solution of N-bromosuccinimide (210 mg, 1.18 mmol) in tetrahydrofuran (12 mL) was added. The mixture was stirred at 0°C for 1 hour. A semi-saturated aqueous sodium thiosulfate solution (40 mL) was added to the reaction solution, and the mixture was stirred at 25°C for 5 minutes. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was separated and purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:5) to afford 047-5. 1H NMR (400MHz, CDCl3) δppm 8.14 (s, 1H), 7.62 (d, J=5.52Hz, 1H), 7.06 (d, J=5.52Hz, 1H), 3.81 (s, 3H).
[0747] Step 5: Synthesis of Compound 047-6
[0748] To the reaction flask, 047-5 (174 mg, 712.80 μmol) and tetrahydrofuran (4 mL) were added sequentially, and the atmosphere was replaced with nitrogen. The temperature was lowered to 0°C, and isopropylmagnesium chloride-lithium chloride complex (2M solution in tetrahydrofuran, 534.60 μL) was added dropwise. The mixture was stirred at 20°C for 0.5 hours. A solution of trimethyl borate (161.02 μL, 1.43 mmol) in tetrahydrofuran (4 mL) was added dropwise at 0°C, and the temperature was raised to 20°C, and stirred for 0.5 hours. 1 mL of methanol was added to the reaction solution to obtain a 047-6 reaction solution, which was used directly in the next step.
[0749] Step 6: Synthesis of Compound 047
[0750] To a reaction flask, add A-1 (222.03 mg, 784.10 μmol), potassium carbonate (394.06 mg, 2.85 mmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (43.89 mg, 106.92 μmol), acetonitrile (8 mL), and water (1.6 mL) in sequence. After replacing the atmosphere with nitrogen, add bis(triphenylphosphine)palladium(II) dichloride (25.02 mg, 35.64 μmol) and palladium acetate (8.00 mg, 35.64 μmol). After replacing the atmosphere with nitrogen, add the reaction solution of 047-6 dropwise. After addition is complete, heat the mixture to 75°C and stir for 1 hour. Filter the reaction mixture through a funnel containing anhydrous sodium sulfate, collect the filtrate, and concentrate to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography (dichloromethane:methanol=15:1), SFC chiral separation [chromatographic column: DAICEL CHIRALCELOJ (250 mm*30 mm, 10 μm); mobile phase: supercritical carbon dioxide-ethanol (0.1% ammonia water)]; isocratic elution: 25% ethanol (0.1% ammonia water)], and preparative high-performance liquid chromatography [chromatographic column: Welch Xtimate C18 150*30 mm*5 μm; mobile phase: water (0.225% formic acid)-acetonitrile]; gradient: 5%-35% acetonitrile] to obtain 047. 1H NMR (400MHz, CDCl3) δppm 8.51 (br s, 1H), 8.28 (s, 1H), 7.72 (s, 1H), 7.65-7.70 (m, 1H), 7.13 (d, J=5.52Hz, 1H), 5.92 (br s, 1H), 5.30-5.37 (m, 1H), 3.80 (s, 3H), 2.41 (br s, 2H), 2.27 (q, J=7.53Hz, 2H), 2.00-2.10 (m, 1H), 1.73-1.93 (m, 3H), 1.21 (t, J=7.53Hz, 3H); ESI-LCMS: m / z=368.1[M+H] + SFC analysis (chromatographic column: Chiralcel OJ-350×4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: ethanol (0.05% diethylamine); gradient: 5% to 40% B (2 min), 40% B (hold 1.2 min), 5% of B (hold 0.5 min); flow rate: 3.0 mL / min; column temperature: 35°C; column pressure: 1500 psi) ee = 98.58%, retention time 1.394 minutes.
[0751] Example 41
[0752] Synthesis route:
[0753] Step 1: Synthesis of Compound 048-2
[0754] To a reaction flask, 048-1 (0.819 g, 3.86 mmol) and tetrahydrofuran (10 mL) were added sequentially. After stirring to dissolve, tetraethyl titanate (1.60 mL, 7.72 mmol) was added, followed by a solution of A-1-2 (468.13 mg, 3.86 mmol) in tetrahydrofuran (10 mL). The mixture was stirred at 75°C for 1 hour. The reaction mixture was allowed to cool to room temperature, and 40 mL of ethyl acetate and 40 mL of saturated sodium bicarbonate aqueous solution were added sequentially. The mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate, water, and ethyl acetate (40 mL x 2). The filtrate was collected and separated. The organic phase was collected and washed sequentially with saturated sodium bicarbonate aqueous solution and saturated brine (100 mL each). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate:petroleum ether = 10-30%) to obtain 048-2. 1 H NMR (400MHz, CDCl3) δppm 8.90 (s, 1H), 8.73 (s, 1H), 3.50-3.63 (m, 2H), 3.10-3.22 (m, 2H), 1.34 (s, 9H).
[0755] Step 2: Synthesis of Compound 048-3
[0756] To the reaction flask, 048-2 (255 mg, 808.94 μmol) and tetrahydrofuran (10 mL) were added sequentially, and the atmosphere was replaced with nitrogen. 9-Borabicyclo[3.3.1]nonane (0.5 M tetrahydrofuran solution, 4.04 mL) was added dropwise at 0°C, and the mixture was heated to 20°C and stirred for 16 hours. Saturated aqueous ammonium chloride (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was collected, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 048-3.
[0757] Step 3: Synthesis of Compound 048-4
[0758] To the reaction flask, 048-3 (170 mg, 535.86 μmol) and ethanol (9 mL) were added sequentially. The mixture was placed at 0°C, and trimethylsilyl chloride (136.02 μL, 1.07 mmol) was added. The mixture was heated to 20°C and stirred for 2 hours. The reaction solution was concentrated to obtain crude 048-4. The product was directly processed into the next step without purification. ESI-LCMS: m / z = 213.0 [M+H] + .
[0759] Step 4: Synthesis of Compound 048-5
[0760] To the reaction flask, 048-4 (115 mg, 539.72 μmol), dichloromethane (9 mL), and N,N-diisopropylethylamine (159.23 μL, 914.17 μmol) were added in sequence. The mixture was placed at 0°C, and a solution of propionic anhydride (72 μL, 558.78 μmol) in dichloromethane (9 mL) was added. The mixture was stirred at 0°C for 1 hour. 10 mL of water was added, the layers were separated, and the aqueous phase was extracted with dichloromethane (10 mL x 3). The organic phases were combined and washed with 20 mL of saturated brine. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was isolated and purified by preparative thin-layer chromatography (dichloromethane:methanol = 15:1, with 1% triethylamine added) to obtain 048-5. ESI-LCMS: m / z = 269.1 [M+H] + .
[0761] Step 5: Synthesis of Compound 048
[0762] To a reaction flask, 048-5 (58 mg, 215.50 μmol), 1,4-dioxane (5 mL), 001-3 (155.08 mg, 431.01 μmol), potassium carbonate (119.14 mg, 862.01 μmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (13.27 mg, 32.33 μmol), and water (1 mL) were added sequentially. The atmosphere was replaced with nitrogen, and palladium acetate (2.42 mg, 10.78 μmol) and bis(triphenylphosphine)palladium(II) dichloride (7.56 mg, 10.78 μmol) were added. The mixture was heated to 75°C and stirred for 2 hours. An additional 001-3 (155.08 mg, 431.01 μmol) was added, and the mixture was stirred at 75°C for 18 hours. The reaction mixture was returned to 20°C and filtered through anhydrous sodium sulfate. The filter cake was rinsed with 15 mL of ethyl acetate. The filtrate was collected and concentrated to obtain the crude product, which was then subjected to preparative thin-layer chromatography (dichloromethane:methanol=20:1) and chiral separation by SFC [column: DAICEL CHIRALPAK AS (250mm*30mm, 10μm); mobile phase: supercritical carbon dioxide-ethanol (0.1% ammonia solution); isocratic elution: 40% ethanol (0.1% ammonia solution)] to afford 048. 1 H NMR (400MHz, CDCl3) δppm 8.56 (br s, 2H), 7.72 (d, J=9.29Hz, 1H), 7.60-7.68 (m, 2H), 7.48 (d, J=8.53Hz, 1H), 6.78 (d, J=9.29Hz, 1H), 5.78 (br d, J=7.03Hz, 1H), 5.69 (q, J=7.70Hz, 1H), 3.78 (s, 3H), 2.98-3.12 (m, 2H), 2.63-2.74 (m, 1H) ), 2.32 (q, J=7.53Hz, 2H), 1.82-1.92 (m, 1H), 1.22-1.26 (m, 3H); ESI-LCMS: m / z=348.2[M+H] + SFC detection (chromatographic column: Chiralpak AD-3 50×4.6mm ID, 3μm; mobile phase: A: supercritical carbon dioxide; B: ethanol (0.05% diethylamine); gradient: 5% to 40% B (1.5 min), 40% B (hold 1.0 min), 5% of B (hold 0.5 min); flow rate: 4 mL / min; column temperature: 35°C; column pressure: 1500 psi)) ee = 100%, retention time 1.927 minutes.
[0763] Biological evaluation
[0764] Experimental Example 1: In vitro activity test of human CYP11B2 monoclonal cells overexpressing human CYP11B2
[0765] The human renal leiomyoma G402 cell line overexpressing human CYP11B2 was used as a compound activity screening system. Detailed information is as follows:
[0766] 1) For information on cells, reagents, and instruments, see Tables 1 and 2.
[0767] Table 1 Cell and reagent information
[0768] Table 2 Instrument information
[0769] 2) Compound information: Test compounds were prepared in DMSO at a working concentration of 10 μM.
[0770] 3) Experimental methods
[0771] Day 1: Digest the cells and resuspend the human renal leiomyoma G402 cells that overexpress human CYP11B2 to 1*10 5 cells / mL, 100 μL was plated into a 96-well plate;
[0772] The next day: The culture medium was changed to DMEM / F12 containing 2.5% charcoal-stripped fetal bovine serum. Test compounds were added: 5 μL of the test compound was added to the cell culture medium to obtain final concentrations of 10,000, 2,500, 625, 156.25, 39.06, 9.77, 2.44, 0.61, 0.15, and 0 nM (DMSO content was 0.1%).
[0773] One hour later, the substrate was added: 30 mM 11-deoxycorticosterone was diluted 1500-fold with culture medium and 5 μL was dispensed into each well to make the final concentration 1 μM, and the cells were incubated for 16 hours.
[0774] Day 3: Collect cell supernatant and add 200 μL of methanol solution containing internal standard (internal standard: 35 ng / mL ketoprofen, 7.5 ng / mL carbamazepine, 5 ng / mL diphenhydramine, or 10 ng / mL tolbutamide). Vortex and centrifuge (4000 × g, 4°C, 5 minutes). Take 100 μL of supernatant and add 100 μL of purified water. Vortex and centrifuge (4000 × g, 4°C, 15 minutes). The supernatant is analyzed by ESI-LCMS / MS.
[0775] 4) Data Analysis
[0776] Ratio = aldosterone peak area / internal standard peak area
[0777] Control activity%=Ratio test compound / Ratio DMSO x 100%
[0778] Ratio test compound is the Ratio value at different concentrations of the test compound
[0779] Ratio DMSO is the Ratio value without adding test compound
[0780] X = Log(compound concentration)
[0781] Y=Control activity%
[0782] The IC values of the test compounds were obtained by fitting the nonlinear regression equation using XLfit 5.5.0. 50 The test results are shown in Table 3.
[0783] Table 3 In vitro activity test results of human CYP11B2 monoclonal cells overexpressing human CYP11B2
[0784] Experimental conclusion: The compound of the present invention has a significant inhibitory effect on human CYP11B2, can inhibit aldosterone production, and can be used clinically to treat primary aldosteronism, refractory hypertension and other metabolic syndromes related to aldosterone abnormalities.
[0785] Experimental Example 2: In vitro activity test of human CYP11B1 monoclonal cells overexpressing human CYP11B1
[0786] The human renal leiomyoma G402 cell line overexpressing human CYP11B1 was used as a compound selectivity screening system. Detailed information is as follows:
[0787] 1) The cells, reagents, and instrument information are consistent with those in Experimental Example 1 (overexpression of human CYP11B2 monoclonal cell activity).
[0788] 2) Compound information: Test compounds were prepared in DMSO at a working concentration of 50 μM.
[0789] 3) Experimental methods
[0790] Day 1: Digest cells and resuspend human renal leiomyoma G402 cells overexpressing CYP11B1 to 1*10 5 cells / mL, 100 μL was plated into a 96-well plate;
[0791] The next day: the culture medium was changed to DMEM / F12 containing 2.5% charcoal-stripped fetal bovine serum;
[0792] Add test compounds: 5 μL of test compounds were added to the cell culture medium to make the final concentrations 50,000, 12,500, 3,125, 1,526, 781.25, 260.42, 86.81, 28.94, 9.65, and 0 nM (DMSO content was 0.5%);
[0793] One hour later, the substrate was added: 30 mM 11-deoxycortisol was diluted 1500-fold with culture medium and 5 μL was dispensed into each well to make the final concentration 1 μM. The cells were then incubated for 16 hours.
[0794] Day 3: Collect cell supernatant and add 200 μL of methanol solution containing internal standard (internal standard: 35 ng / mL ketoprofen, 7.5 ng / mL carbamazepine, 5 ng / mL diphenhydramine, or 10 ng / mL tolbutamide). Vortex and centrifuge (4000 × g, 4°C, 5 minutes). Take 100 μL of supernatant and add 100 μL of purified water. Vortex and centrifuge (4000 × g, 4°C, 15 minutes). The supernatant is analyzed by ESI-LCMS / MS.
[0795] 4) Data Analysis
[0796] Ratio = cortisol peak area / internal standard peak area
[0797] Control activity%=Ratio test compound / Ratio DMSO x100%
[0798] Ratio test compound is the Ratio value at different concentrations of the test compound
[0799] Ratio DMSO is the Ratio value without adding test compound
[0800] X = Log(compound concentration)
[0801] Y=Control activity%
[0802] The IC values of the test compounds were obtained by fitting the nonlinear regression equation using XLfit 5.5.0. 50 The test results are shown in Table 4.
[0803] Table 4: In vitro activity test results of human CYP11B1 monoclonal cells overexpressing human CYP11B1
[0804] Experimental conclusion: The compound of the present invention has a weak inhibitory effect on human CYP11B1, hardly affects the synthesis of cortisol, and has better clinical safety.
[0805] Experimental Example 3: Pharmacokinetic Study in Rats
[0806] Experimental Purpose: Male Sprague-Dawley rats were used as test subjects to determine compound plasma concentrations and evaluate pharmacokinetic behavior after a single dose. Experimental Procedure: Two healthy adult male Sprague-Dawley rats were selected for the oral administration group. The oral administration vehicle consisted of 20% PEG400 / 10% solutol / 70% water. The test compound was mixed with the vehicle, vortexed, and sonicated to produce a 0.25 mg / mL clear solution. Following oral administration of 2 mg / kg to rats, whole blood was collected over a period of time to prepare plasma. Drug concentrations were analyzed by LC-MS / MS, and pharmacokinetic parameters were calculated using Phoenix WinNonlin software (Pharsight, USA). The experimental results are shown in Table 5.
[0807] Table 5 PK test results of the compounds of the present invention in rats
[0808] Experimental conclusion: The compound of the present invention showed a long half-life, a high oral exposure and a good oral bioavailability in the oral pharmacokinetic experiment in rats, demonstrating the good pharmacokinetic properties of oral drugs.
[0809] Experimental Example 4: Pharmacokinetic Study in Cynomolgus Monkeys
[0810] Experimental purpose: Male cynomolgus macaques were used as test animals. After a single dose, the blood concentration of the compound was determined and the pharmacokinetic behavior was evaluated. Experimental procedure: Two healthy male cynomolgus macaques were selected as the oral group. The solvent for the oral group was 20% PEG400 / 10% solutol / 70% water. After the test compound was mixed with the solvent, it was vortexed and sonicated to prepare a 0.6 mg / mL clear solution. The oral dosage for cynomolgus macaques was: 1 mg / kg or 3 mg / kg. After oral administration, whole blood was collected for a certain period of time to prepare plasma. The drug concentration was analyzed by LC-MS / MS method, and the pharmacokinetic parameters were calculated using Phoenix WinNonlin software (Pharsight, USA). The experimental results are shown in Table 6.
[0811] Table 6 PK test results of the compounds of the present invention in cynomolgus monkeys Note: -- indicates not tested.
[0812] Experimental conclusion: The compound of the present invention exhibited a long half-life, a high oral exposure and good oral bioavailability in the oral pharmacokinetic experiment in cynomolgus monkeys, demonstrating the good pharmacokinetic properties of oral drugs.
[0813] Experimental Example 5: Permeability Test
[0814] Experimental purpose: The permeability and efflux rate of the compounds of the present invention were determined using the MDR1-MDCKII monolayer cell model to determine the membrane permeability of the compounds and their potential for efflux via the P-gp transporter.
[0815] Experimental protocol: MDR1-MDCKII cells (from the Netherlands Cancer Institute) were seeded in 96-well plates (from Corning) at a cell density of 3.33×10 5 cells / ml, cultured for 4-7 days to form a copolymerized cell monolayer. Hank's balanced salt buffer (pH 7.40) containing 10mM 4-hydroxyethylpiperazineethanesulfonic acid was used as the transport buffer. The bidirectional transport of the test compound at a concentration of 2μM was tested, and the concentration of DMSO in the incubation system was controlled below 1%. After addition of the sample, the cell plate was placed at 37±1°C, 5% CO2 and saturated humidity and incubated for 2.5 hours. All samples were quantitatively analyzed by LCMS / MS method. The apparent permeability coefficient (P app , cm / s) and efflux ratio (ER). Apparent permeability coefficient (P app , cm / s) is calculated using the following formula: P app =(dC r / dr)x V r / (A x C0). Where, dC r / dt is the cumulative concentration of the compound at the receiving end per unit time (μM / s); V r is the volume of the solution at the receiving end (the volume of the solution at the apical and basal ends is 0.075 mL and 0.250 mL, respectively); A is the relative surface area of the cell monolayer (0.143 cm 2 ); C0 is the starting concentration of the test sample at the dosing end (μM) or the peak area ratio of the reference sample. The efflux ratio is calculated using the following formula: ER = P app (BA) / P app (AB). The experimental results are shown in Table 7.
[0816] Table 7 Compound permeability test results
[0817] Experimental conclusion: The compound of the present invention is a high permeability, low efflux compound with good drugability.
[0818] Experimental Example 6: In vitro metabolic stability study of liver microsomes
[0819] Aim: To evaluate the metabolic stability of the test compounds in human liver microsomes.
[0820] Experimental materials: purchased from Corning or Xenotech, stored in a -80°C freezer; reduced nicotinamide adenine dinucleotide phosphate (NADPH), supplier: Chem-impex international; control compounds: testosterone, diclofenac, propafenone.
[0821] Experimental operation:
[0822] 1. Preparation of working solution
[0823] Stock solution: 10mM DMSO solution. Working solution concentration: dilute the stock solution to 100μM with 100% acetonitrile (organic phase content: 99% acetonitrile, 1% DMSO)
[0824] 2. Experimental Operation
[0825] Prepare two incubation plates, named T60 incubation plate and NCF60 incubation plate, and preheat the incubation plates for 10 minutes.
[0826] Liver microsomes were diluted with 100 mM potassium phosphate buffer to a protein concentration of 0.56 mg / mL.
[0827] Transfer 445 μL of microsomal working solution (liver microsomal protein concentration is 0.56 mg / mL) to preheated incubation plates T60 and NCF60 and pre-incubate in a 37°C water bath for 10 minutes.
[0828] After the pre-incubation, add 5 μL of the test sample or control compound working solution to each of the T60 and NCF60 incubation plates and mix thoroughly. Add 50 μL of potassium phosphate buffer to each well of the NCF60 incubation plate and mix thoroughly to start the reaction.
[0829] To the T0 stop plate, 180 μL of stop solution (200 ng / mL tolbutamide and 200 ng / mL labetalol in acetonitrile) and 6 μL of NADPH regeneration system working solution were added. A 54 μL sample was removed from the T60 incubation plate and transferred to the T0 stop plate (T0 sample generation). The reaction was initiated by adding 44 μL of NADPH regeneration system working solution to each well of the T60 incubation plate. A blank plate was filled with only 54 μL of microsome working solution, 6 μL of NADPH regeneration system working solution, and 180 μL of stop solution. Therefore, in the test or control compound samples, the final reaction concentration of the compound, testosterone, diclofenac, and propafenone was 1 μM, the concentration of liver microsomes was 0.5 mg / mL, and the final concentrations of DMSO and acetonitrile in the reaction system were 0.01% (v / v) and 0.99% (v / v), respectively.
[0830] After incubation for an appropriate time (5, 15, 30, 45, 60 minutes), 180 μL of stop solution was added to each sample well of the stop plate, and then 60 μL of sample was taken from the T60 incubation plate and added to the stop plate to terminate the reaction.
[0831] All samples were shaken and then centrifuged at 4°C for 20 minutes (4000 rpm). 80 μL of supernatant was diluted in 240 μL of pure water per well and mixed for 10 minutes. LC-MS / MS analysis was performed. The results are shown in Table 8.
[0832] Table 8 Stability test results of the compounds of the present invention in human liver microsomes
[0833] Experimental conclusion: The compound of the present invention exhibits a low clearance rate in human liver microsomes and has good metabolic stability.
[0834] Experimental Example 7: Plasma protein binding test of compounds
[0835] Experimental purpose: Equilibrium dialysis was used to evaluate the protein binding rate of the compound of the present invention in the plasma of SD rats, cynomolgus monkeys and humans.
[0836] Test plan:
[0837] 796 μL of blank plasma from humans, SD rats and cynomolgus monkeys (plasma purchased from Bioreclamation IVT) was added to the working solution of the test compound or the working solution of warfarin so that the final concentrations of the test compound and warfarin in the plasma samples were both 2 μM.
[0838] Mix the samples thoroughly. The final concentration of DMSO in the organic phase is 0.5%. Pipette 50 μL of the test compound and warfarin plasma samples into the sample receiving plate. Immediately add the corresponding volume of blank plasma or buffer to make the final volume of each sample well 100 μL. The volume ratio of plasma to dialysis buffer is 1:1. Then, add the stop solution to these samples. These samples will serve as T0 samples for recovery and stability determination.
[0839] The test compound and warfarin plasma sample were added to the dosing port of each dialysis well, and blank dialysis buffer was added to the corresponding receiving port of the dialysis well. The dialysis plate was then sealed with a breathable membrane and placed in a humidified 5% CO2 incubator at 37°C, shaking at 100 rpm for 4 hours.
[0840] After dialysis, transfer 50 μL of post-dialysis buffer and post-dialysis plasma samples to a new sample receiving plate. Add the corresponding volume of blank plasma or buffer to the sample, so that the final volume of each sample well is 100 μL, and the volume ratio of plasma to dialysis buffer is 1:1.
[0841] Data Analysis:
[0842] All samples were subjected to LC / MS / MS analysis after protein precipitation, and the free rate and plasma protein binding rate of the compound were calculated by the following formula: free rate (%) = 100*Fc / Tc, compound plasma protein binding rate (%) = 100% - compound free rate (%), where Fc is the concentration of the compound at the buffer end of the dialysis plate; Tc is the concentration of the compound at the plasma end of the dialysis plate; T0 is the concentration of the compound in the plasma sample at time zero.
[0843] The experimental results are shown in Table 9.
[0844] Table 9 Plasma protein binding results of the compounds of the present invention
[0845] Experimental conclusion: The compound of the present invention has moderate binding to plasma proteins of different species, and the proportion of plasma free drug is moderate, and has good drugability.
[0846] Experimental Example 8: Human Liver Microsome CYP Inhibition Experiment
[0847] Aim: To evaluate the inhibitory activity of the test article against human liver microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) using a 5-in-1 probe substrate of CYP isoenzymes.
[0848] Pooled human liver microsomes (HLM) were purchased from Corning Inc. (Steuben, New York, USA) and stored below -70°C before use.
[0849] A series of diluted test sample working solutions were added to an incubation system containing human liver microsomes, probe substrates, and cofactors of the circulating system. A control containing no test sample but solvent was used as an enzyme activity control (100%). The concentration of metabolites generated by the probe substrate in the sample was determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS). Nonlinear regression analysis of the average percentage activity of the test sample versus the concentration was performed using SigmaPlot (V.11). IC was calculated using a three-parameter or four-parameter sigmoidal logarithmic equation. 50 The experimental results are shown in Table 10.
[0850] Table 10 Cytochrome P450 isoenzyme half-maximal inhibitory concentration IC 50 (μM)
[0851] Experimental conclusion: The compounds of the present invention have no inhibitory effect on CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and the risk of drug-drug interactions is extremely low.
Claims
1. A compound represented by formula (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, in, Ring A is selected from Ring A1 and Ring A2; Ring A1 is selected from Ring A2 is selected from described are each independently optionally substituted with 1, 2 or 3 R1; Ring B is selected from Ring B1 and Ring B2; Ring B1 is selected from phenyl, pyridyl and pyridazinyl, and the phenyl, pyridyl and pyridazinyl are each independently optionally substituted by 1, 2 or 3 R6; Ring B2 is selected from 5-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R6; T is selected from a single bond, CH2, NH and O; T1 is selected from O and CR4R5; R1 is selected from H, =NR, C 1-3 Alkyl and C 1-3 alkyl halide; Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy, wherein R2, R3, R4 and R5 cannot all be H at the same time; Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group; Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl group; Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group; Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl; Structural unit Selected from R 71 is selected from 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R a replaced by; R 81 selected from H, F, Cl, Br, I and C 1-3 alkyl; Ring C is selected from ring C1 and ring C2; Ring C1 is selected from C substituted with one R9 5-6 Cycloalkyl, wherein R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=o)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace; Ring C2 is selected from described Each independently optionally replaced by 1, 2 or 3 R e replace; Each R a are independently selected from F, Cl, Br, I, C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl; Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl; R c and R d Together with the carbon atoms to which they are attached, they form C 3-5 Cycloalkyl or 5-6 membered heterocycloalkyl; Each R e are independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR; R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens; n is 0 or 1; is a single bond or a double bond; The "hetero" in the 5-membered heteroaryl, 5-6-membered heteroaryl, and 4-6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from O, S and N; The conditions are: 1) When Ring A is selected from A1, Ring B is selected from B1, and Ring C is selected from C2; or, 2) When ring A is selected from A1, ring B is selected from B1, and ring C is selected from C substituted with one R9 5-6 When cycloalkyl, the R9 is selected from 2. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R is selected from CH3, CH2CH3, CF3, OCH3 and OCF3.
3. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R a Selected from -S(=O)2-CH2CH3.
4. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R b Each is independently selected from F, Cl, Br, I, CH3, -C(=O)-CH2CH3 and -NHC(=O)-CH2CH3.
5. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R c and R d Together with the carbon atoms to which they are attached, they form 6. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R e Selected from -NHC(=O)-CH2CH3, =NCH3 and =N-OCH3.
7. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from CH3.
8. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each of R2, R3, R4 and R5 is independently selected from H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3, OCH3, OCH2CH3, wherein R2, R3, R4 and R5 cannot all be H at the same time.
9. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R 71 Selected from 10. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R9 is selected from -NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl, piperidinyl and The -NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl and piperidinyl are each independently optionally substituted by 1, 2 or 3 R b replace.
11. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R9 is selected from described Each independently optionally replaced by 1, 2 or 3 R b replace.
12. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R9 is selected from 13. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ring B1 is selected from 14. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring B2 is selected from thienyl, thiazolyl, imidazolyl and pyrazolyl, wherein the thienyl, thiazolyl, imidazolyl and pyrazolyl are independently optionally substituted by 1, 2 or 3 R a replace.
15. The compound according to claim 14, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring B2 is selected from 16. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring A2 is selected from 17. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring C1 is selected from 18. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring C2 is selected from Description Each independently optionally replaced by 1, 2 or 3 R e replace.
19. The compound according to claim 18, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ring C2 is selected from 20. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is selected from: in, is selected from single bonds and double bonds; T2 is selected from CH and N; T4 is selected from CH and N; T3 is selected from C and N; Ring E is selected from m is selected from 0, 1, 2 and 3; p is selected from 0, 1 and 2; Ring B is selected from Ring B1 and Ring B2; Ring B1 is selected from phenyl, pyridyl and pyridazinyl; Ring B2 is selected from 5-membered heteroaryl; T, T1, R1, R2, R3, R6, L, R7 and R8 are as defined in claim 1.
21. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is selected from: in, Ring B is selected from phenyl, pyridyl, pyridazinyl and 5-membered heteroaryl; T1 is selected from O and CR4R5; Each R2, R3, R4 and R5 are independently selected from H, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl and C 1- 3-haloalkoxy; Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group; Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl group; Alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a double bond or a cyclopropyl group; Each R6 is independently selected from H, F, Cl, Br, I and C 1-3 alkyl; R9 is selected from -NHC(=O)-C 1-3 alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl and The -NHC(=O)-C 1-3 Alkyl, -NH-C(=O)-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R b replace; Each R b are independently selected from F, Cl, Br, I, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -NH-C(=O)-C 1-3 alkyl; Each R e are independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -NHC(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkoxy, -NHC(=O)-C 1-3 Alkylamino and =NR; R is selected from C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 halogens; m is selected from 0, 1, 2 and 3; is a single bond or a double bond; The “hetero” in the 5-membered heteroaryl, 5-6-membered heteroaryl, and 4-6-membered heterocycloalkyl group represents 1, 2, 3, or 4 heteroatoms or heteroatom groups independently selected from O, S, and N.
22. A compound represented by the following formula, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
23. The compound according to claim 21, its stereoisomer or pharmaceutically acceptable salt thereof, which is selected from, 24. Use of the compound according to any one of claims 1 to 23, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a medicament for treating diseases associated with aldosterone synthase inhibitors.
25. Use of the compound according to any one of claims 1 to 23, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a drug for treating refractory hypertension.
Citation Information
Patent Citations
Spiro-imidazo compounds
CN101421273A
Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and / or 11-beta-hydroxylase and / or aromatase
CN101506216A
Benzoxazolone derivatives as aldosterone symthase inhibitors
CN102459247A
New dihydroquinoline-2-one derivatives
CN103814021A
New bicyclic dihydroquinoline-2-one derivatives
CN103827101A
Cited By
Compounds comprising a hetero-fused ring structure
CN122771982A
Fused ring derivative, preparation method therefor and use thereof in medicine
WO2025098465A1
Aldosterone synthetase inhibitor, and preparation method therefor and use thereof
WO2025140409A1
Pyrano-pyridine compound, preparation method therefor, pharmaceutical composition thereof and use thereof
WO2025180518A1
Pyrido ring compound, preparation therefor and use thereof
WO2025256482A1
